{"matching_results": 32870, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "americanbankingnews.com", "matching_results": 1004, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 711}, {"key": "negative", "matching_results": 284}, {"key": "neutral", "matching_results": 9}]}]}, {"key": "watchlistnews.com", "matching_results": 782, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 570}, {"key": "negative", "matching_results": 212}]}]}, {"key": "freelancer.com.co", "matching_results": 764, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 718}, {"key": "negative", "matching_results": 45}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "tickerreport.com", "matching_results": 725, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 597}, {"key": "negative", "matching_results": 125}, {"key": "neutral", "matching_results": 3}]}]}, {"key": "thelincolnianonline.com", "matching_results": 719, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 507}, {"key": "negative", "matching_results": 212}]}]}, {"key": "dailypolitical.com", "matching_results": 713, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 572}, {"key": "negative", "matching_results": 139}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "theolympiareport.com", "matching_results": 701, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 482}, {"key": "negative", "matching_results": 219}]}]}, {"key": "zolmax.com", "matching_results": 687, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 513}, {"key": "negative", "matching_results": 173}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "wkrb13.com", "matching_results": 661, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 494}, {"key": "negative", "matching_results": 167}]}]}, {"key": "findmarketresearch.org", "matching_results": 556, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 469}, {"key": "negative", "matching_results": 87}]}]}]}], "results": [{"id": "VSN_pfnkn-rniFOL-PKz6Dh7GnxyESIif1x7EGZzYiuslQ1tcbeGqFvHk_SKDGsq", "result_metadata": {"score": 38.053486}, "author": "Swapna", "enriched_title": {"entities": [], "sentiment": {"document": {"score": -0.233393, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "a significant rate", "keywords": [{"text": "significant rate"}]}, "sentence": "Global dengue vaccine market revenue is expected to expand at a significant rate owing to a large unmet need", "object": {"text": "to a large unmet need", "keywords": [{"text": "large unmet need"}]}, "action": {"verb": {"text": "owe", "tense": "present"}, "text": "owing", "normalized": "owe"}}], "concepts": [{"text": "Dengue fever", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Dengue_fever"}], "categories": [{"score": 0.898555, "label": "/health and fitness/disease"}, {"score": 0.872028, "label": "/health and fitness/disease/epidemic"}, {"score": 0.731996, "label": "/health and fitness/disease/cold and flu"}], "relations": [], "keywords": [{"text": "Global dengue", "sentiment": {"score": -0.233393, "label": "negative"}, "relevance": 0.968712, "count": 1}, {"text": "vaccine market revenue", "sentiment": {"score": -0.233393, "label": "negative"}, "relevance": 0.645259, "count": 1}, {"text": "significant rate", "sentiment": {"score": -0.233393, "label": "negative"}, "relevance": 0.181481, "count": 1}, {"text": "large unmet", "sentiment": {"score": -0.233393, "label": "negative"}, "relevance": 0.074148, "count": 1}]}, "crawl_date": "2018-11-29T23:32:45Z", "url": "https://www.findmarketresearch.org/2018/11/global-dengue-vaccine-market-revenue-is-expected-to-expand-at-a-significant-rate-owing-to-a-large-unmet-need/", "host": "findmarketresearch.org", "text": "Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-29T06:55:00+05:00", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": -0.5609, "label": "negative"}, "text": "dengue", "relevance": 0.804172, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Dengue fever", "dbpedia_resource": "http://dbpedia.org/resource/Dengue_fever"}}, {"count": 3, "sentiment": {"score": -0.128492, "label": "negative"}, "text": "Mn", "relevance": 0.422933, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 2, "sentiment": {"score": -0.616433, "label": "negative"}, "text": "Asia-Pacific", "relevance": 0.356565, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sanofi S.A.", "relevance": 0.342568, "type": "Company", "disambiguation": {"subtype": [], "name": "Sanofi", "dbpedia_resource": "http://dbpedia.org/resource/Sanofi"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.248674, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.245014, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": -0.750475, "label": "negative"}, "text": "Latin America", "relevance": 0.219824, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Biological E. Limited", "relevance": 0.217753, "type": "Company", "disambiguation": {"subtype": [], "name": "Biological E. Limited", "dbpedia_resource": "http://dbpedia.org/resource/Biological_E._Limited"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Panacea Biotech Ltd.", "relevance": 0.216347, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Butantan Institute", "relevance": 0.208563, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merck & Co. Inc.", "relevance": 0.198457, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.193268, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "17.3%", "relevance": 0.193268, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "17.4%", "relevance": 0.193268, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "70.3%", "relevance": 0.193268, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.193268, "type": "TwitterHandle"}], "sentiment": {"document": {"score": -0.39309, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Burdening occurrence of dengue fever across the Asia-Pacific region", "keywords": [{"text": "dengue fever"}, {"text": "Asia-Pacific region"}, {"text": "occurrence"}]}, "sentence": "Burdening occurrence of dengue fever across the Asia-Pacific region has prompted the demand for effective vaccines and medications to supress this viral malaise.", "object": {"text": "the demand for effective vaccines and medications", "keywords": [{"text": "effective vaccines"}, {"text": "demand"}, {"text": "medications"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has prompted", "normalized": "have prompt"}}, {"subject": {"text": "Burdening occurrence of dengue fever across the Asia-Pacific region", "keywords": [{"text": "dengue fever"}, {"text": "Asia-Pacific region"}, {"text": "occurrence"}]}, "sentence": "Burdening occurrence of dengue fever across the Asia-Pacific region has prompted the demand for effective vaccines and medications to supress this viral malaise.", "object": {"text": "the demand for effective vaccines and medications to supress this viral malaise", "keywords": [{"text": "viral malaise"}, {"text": "effective vaccines"}, {"text": "demand"}, {"text": "medications"}]}, "action": {"verb": {"text": "prompt", "tense": "past"}, "text": "has prompted", "normalized": "have prompt"}}, {"subject": {"text": "several pharmaceutical companies", "keywords": [{"text": "pharmaceutical companies"}], "entities": []}, "sentence": " While several pharmaceutical companies are striving to develop a cure for dengue, the fever\u2019s incidence rate in Asia-Pacific is rising at an alarming rate.", "object": {"text": "to develop a cure for dengue", "keywords": [{"text": "dengue"}, {"text": "cure"}], "entities": [{"type": "HealthCondition", "text": "dengue", "disambiguation": {"subtype": [], "name": "Dengue fever", "dbpedia_resource": "http://dbpedia.org/resource/Dengue_fever"}}]}, "action": {"verb": {"text": "strive", "tense": "present"}, "text": "striving", "normalized": "strive"}}, {"subject": {"text": "several pharmaceutical companies", "keywords": [{"text": "pharmaceutical companies"}], "entities": []}, "sentence": " While several pharmaceutical companies are striving to develop a cure for dengue, the fever\u2019s incidence rate in Asia-Pacific is rising at an alarming rate.", "object": {"text": "a cure for dengue", "keywords": [{"text": "dengue"}, {"text": "cure"}], "entities": [{"type": "HealthCondition", "text": "dengue", "disambiguation": {"subtype": [], "name": "Dengue fever", "dbpedia_resource": "http://dbpedia.org/resource/Dengue_fever"}}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "are striving to develop", "normalized": "be strive to develop"}}, {"subject": {"text": "the fever\u2019s incidence rate in Asia-Pacific", "keywords": [{"text": "incidence rate"}, {"text": "Asia-Pacific"}, {"text": "fever"}], "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " While several pharmaceutical companies are striving to develop a cure for dengue, the fever\u2019s incidence rate in Asia-Pacific is rising at an alarming rate.", "object": {"text": "rising at an alarming rate", "keywords": [{"text": "rate"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the fever\u2019s incidence rate in Asia-Pacific", "keywords": [{"text": "incidence rate"}, {"text": "Asia-Pacific"}, {"text": "fever"}], "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " While several pharmaceutical companies are striving to develop a cure for dengue, the fever\u2019s incidence rate in Asia-Pacific is rising at an alarming rate.", "object": {"text": "at an alarming rate", "keywords": [{"text": "rate"}]}, "action": {"verb": {"text": "rise", "tense": "present"}, "text": "is rising", "normalized": "be rise"}}, {"subject": {"text": "by Future Market Insights", "keywords": [{"text": "Future Market Insights"}]}, "sentence": " A recent report published by Future Market Insights predicts that in 2017, an estimated 70.3% of global dengue vaccines market will be dominated by Asia-Pacific.", "object": {"text": "A recent report", "keywords": [{"text": "recent report"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "A recent report published by Future Market Insights", "keywords": [{"text": "Future Market Insights"}, {"text": "recent report"}]}, "sentence": " A recent report published by Future Market Insights predicts that in 2017, an estimated 70.3% of global dengue vaccines market will be dominated by Asia-Pacific.", "object": {"text": "that in 2017, an estimated 70.3% of global dengue vaccines market will be dominated by Asia-Pacific", "keywords": [{"text": "global dengue vaccines"}, {"text": "Asia-Pacific"}, {"text": "70.3"}, {"text": "market"}], "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}, {"type": "Quantity", "text": "70.3"}]}, "action": {"verb": {"text": "predict", "tense": "present"}, "text": "predicts", "normalized": "predict"}}, {"subject": {"text": "by Asia-Pacific", "keywords": [{"text": "Asia-Pacific"}], "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " A recent report published by Future Market Insights predicts that in 2017, an estimated 70.3% of global dengue vaccines market will be dominated by Asia-Pacific.", "object": {"text": "an estimated 70.3% of global dengue vaccines market", "keywords": [{"text": "global dengue vaccines"}, {"text": "70.3"}, {"text": "market"}], "entities": [{"type": "Quantity", "text": "70.3"}]}, "action": {"verb": {"text": "dominate", "tense": "future"}, "text": "will be dominated", "normalized": "will be dominate"}}, {"subject": {"text": "the region", "keywords": [{"text": "region"}]}, "sentence": " Through 2027, the region will continue to be the largest market for dengue vaccines, procuring a majority revenue share and projecting revenue growth at a 17.4% CAGR.", "action": {"verb": {"text": "continue", "tense": "future"}, "text": "will continue to be", "normalized": "will continue to be"}}, {"subject": {"text": "the region", "keywords": [{"text": "region"}]}, "sentence": " Through 2027, the region will continue to be the largest market for dengue vaccines, procuring a majority revenue share and projecting revenue growth at a 17.4% CAGR.", "object": {"text": "the largest market", "keywords": [{"text": "largest market"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "will continue to be", "normalized": "will continue to be"}}, {"subject": {"text": "$ 288.7 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Quantity", "text": "$ 288.7"}]}, "sentence": " Future Market Insights also observes Latin America as the second-largest market for dengue vaccines, and is expected to rake in US$ 288.7 Mn towards the end of 2027.", "object": {"text": "in US", "entities": []}, "action": {"verb": {"text": "rake", "tense": "future"}, "text": "is expected to rake", "normalized": "be expect to rake"}}, {"subject": {"text": "The report, titled \u201cDengue Vaccines Market: Global Industry Analysis and Opportunity Assessment, 2017-2027,\u201d", "keywords": [{"text": "Dengue Vaccines Market"}, {"text": "Global Industry Analysis"}, {"text": "Opportunity Assessment"}]}, "sentence": " The report, titled \u201cDengue Vaccines Market: Global Industry Analysis and Opportunity Assessment, 2017-2027,\u201d expects that more and more pharmaceutical giants from across the globe will be partaking in the market\u2019s growth in the years to come.", "object": {"text": "that more and more pharmaceutical giants from across the globe will be partaking in the market\u2019s growth in the years to come", "keywords": [{"text": "pharmaceutical giants"}, {"text": "globe"}, {"text": "market"}, {"text": "growth"}]}, "action": {"verb": {"text": "expect", "tense": "present"}, "text": "expects", "normalized": "expect"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "object": {"text": "witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd.", "keywords": [{"text": "Takeda Pharmaceutical Company"}, {"text": "Biological E. Limited"}, {"text": "Panacea Biotech"}, {"text": "Sanofi S.A."}], "entities": [{"type": "Company", "text": "Sanofi S.A.", "disambiguation": {"subtype": [], "name": "Sanofi", "dbpedia_resource": "http://dbpedia.org/resource/Sanofi"}}, {"type": "Company", "text": "Biological E. Limited", "disambiguation": {"subtype": [], "name": "Biological E. Limited", "dbpedia_resource": "http://dbpedia.org/resource/Biological_E._Limited"}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Organization", "text": "Butantan Institute"}, {"type": "Company", "text": "Panacea Biotech Ltd."}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "object": {"text": "active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development", "keywords": [{"text": "Panacea Biotech Ltd."}, {"text": "Takeda Pharmaceutical Company"}, {"text": "Biological E. Limited"}, {"text": "Sanofi S.A."}], "entities": [{"type": "Company", "text": "Sanofi S.A.", "disambiguation": {"subtype": [], "name": "Sanofi", "dbpedia_resource": "http://dbpedia.org/resource/Sanofi"}}, {"type": "Company", "text": "Biological E. Limited", "disambiguation": {"subtype": [], "name": "Biological E. Limited", "dbpedia_resource": "http://dbpedia.org/resource/Biological_E._Limited"}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Organization", "text": "Butantan Institute"}, {"type": "Company", "text": "Panacea Biotech Ltd."}]}, "action": {"verb": {"text": "witness", "tense": "present"}, "text": "is witnessing", "normalized": "be witness"}}, {"subject": {"text": "by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute", "keywords": [{"text": "Takeda Pharmaceutical Company"}, {"text": "GlaxoSmithKline plc"}, {"text": "Biological E. Limited"}, {"text": "Co. Inc."}], "entities": [{"type": "Company", "text": "Biological E. Limited", "disambiguation": {"subtype": [], "name": "Biological E. Limited", "dbpedia_resource": "http://dbpedia.org/resource/Biological_E._Limited"}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Organization", "text": "Butantan Institute"}]}, "sentence": " Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "object": {"text": "vaccines", "keywords": [{"text": "vaccines"}]}, "action": {"verb": {"text": "formulate", "tense": "past"}, "text": "being formulated", "normalized": "be formulate"}}, {"subject": {"text": "government institutes", "keywords": [{"text": "government institutes"}]}, "sentence": " The report further reveals that government institutes will remain the largest end-users of dengue vaccines in the world.", "action": {"verb": {"text": "remain", "tense": "future"}, "text": "will remain", "normalized": "will remain"}}, {"subject": {"text": "a little less than US$ 650 Mn worth of revenues", "keywords": [{"text": "Mn worth"}, {"text": "revenues"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "sentence": " Through 2027, a little less than US$ 650 Mn worth of revenues is expected to arise from sales of dengue vaccines across government institutes.", "object": {"text": "from sales of dengue vaccines across government institutes", "keywords": [{"text": "dengue vaccines"}, {"text": "sales"}, {"text": "government"}]}, "action": {"verb": {"text": "arise", "tense": "future"}, "text": "is expected to arise", "normalized": "be expect to arise"}}, {"subject": {"text": "hospitals", "keywords": [{"text": "hospitals"}]}, "sentence": " Meanwhile, hospitals will also dominate the market by registering a 17.3% revenue CAGR.", "object": {"text": "the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "dominate", "tense": "future"}, "text": "will also dominate", "normalized": "will also dominate"}}, {"subject": {"text": "hospitals", "keywords": [{"text": "hospitals"}]}, "sentence": " Meanwhile, hospitals will also dominate the market by registering a 17.3% revenue CAGR.", "object": {"text": "a 17.3% revenue CAGR", "keywords": [{"text": "revenue CAGR"}], "entities": [{"type": "Quantity", "text": "17.3"}]}, "action": {"verb": {"text": "register", "tense": "present"}, "text": "registering", "normalized": "register"}}, {"subject": {"text": "The market", "keywords": [{"text": "market"}]}, "sentence": " The market, at present, will witness sales of the sole of vaccine, Dengvaxia, developed by Sanofi.", "object": {"text": "sales of the sole of vaccine, Dengvaxia, developed by Sanofi", "keywords": [{"text": "Sanofi"}, {"text": "sole"}, {"text": "vaccine"}, {"text": "sales"}], "entities": [{"type": "Company", "text": "Sanofi S.A.", "disambiguation": {"subtype": [], "name": "Sanofi", "dbpedia_resource": "http://dbpedia.org/resource/Sanofi"}}]}, "action": {"verb": {"text": "witness", "tense": "future"}, "text": "will witness", "normalized": "will witness"}}, {"subject": {"text": "factors shaping up the dynamics of global dengue vaccines market", "keywords": [{"text": "global dengue vaccines"}, {"text": "factors"}, {"text": "dynamics"}, {"text": "market"}], "entities": []}, "sentence": " Furthermore, factors shaping up the dynamics of global dengue vaccines market, also compiled in the report, are:", "action": {"verb": {"text": "compile", "tense": "past"}, "text": "compiled", "normalized": "compile"}}, {"subject": {"text": "the economic turmoil in Latin America", "keywords": [{"text": "economic turmoil"}, {"text": "Latin America"}], "entities": [{"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}]}, "sentence": " Apart from the burdening outbreak of dengue in several countries, the economic turmoil in Latin America is projected to impact the global market\u2019s growth at a macroeconomic level.", "object": {"text": "projected"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the global market\u2019s growth", "keywords": [{"text": "global market"}, {"text": "growth"}], "entities": []}, "sentence": " Apart from the burdening outbreak of dengue in several countries, the economic turmoil in Latin America is projected to impact the global market\u2019s growth at a macroeconomic level.", "object": {"text": "at a macroeconomic level", "keywords": [{"text": "macroeconomic level"}]}, "action": {"verb": {"text": "impact", "tense": "future"}, "text": "is projected to impact", "normalized": "be project to impact"}}, {"subject": {"text": "growth", "keywords": [{"text": "growth"}]}, "sentence": " Apart from the burdening outbreak of dengue in several countries, the economic turmoil in Latin America is projected to impact the global market\u2019s growth at a macroeconomic level.", "object": {"text": "the global market", "keywords": [{"text": "global market"}], "entities": []}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "lack of skilled professionals and unavailability of optimum diagnostic systems", "keywords": [{"text": "optimum diagnostic systems"}, {"text": "skilled professionals"}, {"text": "lack"}, {"text": "unavailability"}]}, "sentence": " However, lack of skilled professionals and unavailability of optimum diagnostic systems has given rise to cases where dengue fever is being treated as an undistinguished febrile disease.", "object": {"text": "rise", "keywords": [{"text": "rise"}]}, "action": {"verb": {"text": "give", "tense": "past"}, "text": "has given", "normalized": "have give"}}, {"subject": {"text": "dengue fever", "keywords": [{"text": "dengue fever"}]}, "sentence": " However, lack of skilled professionals and unavailability of optimum diagnostic systems has given rise to cases where dengue fever is being treated as an undistinguished febrile disease.", "object": {"text": "being treated as an undistinguished febrile disease", "keywords": [{"text": "undistinguished febrile disease"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "dengue fever", "keywords": [{"text": "dengue fever"}]}, "sentence": " However, lack of skilled professionals and unavailability of optimum diagnostic systems has given rise to cases where dengue fever is being treated as an undistinguished febrile disease.", "object": {"text": "as an undistinguished febrile disease", "keywords": [{"text": "undistinguished febrile disease"}]}, "action": {"verb": {"text": "treat", "tense": "past"}, "text": "is being treated", "normalized": "be be treat"}}, {"subject": {"text": "The global market for dengue vaccines", "keywords": [{"text": "dengue vaccines"}, {"text": "global market"}], "entities": []}, "sentence": " The global market for dengue vaccines holds an opportunistic breakthrough when drugmakers will be able to successfully develop effective vaccines for all age group", "object": {"text": "an opportunistic breakthrough", "keywords": [{"text": "opportunistic breakthrough"}]}, "action": {"verb": {"text": "hold", "tense": "present"}, "text": "holds", "normalized": "hold"}}, {"subject": {"text": "drugmakers", "keywords": [{"text": "drugmakers"}]}, "sentence": " The global market for dengue vaccines holds an opportunistic breakthrough when drugmakers will be able to successfully develop effective vaccines for all age group", "object": {"text": "effective vaccines", "keywords": [{"text": "effective vaccines"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "develop", "normalized": "develop"}}, {"subject": {"text": "dengue vaccines", "keywords": [{"text": "dengue vaccines"}]}, "sentence": " On the long run, the global market for dengue vaccines, which is presently valued at close to US$ 250 Mn, will soar vigorously to rake in US$ 1,250.6 Mn revenues by the end of 2027.", "object": {"text": "presently valued at close to US$ 250 Mn,", "keywords": [{"text": "Mn"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "dengue vaccines", "keywords": [{"text": "dengue vaccines"}]}, "sentence": " On the long run, the global market for dengue vaccines, which is presently valued at close to US$ 250 Mn, will soar vigorously to rake in US$ 1,250.6 Mn revenues by the end of 2027.", "object": {"text": "at close to US$ 250 Mn", "keywords": [{"text": "Mn"}]}, "action": {"verb": {"text": "value", "tense": "past"}, "text": "valued", "normalized": "value"}}, {"subject": {"text": "the global market for dengue vaccines, which is presently valued at close to US$ 250 Mn,", "keywords": [{"text": "dengue vaccines"}, {"text": "global market"}, {"text": "Mn"}], "entities": []}, "sentence": " On the long run, the global market for dengue vaccines, which is presently valued at close to US$ 250 Mn, will soar vigorously to rake in US$ 1,250.6 Mn revenues by the end of 2027.", "action": {"verb": {"text": "soar", "tense": "future"}, "text": "will soar", "normalized": "will soar"}}], "concepts": [{"text": "Fever", "relevance": 0.972152, "dbpedia_resource": "http://dbpedia.org/resource/Fever"}, {"text": "Dengue fever", "relevance": 0.759115, "dbpedia_resource": "http://dbpedia.org/resource/Dengue_fever"}, {"text": "Malaria", "relevance": 0.728989, "dbpedia_resource": "http://dbpedia.org/resource/Malaria"}, {"text": "GlaxoSmithKline", "relevance": 0.721539, "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}, {"text": "Pharmaceutical industry", "relevance": 0.708993, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Economics", "relevance": 0.657243, "dbpedia_resource": "http://dbpedia.org/resource/Economics"}, {"text": "Revenue", "relevance": 0.624928, "dbpedia_resource": "http://dbpedia.org/resource/Revenue"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.612325, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Asia-Pacific", "relevance": 0.591656, "dbpedia_resource": "http://dbpedia.org/resource/Asia-Pacific"}, {"text": "Dengue", "relevance": 0.57362, "dbpedia_resource": "http://dbpedia.org/resource/Dengue"}, {"text": "Biotechnology", "relevance": 0.521212, "dbpedia_resource": "http://dbpedia.org/resource/Biotechnology"}, {"text": "Sanofi-Aventis", "relevance": 0.516145, "dbpedia_resource": "http://dbpedia.org/resource/Sanofi-Aventis"}, {"text": "Macroeconomics", "relevance": 0.491797, "dbpedia_resource": "http://dbpedia.org/resource/Macroeconomics"}, {"text": "Aspirin", "relevance": 0.454998, "dbpedia_resource": "http://dbpedia.org/resource/Aspirin"}, {"text": "Pharmacology", "relevance": 0.452041, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Vaccine", "relevance": 0.438285, "dbpedia_resource": "http://dbpedia.org/resource/Vaccine"}, {"text": "HPV vaccine", "relevance": 0.418828, "dbpedia_resource": "http://dbpedia.org/resource/HPV_vaccine"}], "categories": [{"score": 0.975514, "label": "/health and fitness/disease"}, {"score": 0.904593, "label": "/health and fitness/disease/epidemic"}, {"score": 0.774834, "label": "/health and fitness/disease/cold and flu"}], "relations": [{"type": "agentOf", "sentence": "A recent report published by Future Market Insights predicts that in 2017, an estimated 70.3% of global dengue vaccines market will be dominated by Asia-Pacific.", "score": 0.711673, "arguments": [{"text": "Future Market Insights", "location": [347, 369], "entities": [{"type": "Organization", "text": "Future Market Insights"}]}, {"text": "published", "location": [334, 343], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "agentOf", "sentence": "A recent report published by Future Market Insights predicts that in 2017, an estimated 70.3% of global dengue vaccines market will be dominated by Asia-Pacific.", "score": 0.85028, "arguments": [{"text": "Future Market Insights", "location": [347, 369], "entities": [{"type": "Organization", "text": "Future Market Insights"}]}, {"text": "predicts", "location": [370, 378], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "partOfMany", "sentence": "Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "score": 0.617823, "arguments": [{"text": "Merck & Co. Inc.", "location": [1283, 1299], "entities": [{"type": "Organization", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [1182, 1191], "entities": [{"type": "Organization", "text": "pharmaceutical companies"}]}]}, {"type": "partOfMany", "sentence": "Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "score": 0.564008, "arguments": [{"text": "Vabiotech", "location": [1301, 1310], "entities": [{"type": "Organization", "text": "Vabiotech", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [1182, 1191], "entities": [{"type": "Organization", "text": "pharmaceutical companies"}]}]}, {"type": "partOfMany", "sentence": "Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "score": 0.537026, "arguments": [{"text": "Butantan Institute", "location": [1312, 1330], "entities": [{"type": "Organization", "text": "Butantan Institute", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [1182, 1191], "entities": [{"type": "Organization", "text": "pharmaceutical companies"}]}]}, {"type": "employedBy", "sentence": "The report further reveals that government institutes will remain the largest end-users of dengue vaccines in the world.", "score": 0.943342, "arguments": [{"text": "institutes", "location": [1442, 1452], "entities": [{"type": "Person", "text": "institutes"}]}, {"text": "government", "location": [1431, 1441], "entities": [{"type": "GeopoliticalEntity", "text": "government", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "Through 2027, a little less than US$ 650 Mn worth of revenues is expected to arise from sales of dengue vaccines across government institutes.", "score": 0.931626, "arguments": [{"text": "institutes", "location": [1651, 1661], "entities": [{"type": "Person", "text": "institutes"}]}, {"text": "government", "location": [1640, 1650], "entities": [{"type": "GeopoliticalEntity", "text": "government", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "hasAttribute", "sentence": "The report further reveals that government institutes will remain the largest end-users of dengue vaccines in the world.", "score": 0.748367, "arguments": [{"text": "institutes", "location": [1442, 1452], "entities": [{"type": "Person", "text": "institutes"}]}, {"text": "dengue vaccines", "location": [1490, 1505], "entities": [{"type": "HealthCondition", "text": "dengue vaccines"}]}]}, {"type": "hasAttribute", "sentence": "Through 2027, a little less than US$ 650 Mn worth of revenues is expected to arise from sales of dengue vaccines across government institutes.", "score": 0.821245, "arguments": [{"text": "institutes", "location": [1651, 1661], "entities": [{"type": "Person", "text": "institutes"}]}, {"text": "dengue vaccines", "location": [1617, 1632], "entities": [{"type": "HealthCondition", "text": "dengue vaccines"}]}]}, {"type": "agentOf", "sentence": "Through 2027, a little less than US$ 650 Mn worth of revenues is expected to arise from sales of dengue vaccines across government institutes.", "score": 0.59603, "arguments": [{"text": "Mn", "location": [1561, 1563], "entities": [{"type": "Person", "text": "Mn"}]}, {"text": "arise", "location": [1597, 1602], "entities": [{"type": "EventCommunication", "text": "arise"}]}]}, {"type": "instrumentOf", "sentence": "Furthermore, factors shaping up the dynamics of global dengue vaccines market, also compiled in the report, are: Apart from the burdening outbreak of dengue in several countries, the economic turmoil in Latin America is projected to impact the global market's growth at a macroeconomic level.", "score": 0.246631, "arguments": [{"text": "dengue", "location": [2000, 2006], "entities": [{"type": "HealthCondition", "text": "dengue fever"}]}, {"text": "outbreak", "location": [1988, 1996], "entities": [{"type": "NaturalDisaster", "text": "outbreak"}]}]}, {"type": "locatedAt", "sentence": "Furthermore, factors shaping up the dynamics of global dengue vaccines market, also compiled in the report, are: Apart from the burdening outbreak of dengue in several countries, the economic turmoil in Latin America is projected to impact the global market's growth at a macroeconomic level.", "score": 0.360653, "arguments": [{"text": "outbreak", "location": [1988, 1996], "entities": [{"type": "NaturalDisaster", "text": "outbreak"}]}, {"text": "countries", "location": [2018, 2027], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Furthermore, factors shaping up the dynamics of global dengue vaccines market, also compiled in the report, are: Apart from the burdening outbreak of dengue in several countries, the economic turmoil in Latin America is projected to impact the global market's growth at a macroeconomic level.", "score": 0.52889, "arguments": [{"text": "countries", "location": [2018, 2027], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Latin America", "location": [2053, 2066], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "hasAttribute", "sentence": "Live attenuated vaccines are being developed & produced economically, thereby comforting vaccine makers as well as patients However, lack of skilled professionals and unavailability of optimum diagnostic systems has given rise to cases where dengue fever is being treated as an undistinguished febrile disease.", "score": 0.666337, "arguments": [{"text": "professionals", "location": [2292, 2305], "entities": [{"type": "Person", "text": "professionals"}]}, {"text": "dengue fever", "location": [2385, 2397], "entities": [{"type": "HealthCondition", "text": "dengue fever"}]}]}, {"type": "timeOf", "sentence": "A recent report published by Future Market Insights predicts that in 2017, an estimated 70.3% of global dengue vaccines market will be dominated by Asia-Pacific.", "score": 0.781182, "arguments": [{"text": "2017", "location": [387, 391], "entities": [{"type": "Date", "text": "2017"}]}, {"text": "predicts", "location": [370, 378], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "hasAttribute", "sentence": "The global market for dengue vaccines holds an opportunistic breakthrough when drugmakers will be able to successfully develop effective vaccines for all age group Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-1763 On the long run, the global market for dengue vaccines, which is presently valued at close to US$ 250 Mn, will soar vigorously to rake in US$ 1,250.6 Mn revenues by the end of 2027.", "score": 0.705573, "arguments": [{"text": "drugmakers", "location": [2533, 2543], "entities": [{"type": "Person", "text": "drugmakers"}]}, {"text": "dengue vaccines", "location": [2476, 2491], "entities": [{"type": "HealthCondition", "text": "dengue vaccines"}]}]}, {"type": "populationOf", "sentence": "The global market for dengue vaccines holds an opportunistic breakthrough when drugmakers will be able to successfully develop effective vaccines for all age group Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-1763 On the long run, the global market for dengue vaccines, which is presently valued at close to US$ 250 Mn, will soar vigorously to rake in US$ 1,250.6 Mn revenues by the end of 2027.", "score": 0.585983, "arguments": [{"text": "1,250.6", "location": [2869, 2876], "entities": [{"type": "Cardinal", "text": "1,250.6"}]}, {"text": "US$", "location": [2865, 2868], "entities": [{"type": "GeopoliticalEntity", "text": "US$"}]}]}, {"type": "locatedAt", "sentence": "A recent report published by Future Market Insights predicts that in 2017, an estimated 70.3% of global dengue vaccines market will be dominated by Asia-Pacific.", "score": 0.550537, "arguments": [{"text": "Pacific", "location": [471, 478], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}, {"text": "Asia", "location": [466, 470], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "hasAttribute", "sentence": "Future Market Insights also observes Latin America as the second-largest market for dengue vaccines, and is expected to rake in US$ 288.7 Mn towards the end of 2027.", "score": 0.508396, "arguments": [{"text": "Mn", "location": [785, 787], "entities": [{"type": "Person", "text": "Mn"}]}, {"text": "dengue vaccines", "location": [731, 746], "entities": [{"type": "HealthCondition", "text": "dengue vaccines"}]}]}, {"type": "hasAttribute", "sentence": "Through 2027, a little less than US$ 650 Mn worth of revenues is expected to arise from sales of dengue vaccines across government institutes.", "score": 0.556831, "arguments": [{"text": "Mn", "location": [1561, 1563], "entities": [{"type": "Person", "text": "Mn"}]}, {"text": "dengue vaccines", "location": [1617, 1632], "entities": [{"type": "HealthCondition", "text": "dengue vaccines"}]}]}, {"type": "populationOf", "sentence": "Future Market Insights also observes Latin America as the second-largest market for dengue vaccines, and is expected to rake in US$ 288.7 Mn towards the end of 2027.", "score": 0.574871, "arguments": [{"text": "288.7", "location": [779, 784], "entities": [{"type": "Cardinal", "text": "288.7"}]}, {"text": "US$", "location": [775, 778], "entities": [{"type": "GeopoliticalEntity", "text": "US$"}]}]}, {"type": "partOfMany", "sentence": "Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "score": 0.816563, "arguments": [{"text": "drugmaker", "location": [1123, 1132], "entities": [{"type": "Person", "text": "Sanofi S.A."}]}, {"text": "French", "location": [1116, 1122], "entities": [{"type": "GeopoliticalEntity", "text": "French", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOfMany", "sentence": "Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "score": 0.703763, "arguments": [{"text": "Biological E. Limited", "location": [1200, 1221], "entities": [{"type": "Organization", "text": "Biological E. Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [1182, 1191], "entities": [{"type": "Organization", "text": "pharmaceutical companies"}]}]}, {"type": "partOfMany", "sentence": "Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "score": 0.829056, "arguments": [{"text": "Takeda Pharmaceutical Company Limited", "location": [1223, 1260], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [1182, 1191], "entities": [{"type": "Organization", "text": "pharmaceutical companies"}]}]}, {"type": "partOfMany", "sentence": "Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "score": 0.579328, "arguments": [{"text": "GlaxoSmithKline plc", "location": [1262, 1281], "entities": [{"type": "Organization", "text": "GlaxoSmithKline plc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [1182, 1191], "entities": [{"type": "Organization", "text": "pharmaceutical companies"}]}]}], "keywords": [{"text": "Future Market Insights", "sentiment": {"score": -0.67407, "label": "negative"}, "relevance": 0.819683, "count": 2}, {"text": "occurrence of dengue fever", "sentiment": {"score": -0.519307, "label": "negative"}, "relevance": 0.75463, "count": 1}, {"text": "global dengue vaccines market", "sentiment": {"score": -0.689106, "label": "negative"}, "relevance": 0.747382, "count": 1}, {"text": "effective vaccines", "sentiment": {"score": 0.642191, "mixed": "1", "label": "positive"}, "relevance": 0.724784, "count": 2}, {"text": "recent report", "sentiment": {"score": -0.689106, "label": "negative"}, "relevance": 0.702708, "count": 1}, {"text": "largest market", "sentiment": {"score": 0.697686, "label": "positive"}, "relevance": 0.657464, "count": 1}, {"text": "pharmaceutical companies", "sentiment": {"score": -0.829124, "label": "negative"}, "relevance": 0.623678, "count": 1}, {"text": "Asia-Pacific region", "sentiment": {"score": -0.519307, "label": "negative"}, "relevance": 0.61729, "count": 1}, {"text": "Latin America", "sentiment": {"score": -0.813651, "label": "negative"}, "relevance": 0.599493, "count": 2}, {"text": "dengue vaccines", "sentiment": {"score": 0.719362, "mixed": "1", "label": "positive"}, "relevance": 0.568665, "count": 4}, {"text": "lack of skilled professionals", "sentiment": {"score": -0.466038, "label": "negative"}, "relevance": 0.560582, "count": 1}, {"text": "burdening outbreak of dengue", "sentiment": {"score": -0.927932, "label": "negative"}, "relevance": 0.554663, "count": 1}, {"text": "economic turmoil", "sentiment": {"score": -0.927932, "label": "negative"}, "relevance": 0.553588, "count": 1}, {"text": "global market", "sentiment": {"score": 0.969978, "label": "positive"}, "relevance": 0.547718, "count": 2}, {"text": "Global Industry Analysis", "sentiment": {"score": 0.553906, "label": "positive"}, "relevance": 0.54716, "count": 1}, {"text": "Dengue Vaccines Market", "sentiment": {"score": 0.553906, "label": "positive"}, "relevance": 0.546611, "count": 1}, {"text": "second-largest market", "sentiment": {"score": -0.658804, "label": "negative"}, "relevance": 0.539995, "count": 1}, {"text": "Biological E. Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.53896, "count": 1}, {"text": "dengue fever", "sentiment": {"score": -0.466038, "label": "negative"}, "relevance": 0.538687, "count": 1}, {"text": "dynamics of global dengue vaccines market", "sentiment": {"score": -0.927932, "label": "negative"}, "relevance": 0.533416, "count": 1}, {"text": "dengue", "sentiment": {"score": -0.829124, "label": "negative"}, "relevance": 0.533249, "count": 1}, {"text": "active participation of French drugmaker", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521093, "count": 1}, {"text": "Takeda Pharmaceutical Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519565, "count": 1}, {"text": "report", "sentiment": {"score": -0.588914, "mixed": "1", "label": "negative"}, "relevance": 0.519004, "count": 3}, {"text": "long run", "sentiment": {"score": 0.969978, "label": "positive"}, "relevance": 0.518848, "count": 1}, {"text": "alarming rate", "sentiment": {"score": -0.829124, "label": "negative"}, "relevance": 0.518822, "count": 1}, {"text": "factors", "sentiment": {"score": -0.927932, "label": "negative"}, "relevance": 0.516692, "count": 1}, {"text": "largest end-users of dengue vaccines", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513805, "count": 1}, {"text": "unavailability of optimum diagnostic systems", "sentiment": {"score": -0.466038, "label": "negative"}, "relevance": 0.513165, "count": 1}, {"text": "sales of dengue vaccines", "sentiment": {"score": -0.760372, "label": "negative"}, "relevance": 0.512639, "count": 1}, {"text": "companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510594, "count": 1}, {"text": "market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510579, "count": 3}, {"text": "vaccines", "sentiment": {"score": 0.722235, "label": "positive"}, "relevance": 0.510045, "count": 2}, {"text": "region", "sentiment": {"score": 0.697686, "label": "positive"}, "relevance": 0.508623, "count": 1}, {"text": "countries", "sentiment": {"score": -0.927932, "label": "negative"}, "relevance": 0.508423, "count": 1}, {"text": "Merck", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.506586, "count": 1}, {"text": "hospitals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.506551, "count": 1}, {"text": "cure", "sentiment": {"score": -0.829124, "label": "negative"}, "relevance": 0.506229, "count": 1}, {"text": "globe", "sentiment": {"score": 0.553906, "label": "positive"}, "relevance": 0.506067, "count": 1}, {"text": "cases", "sentiment": {"score": -0.466038, "label": "negative"}, "relevance": 0.506062, "count": 1}, {"text": "end", "sentiment": {"score": -0.658804, "label": "negative"}, "relevance": 0.505845, "count": 2}, {"text": "demand", "sentiment": {"score": -0.519307, "label": "negative"}, "relevance": 0.505318, "count": 1}, {"text": "Sanofi", "sentiment": {"score": -0.927932, "label": "negative"}, "relevance": 0.504464, "count": 1}, {"text": "medications", "sentiment": {"score": -0.519307, "label": "negative"}, "relevance": 0.50385, "count": 1}, {"text": "Opportunity Assessment", "sentiment": {"score": 0.553906, "label": "positive"}, "relevance": 0.503215, "count": 1}, {"text": "Sanofi S.A.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.502219, "count": 1}, {"text": "patients", "sentiment": {"score": -0.466038, "label": "negative"}, "relevance": 0.50216, "count": 1}, {"text": "world", "sentiment": {"score": -0.760372, "label": "negative"}, "relevance": 0.50216, "count": 1}, {"text": "majority revenue share", "sentiment": {"score": 0.697686, "label": "positive"}, "relevance": 0.501742, "count": 1}, {"text": "market\u2019s growth", "sentiment": {"score": 0.553906, "label": "positive"}, "relevance": 0.500094, "count": 1}]}, "extracted_metadata": {"sha1": "a1c6b695c5594dc1dfeeabad734943ccc5b35bb7", "filename": "1543534365706.zip-902d861dea31d3cb52a527e7c22fa795.xml", "file_type": "json"}, "external_links": ["https://www.futuremarketinsights.com/reports/dengue-vaccines-market", "https://www.futuremarketinsights.com/customization-available/rep-gb-1763"], "title": "Global dengue vaccine market revenue is expected to expand at a significant rate owing to a large unmet need", "forum_title": "Research Insights | Find Market Research - Part 80"}, {"id": "jlF-2vAfZfQWax9phbxAEyoDJadQqnQnByPDXSTzzJMJKH7zIZDWehU01kvW88hT", "result_metadata": {"score": 37.206825}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "HBK Investments LP", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.896398, "label": "/finance/investing"}, {"score": 0.896398, "label": "/finance/investing/beginning investing"}, {"score": 0.88517, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "HBK Investments LP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.997108, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.660062, "count": 1}, {"text": "Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.248164, "count": 1}]}, "crawl_date": "2018-11-29T15:02:01Z", "url": "https://www.finanznachrichten.de/nachrichten-2018-11/45401939-hbk-investments-lp-form-8-3-takeda-pharmaceutical-co-ltd-008.htm", "host": "finanznachrichten.de", "text": "N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening", "main_image_url": "https://fns1.de/g/fb.png", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-29T14:34:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "HBK Investments", "relevance": 0.988692, "type": "Company", "disambiguation": {"subtype": [], "name": "HBK Investments", "dbpedia_resource": "http://dbpedia.org/resource/HBK_Investments"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.910266, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire Plc", "relevance": 0.83781, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.749921, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.679365, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.679365, "type": "Quantity"}], "sentiment": {"document": {"score": -0.418973, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \"N/A\" YES : Shire Plc 2.", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the offeror or offeree", "keywords": [{"text": "offeror"}, {"text": "offeree"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security:", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}], "concepts": [{"text": "Offer and acceptance", "relevance": 0.945303, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Uniform Commercial Code", "relevance": 0.805651, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Hedge fund", "relevance": 0.778056, "dbpedia_resource": "http://dbpedia.org/resource/Hedge_fund"}, {"text": "Investment", "relevance": 0.727384, "dbpedia_resource": "http://dbpedia.org/resource/Investment"}, {"text": "Collective investment scheme", "relevance": 0.687831, "dbpedia_resource": "http://dbpedia.org/resource/Collective_investment_scheme"}, {"text": "Security", "relevance": 0.670192, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Mutual fund", "relevance": 0.64546, "dbpedia_resource": "http://dbpedia.org/resource/Mutual_fund"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.643202, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Name", "relevance": 0.641726, "dbpedia_resource": "http://dbpedia.org/resource/Name"}], "categories": [{"score": 0.810546, "label": "/finance/investing/funds"}, {"score": 0.803437, "label": "/real estate/buying and selling homes"}, {"score": 0.79765, "label": "/finance/investing/beginning investing"}], "relations": [{"type": "employedBy", "sentence": "KEY INFORMATION (a) Full name of discloser: HBK Investments L.P. on behalf of itself, its subadvisors and its managed funds (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient.", "score": 0.40878, "arguments": [{"text": "Owner", "location": [302, 307], "entities": [{"type": "Person", "text": "controller"}]}, {"text": "its", "location": [280, 283], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}], "keywords": [{"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.836882, "count": 1}, {"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.710942, "count": 1}, {"text": "RELEVANT SECURITIES", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.661949, "count": 2}, {"text": "Full name of discloser", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.650582, "count": 1}, {"text": "cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.638611, "count": 1}, {"text": "offeree Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.630726, "count": 1}, {"text": "short positions", "sentiment": {"score": -0.74856, "label": "negative"}, "relevance": 0.610741, "count": 2}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.604915, "count": 1}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.591141, "count": 1}, {"text": "KEY INFORMATION", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.587397, "count": 1}, {"text": "possible cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.584722, "count": 1}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.569999, "count": 1}, {"text": "HBK Investments L.P.", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.558284, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.547794, "count": 1}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.538369, "count": 1}, {"text": "offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536107, "count": 1}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530624, "count": 1}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528867, "count": 1}, {"text": "INTERESTS", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.526285, "count": 2}, {"text": "funds", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.524728, "count": 1}, {"text": "form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524176, "count": 1}, {"text": "identity of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520619, "count": 1}, {"text": "PERSON", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.520018, "count": 1}, {"text": "naming of nominee", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.518707, "count": 1}, {"text": "trust", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516895, "count": 1}, {"text": "disclosure", "sentiment": {"score": -0.588915, "label": "negative"}, "relevance": 0.516571, "count": 3}, {"text": "controller of interests", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.515788, "count": 1}, {"text": "behalf", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.51522, "count": 1}, {"text": "Owner", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.514845, "count": 1}, {"text": "disclosures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513259, "count": 1}, {"text": "addition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512792, "count": 1}, {"text": "November", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51275, "count": 1}, {"text": "separate form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51168, "count": 1}, {"text": "positions", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.511087, "count": 1}, {"text": "relation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510316, "count": 1}, {"text": "respect", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509669, "count": 1}, {"text": "trustee", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509135, "count": 1}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.508722, "count": 1}, {"text": "company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.507066, "count": 1}, {"text": "party", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.506578, "count": 1}, {"text": "beneficiaries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.504995, "count": 1}, {"text": "POSITIONS OF THE PERSON", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.504835, "count": 1}, {"text": "Rule", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.504747, "count": 1}, {"text": "Code", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.50177, "count": 1}, {"text": "additional class of relevant security", "sentiment": {"score": 0.450809, "mixed": "1", "label": "positive"}, "relevance": 0.501304, "count": 1}, {"text": "vehicle companies", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.497103, "count": 1}, {"text": "relevant securities of the offeror", "sentiment": {"score": -0.588915, "label": "negative"}, "relevance": 0.491446, "count": 1}, {"text": "copy table", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.484997, "count": 1}, {"text": "offeree", "sentiment": {"score": 0.450809, "mixed": "1", "label": "positive"}, "relevance": 0.482571, "count": 5}, {"text": "Class of relevant security", "sentiment": {"score": -0.588915, "label": "negative"}, "relevance": 0.46976, "count": 1}]}, "extracted_metadata": {"sha1": "bb441bceca7776f5ad96331f2792d6b16c4c906a", "filename": "1543503721668.zip-66e588fd21a22029bab9ba443d2183a3.xml", "file_type": "json"}, "title": "HBK Investments LP - Form 8.3 - Takeda Pharmaceutical Co Ltd", "forum_title": "FinanzNachrichten.de: News"}, {"id": "vAGyKYxnVpwiq0GDfKgIWoCbGRZ5Q8mTvb_JDG3Q3Iize-m0Qk3MJf7obX3McrX2", "result_metadata": {"score": 33.61737}, "author": "ABMN Staff", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Takeda Pharmaceutical (TKPYY)", "keywords": [{"text": "(TKPYY)"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": "Takeda Pharmaceutical (TKPYY) Receives Daily News Impact Score of 1.14", "object": {"text": "Daily News Impact Score", "keywords": [{"text": "Daily News Impact"}, {"text": "Score"}]}, "action": {"verb": {"text": "Receives", "tense": "present"}, "text": "Receives", "normalized": "Receives"}}], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.916982, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.95857, "count": 1}, {"text": "Daily News Impact Score", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.04143, "count": 1}]}, "crawl_date": "2018-11-30T11:42:45Z", "url": "https://www.americanbankingnews.com/2018/11/30/takeda-pharmaceutical-tkpyy-receives-daily-news-impact-score-of-1-14.html", "host": "americanbankingnews.com", "text": "Takeda Pharmaceutical earned a news sentiment score of 1.14 on their scale.", "main_image_url": "https://www.marketbeat.com/logos/takeda-pharmaceutical-co-ltd-logo.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-30T05:26:00-06:00", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": -0.666464, "label": "negative"}, "text": "Takeda Pharmaceutical", "relevance": 0.933408, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "one year", "relevance": 0.933408, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$28.81 billion", "relevance": 0.933408, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$18.18", "relevance": 0.933408, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$18.38", "relevance": 0.933408, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$31.29", "relevance": 0.933408, "type": "Quantity"}], "sentiment": {"document": {"score": -0.4408, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Media", "keywords": [{"text": "Media"}]}, "sentence": "Media headlines about Takeda Pharmaceutical (OTCMKTS:TKPYY) have trended somewhat positive recently, InfoTrie Sentiment reports.", "object": {"text": "about Takeda Pharmaceutical (OTCMKTS:TKPYY)", "keywords": [{"text": "Takeda Pharmaceutical"}, {"text": "OTCMKTS"}, {"text": "TKPYY"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "headline", "tense": "present"}, "text": "headlines", "normalized": "headline"}}, {"subject": {"text": "trended somewhat positive"}, "sentence": "Media headlines about Takeda Pharmaceutical (OTCMKTS:TKPYY) have trended somewhat positive recently, InfoTrie Sentiment reports.", "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "TKPYY)"}, "sentence": "Media headlines about Takeda Pharmaceutical (OTCMKTS:TKPYY) have trended somewhat positive recently, InfoTrie Sentiment reports.", "object": {"text": "somewhat positive"}, "action": {"verb": {"text": "trend", "tense": "past"}, "text": "have trended", "normalized": "have trend"}}, {"subject": {"text": "The research firm", "keywords": [{"text": "research firm"}]}, "sentence": " The research firm identifies positive and negative news coverage by analyzing more than 6,000 news and blog sources in real-time.", "object": {"text": "positive and negative news coverage", "keywords": [{"text": "negative news coverage"}]}, "action": {"verb": {"text": "identify", "tense": "present"}, "text": "identifies", "normalized": "identify"}}, {"subject": {"text": "The research firm", "keywords": [{"text": "research firm"}]}, "sentence": " The research firm identifies positive and negative news coverage by analyzing more than 6,000 news and blog sources in real-time.", "object": {"text": "more than 6,000 news", "keywords": [{"text": "news"}]}, "action": {"verb": {"text": "analyze", "tense": "present"}, "text": "analyzing", "normalized": "analyze"}}, {"subject": {"text": "The firm", "keywords": [{"text": "firm"}]}, "sentence": " The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable.", "object": {"text": "coverage of public companies", "keywords": [{"text": "public companies"}, {"text": "coverage"}]}, "action": {"verb": {"text": "rank", "tense": "present"}, "text": "ranks", "normalized": "rank"}}, {"subject": {"text": "scores closest to five", "keywords": [{"text": "scores"}]}, "sentence": " The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable.", "object": {"text": "the most favorable"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "being", "normalized": "be"}}, {"subject": {"text": "Takeda Pharmaceutical", "entities": [{"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " Takeda Pharmaceutical earned a news sentiment score of 1.14 on their scale.", "object": {"text": "a news sentiment score of 1.14", "keywords": [{"text": "news sentiment score"}]}, "action": {"verb": {"text": "earn", "tense": "past"}, "text": "earned", "normalized": "earn"}}, {"subject": {"text": "InfoTrie", "keywords": [{"text": "InfoTrie"}]}, "sentence": " InfoTrie also gave news headlines about the company an news buzz score of 10 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock\u2019s share price in the immediate future.", "object": {"text": "that recent news coverage is extremely likely to have an effect on the stock\u2019s share price in the immediate future", "keywords": [{"text": "recent news coverage"}, {"text": "immediate future"}, {"text": "effect"}, {"text": "stock"}]}, "action": {"verb": {"text": "indicate", "tense": "present"}, "text": "indicating", "normalized": "indicate"}}, {"subject": {"text": "recent news coverage", "keywords": [{"text": "recent news coverage"}]}, "sentence": " InfoTrie also gave news headlines about the company an news buzz score of 10 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock\u2019s share price in the immediate future.", "object": {"text": "an effect on the stock\u2019s share price", "keywords": [{"text": "effect"}, {"text": "stock"}, {"text": "price"}]}, "action": {"verb": {"text": "have", "tense": "future"}, "text": "to have", "normalized": "to have"}}, {"subject": {"text": "price", "keywords": [{"text": "price"}]}, "sentence": " InfoTrie also gave news headlines about the company an news buzz score of 10 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock\u2019s share price in the immediate future.", "action": {"verb": {"text": "share", "tense": "present"}, "text": "share", "normalized": "share"}}, {"subject": {"text": "TKPYY", "keywords": [{"text": "TKPYY"}]}, "sentence": " OTCMKTS:TKPYY opened at $18.38 on Friday.", "action": {"verb": {"text": "open", "tense": "past"}, "text": "opened", "normalized": "open"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.12 and a current ratio of 1.42.", "object": {"text": "a debt-to-equity ratio of 0.48", "keywords": [{"text": "debt-to-equity ratio"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda Pharmaceutical", "entities": [{"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " Takeda Pharmaceutical has a one year low of $18.18 and a one year high of $31.29.", "object": {"text": "a one year low of $18.18 and a one year high of $31.29", "entities": [{"type": "Quantity", "text": "one year"}, {"type": "Quantity", "text": "$18.18"}, {"type": "Quantity", "text": "$31.29"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The stock", "keywords": [{"text": "stock"}]}, "sentence": " The stock has a market capitalization of $28.81 billion, a P/E ratio of 13.46 and a beta of 0.44.", "object": {"text": "a market capitalization of $28.81 billion, a P/E ratio of 13.46 and a beta of 0.44", "keywords": [{"text": "market capitalization"}, {"text": "P/E ratio"}, {"text": "beta"}], "entities": [{"type": "Quantity", "text": "$28.81 billion"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}], "concepts": [{"text": "Stock market", "relevance": 0.92712, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "Financial ratio", "relevance": 0.906898, "dbpedia_resource": "http://dbpedia.org/resource/Financial_ratio"}, {"text": "Financial ratios", "relevance": 0.780153, "dbpedia_resource": "http://dbpedia.org/resource/Financial_ratios"}, {"text": "Dot-com bubble", "relevance": 0.697707, "dbpedia_resource": "http://dbpedia.org/resource/Dot-com_bubble"}, {"text": "Stock", "relevance": 0.693959, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Market capitalization", "relevance": 0.684985, "dbpedia_resource": "http://dbpedia.org/resource/Market_capitalization"}, {"text": "Usenet", "relevance": 0.664953, "dbpedia_resource": "http://dbpedia.org/resource/Usenet"}, {"text": "Public company", "relevance": 0.590427, "dbpedia_resource": "http://dbpedia.org/resource/Public_company"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.5607, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "P/E ratio", "relevance": 0.558795, "dbpedia_resource": "http://dbpedia.org/resource/P/E_ratio"}, {"text": "Scores", "relevance": 0.558327, "dbpedia_resource": "http://dbpedia.org/resource/Scores"}], "categories": [{"score": 0.963776, "label": "/business and industrial/business news"}, {"score": 0.95958, "label": "/finance/financial news"}, {"score": 0.954662, "label": "/news/national news"}], "relations": [{"type": "partOf", "sentence": "Media headlines about Takeda Pharmaceutical (OTCMKTS:TKPYY) have trended somewhat positive recently, InfoTrie Sentiment reports.", "score": 0.393455, "arguments": [{"text": "Media", "location": [0, 5], "entities": [{"type": "Organization", "text": "Media"}]}, {"text": "InfoTrie Sentiment", "location": [101, 119], "entities": [{"type": "Organization", "text": "InfoTrie Sentiment", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Media headlines about Takeda Pharmaceutical (OTCMKTS:TKPYY) have trended somewhat positive recently, InfoTrie Sentiment reports.", "score": 0.992826, "arguments": [{"text": "InfoTrie Sentiment", "location": [101, 119], "entities": [{"type": "Organization", "text": "InfoTrie Sentiment", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "reports", "location": [120, 127], "entities": [{"type": "EventCommunication", "text": "reports"}]}]}, {"type": "partOf", "sentence": "The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable.", "score": 0.396736, "arguments": [{"text": "firm", "location": [263, 267], "entities": [{"type": "Organization", "text": "research firm"}]}, {"text": "companies", "location": [293, 302], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Takeda Pharmaceutical earned a news sentiment score of 1.14 on their scale.", "score": 0.756272, "arguments": [{"text": "Takeda Pharmaceutical", "location": [380, 401], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical"}]}, {"text": "earned", "location": [402, 408], "entities": [{"type": "EventEducation", "text": "earned"}]}]}, {"type": "partOfMany", "sentence": "Takeda Pharmaceutical earned a news sentiment score of 1.14 on their scale.", "score": 0.637129, "arguments": [{"text": "Takeda Pharmaceutical", "location": [380, 401], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical"}]}, {"text": "their", "location": [443, 448], "entities": [{"type": "Person", "text": "their"}]}]}], "keywords": [{"text": "negative news coverage", "sentiment": {"score": -0.669096, "label": "negative"}, "relevance": 0.860832, "count": 1}, {"text": "Media headlines", "sentiment": {"score": 0.831632, "label": "positive"}, "relevance": 0.846637, "count": 1}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": -0.302375, "mixed": "1", "label": "negative"}, "relevance": 0.817416, "count": 3}, {"text": "research firm", "sentiment": {"score": -0.669096, "label": "negative"}, "relevance": 0.813339, "count": 1}, {"text": "news headlines", "sentiment": {"score": -0.435828, "label": "negative"}, "relevance": 0.726401, "count": 1}, {"text": "InfoTrie Sentiment reports", "sentiment": {"score": 0.831632, "label": "positive"}, "relevance": 0.688622, "count": 1}, {"text": "coverage of public companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.629545, "count": 1}, {"text": "market capitalization", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.594695, "count": 1}, {"text": "news", "sentiment": {"score": -0.669096, "label": "negative"}, "relevance": 0.551744, "count": 1}, {"text": "immediate future", "sentiment": {"score": -0.435828, "label": "negative"}, "relevance": 0.54941, "count": 1}, {"text": "real-time", "sentiment": {"score": -0.669096, "label": "negative"}, "relevance": 0.54941, "count": 1}, {"text": "news sentiment score", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.549085, "count": 1}, {"text": "year high", "sentiment": {"score": -0.809625, "label": "negative"}, "relevance": 0.544192, "count": 1}, {"text": "recent news coverage", "sentiment": {"score": -0.435828, "label": "negative"}, "relevance": 0.53914, "count": 1}, {"text": "firm", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531461, "count": 1}, {"text": "scores", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530361, "count": 1}, {"text": "stock\u2019s share price", "sentiment": {"score": -0.435828, "label": "negative"}, "relevance": 0.530179, "count": 1}, {"text": "news buzz score", "sentiment": {"score": -0.435828, "label": "negative"}, "relevance": 0.523819, "count": 1}, {"text": "company", "sentiment": {"score": -0.435828, "label": "negative"}, "relevance": 0.522394, "count": 2}, {"text": "effect", "sentiment": {"score": -0.435828, "label": "negative"}, "relevance": 0.518907, "count": 1}, {"text": "stock", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515576, "count": 1}, {"text": "debt", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513145, "count": 1}, {"text": "scale", "sentiment": {"score": -0.435828, "label": "negative"}, "relevance": 0.511425, "count": 2}, {"text": "beta", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.506308, "count": 1}, {"text": "equity ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.452909, "count": 1}, {"text": "year low", "sentiment": {"score": -0.809625, "label": "negative"}, "relevance": 0.435831, "count": 1}, {"text": "blog sources", "sentiment": {"score": -0.669096, "label": "negative"}, "relevance": 0.431515, "count": 1}, {"text": "quick ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.41924, "count": 1}, {"text": "E ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.405608, "count": 1}, {"text": "current ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.402976, "count": 1}, {"text": "OTCMKTS", "sentiment": {"score": 0.831632, "label": "positive"}, "relevance": 0.402345, "count": 2}, {"text": "InfoTrie", "sentiment": {"score": -0.435828, "label": "negative"}, "relevance": 0.393293, "count": 1}, {"text": "Friday", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.367733, "count": 1}]}, "extracted_metadata": {"sha1": "cae2fd35bce56c7f0e374398ff0080b6a53b84a4", "filename": "1543578165991.zip-54e6be198bad5b27ee78d80b6bd4b923.xml", "file_type": "json"}, "external_links": ["https://www.marketbeat.com/stocks/OTCMKTS/TKPYY/news/"], "title": "Takeda Pharmaceutical (TKPYY) Receives Daily News Impact Score of 1.14", "forum_title": "FY2018 EPS Estimates for Ferroglobe PLC (GSM) Reduced by Analyst - American Banking News"}, {"id": "ZHCpS18J_0kkrUbs9nDq5ZpSSgl3NbYbqdJ3JBBP_20tuh0eEMImVsH0EWzH1tdf", "result_metadata": {"score": 33.567795}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0.328886, "label": "positive"}, "text": "Barclays", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.916818, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "TAKEDA PHARMACEUTICAL CO LTD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.962751, "count": 1}, {"text": "Barclays", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.899735, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.775396, "count": 1}]}, "crawl_date": "2018-11-30T13:32:12Z", "url": "http://www.4-traders.com/BARCLAYS-9583556/news/Barclays-Form-8-3-TAKEDA-PHARMACEUTICAL-CO-LTD-27687642/", "host": "4-traders.com", "text": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC. are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-30T00:00:00+01:00", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ADR Purchase", "relevance": 0.816696, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.756887, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.667459, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.621544, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.535082, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.516667, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Class of Product Nature", "relevance": 0.5138, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.46599, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.426983, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.411284, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,374,000 1.31%", "relevance": 0.411284, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,521,600 1.32%", "relevance": 0.411284, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,941,600 1.38%", "relevance": 0.411284, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,197,841 1.41%", "relevance": 0.411284, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "13,158,986 1.66%", "relevance": 0.411284, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "13,337,016 1.68%", "relevance": 0.411284, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "34,652,616 4.36%", "relevance": 0.411284, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "34,878,427 4.39%", "relevance": 0.411284, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.411284, "type": "Quantity"}], "sentiment": {"document": {"score": 0.602698, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "relevant securities this form", "keywords": [{"text": "relevant securities"}, {"text": "form"}]}, "sentence": " relevant securities this form relates: (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: 29 November 2018 (f) In addition to the company in 1(c) above, is the discloser making YES: disclosures in respect of any other party to the offer?", "object": {"text": "an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: 29 November 2018 (f) In addition to the company in 1(c) above, is the discloser making YES: disclosures in respect of any other party to the offer", "keywords": [{"text": "exempt fund manager"}, {"text": "Date position"}, {"text": "discloser making"}, {"text": "disclosures"}], "entities": [{"type": "JobTitle", "text": "fund manager"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "an exempt fund manager", "keywords": [{"text": "exempt fund manager"}], "entities": [{"type": "JobTitle", "text": "fund manager"}]}, "sentence": " relevant securities this form relates: (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: 29 November 2018 (f) In addition to the company in 1(c) above, is the discloser making YES: disclosures in respect of any other party to the offer?", "object": {"text": "identity of offeror/offeree", "keywords": [{"text": "identity"}, {"text": "offeror/offeree"}]}, "action": {"verb": {"text": "specify", "tense": "present"}, "text": "specify", "normalized": "specify"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% TOTAL: 34,878,427 4.39% 34,652,616 4.36% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "agreements"}, {"text": "options"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "10,521,600 1.32"}, {"type": "Quantity", "text": "10,941,600 1.38"}, {"type": "Quantity", "text": "34,652,616 4.36"}, {"type": "Quantity", "text": "34,878,427 4.39"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,197,841 1.41% 13,337,016 1.68% (2) Cash-settled derivatives: 13,158,986 1.66% 10,374,000 1.31% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% TOTAL: 34,878,427 4.39% 34,652,616 4.36% All interests and all short positions should be disclosed.", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "34,878,427 4.39% 34,652,616 4.36% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "34,652,616 4.36"}, {"type": "Quantity", "text": "34,878,427 4.39"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,197,841 1.41% 13,337,016 1.68% (2) Cash-settled derivatives: 13,158,986 1.66% 10,374,000 1.31% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% TOTAL: 34,878,427 4.39% 34,652,616 4.36% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors' and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors' and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 30 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "disclosure requirements"}, {"text": "relation"}, {"text": "consultation"}, {"text": "Code"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "disclosure requirements"}, {"text": "relation"}, {"text": "consultation"}, {"text": "Code"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "Barclays plc", "keywords": [{"text": "Barclays plc"}], "entities": [{"type": "Company", "text": "BARCLAYS PLC", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}]}, "sentence": " Barclays plc published this content on 30 November 2018 and is solely responsible for the information contained herein.", "object": {"text": "this content", "keywords": [{"text": "content"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "by Public", "keywords": [{"text": "Public"}]}, "sentence": " Distributed by Public, unedited and unaltered, on 30 November 2018 13:16:05 UTC", "object": {"text": "05 UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "Distributed", "tense": "past"}, "text": "Distributed", "normalized": "Distributed"}}], "concepts": [{"text": "Option", "relevance": 0.965085, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.753108, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.687437, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.600467, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.537508, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option style", "relevance": 0.417244, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Options", "relevance": 0.380531, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Moneyness", "relevance": 0.375794, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "United States dollar", "relevance": 0.345174, "dbpedia_resource": "http://dbpedia.org/resource/United_States_dollar"}, {"text": "Security", "relevance": 0.34415, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Barclays", "relevance": 0.326659, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "Derivative", "relevance": 0.325793, "dbpedia_resource": "http://dbpedia.org/resource/Derivative_(finance)"}, {"text": "Contract", "relevance": 0.322126, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Bond", "relevance": 0.320151, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "December", "relevance": 0.319465, "dbpedia_resource": "http://dbpedia.org/resource/December"}, {"text": "Japanese yen", "relevance": 0.312438, "dbpedia_resource": "http://dbpedia.org/resource/Japanese_yen"}], "categories": [{"score": 0.856959, "label": "/real estate/buying and selling homes"}, {"score": 0.803094, "label": "/finance/financial news"}, {"score": 0.78625, "label": "/finance/investing"}], "relations": [{"type": "agentOf", "sentence": "settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV SWAP Long 300 4,172.5827 JPY Ordinary NPV SWAP Long 300 4,181.4279 JPY Ordinary NPV SWAP Long 800 4,180.6273 JPY Ordinary NPV SWAP Long 3,100 4,174.6347 JPY Ordinary NPV CFD Long 5,400 4,207.5792 JPY Ordinary NPV SWAP Long 8,400 4,160.0000 JPY Ordinary NPV SWAP Short 400 4,174.5000 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product description e.g. call option Exercising/", "score": 0.726237, "arguments": [{"text": "i", "location": [5907, 5908], "entities": [{"type": "Person", "text": "JPY Ordinary NPV CFD"}]}, {"text": "Writing", "location": [5910, 5917], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4.", "score": 0.582263, "arguments": [{"text": "Price", "location": [6507, 6512], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [6517, 6521], "entities": [{"type": "Organization", "text": "unit"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [6881, 6887], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [6898, 6905], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 30 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [7807, 7813], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [7821, 7825], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the 'Code') 1.", "score": 0.846433, "arguments": [{"text": "Rule 8", "location": [8253, 8259], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [8267, 8280], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [7888, 7912], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [7880, 7885], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [10399, 10423], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [10391, 10396], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [8047, 8052], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [8066, 8093], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [10558, 10563], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [10577, 10604], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC.", "score": 0.419441, "arguments": [{"text": "person", "location": [8329, 8335], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [8361, 8373], "entities": [{"type": "Organization", "text": "BARCLAYS PLC\nAttachments\nOriginal", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "View source version on businesswire.com: https://www.businesswire.com/news/home/20181130005206/en/ BARCLAYS PLC Source: BARCLAYS PLC Attachments Original document Permalink Disclaimer Barclays plc published this content on 30 November 2018 and is solely responsible for the information contained herein.", "score": 0.990154, "arguments": [{"text": "Permalink Disclaimer\nBarclays plc", "location": [10770, 10803], "entities": [{"type": "Organization", "text": "BARCLAYS PLC\nAttachments\nOriginal", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "published", "location": [10804, 10813], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "timeOf", "sentence": "View source version on businesswire.com: https://www.businesswire.com/news/home/20181130005206/en/ BARCLAYS PLC Source: BARCLAYS PLC Attachments Original document Permalink Disclaimer Barclays plc published this content on 30 November 2018 and is solely responsible for the information contained herein.", "score": 0.648658, "arguments": [{"text": "November 2018", "location": [10833, 10846], "entities": [{"type": "Date", "text": "November 2018"}]}, {"text": "published", "location": [10804, 10813], "entities": [{"type": "EventCommunication", "text": "published"}]}]}], "keywords": [{"text": "RELEVANT SECURITIES", "sentiment": {"score": -0.542023, "label": "negative"}, "relevance": 0.750407, "count": 6}, {"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": -0.542023, "label": "negative"}, "relevance": 0.653513, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.634025, "count": 2}, {"text": "unit security securities ADR Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.610005, "count": 1}, {"text": "JPY Ordinary NPV Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.607834, "count": 10}, {"text": "USD Ordinary NPV Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.601036, "count": 1}, {"text": "USD ADR Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.591021, "count": 7}, {"text": "Takeover Code", "sentiment": {"score": 0.397026, "mixed": "1", "label": "positive"}, "relevance": 0.587554, "count": 2}, {"text": "Details of any open stock", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.582608, "count": 1}, {"text": "additional class of relevant security", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.575164, "count": 2}, {"text": "Name of offeror", "sentiment": {"score": 0.598359, "label": "positive"}, "relevance": 0.574242, "count": 2}, {"text": "relevant Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.568229, "count": 1}, {"text": "Full name of discloser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.567917, "count": 1}, {"text": "short positions", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.563235, "count": 3}, {"text": "Date position", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.550606, "count": 1}, {"text": "sale Number of Price", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.546283, "count": 1}, {"text": "Panel's Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.546177, "count": 2}, {"text": "View source version", "sentiment": {"score": -0.481928, "label": "negative"}, "relevance": 0.540592, "count": 1}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": -0.542023, "label": "negative"}, "relevance": 0.53961, "count": 1}, {"text": "Purchases", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.539141, "count": 1}, {"text": "currency of all prices", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.53737, "count": 2}, {"text": "Class of relevant security", "sentiment": {"score": 0.763796, "label": "positive"}, "relevance": 0.536409, "count": 2}, {"text": "relevant securities of the offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533304, "count": 1}, {"text": "Ordinary NPV Call Options", "sentiment": {"score": 0.839232, "label": "positive"}, "relevance": 0.532221, "count": 8}, {"text": "Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530215, "count": 1}, {"text": "copy table", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.529133, "count": 2}, {"text": "nature of the rights", "sentiment": {"score": 0.763796, "label": "positive"}, "relevance": 0.529111, "count": 1}, {"text": "options", "sentiment": {"score": 0.769049, "label": "positive"}, "relevance": 0.528465, "count": 5}, {"text": "Class of Product Nature", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.525564, "count": 1}, {"text": "POSITIONS OF THE PERSON", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.524705, "count": 1}, {"text": "voting rights", "sentiment": {"score": 0.770001, "label": "positive"}, "relevance": 0.522978, "count": 1}, {"text": "Expiry date Option money", "sentiment": {"score": 0.568074, "label": "positive"}, "relevance": 0.522425, "count": 1}, {"text": "employee options", "sentiment": {"score": 0.763796, "label": "positive"}, "relevance": 0.517316, "count": 1}, {"text": "INTERESTS", "sentiment": {"score": -0.542023, "label": "negative"}, "relevance": 0.516828, "count": 3}, {"text": "Ordinary NPV Interests Short Positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516644, "count": 1}, {"text": "PERSON", "sentiment": {"score": 0.34423, "mixed": "1", "label": "positive"}, "relevance": 0.5164, "count": 7}, {"text": "controller of interest", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.515949, "count": 1}, {"text": "Supplemental Form", "sentiment": {"score": 0.708155, "label": "positive"}, "relevance": 0.515327, "count": 4}, {"text": "agreements", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.514843, "count": 5}, {"text": "identity of offeror", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.514734, "count": 1}, {"text": "option arrangement", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.513871, "count": 1}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.513137, "count": 2}, {"text": "voting rights of any relevant securities", "sentiment": {"score": 0.770001, "label": "positive"}, "relevance": 0.512918, "count": 1}, {"text": "Code", "sentiment": {"score": -0.429178, "mixed": "1", "label": "negative"}, "relevance": 0.5117, "count": 5}, {"text": "relation", "sentiment": {"score": 0.659149, "label": "positive"}, "relevance": 0.51089, "count": 5}, {"text": "Details", "sentiment": {"score": 0.763796, "label": "positive"}, "relevance": 0.510571, "count": 2}, {"text": "Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510083, "count": 1}, {"text": "FORM", "sentiment": {"score": -0.542023, "label": "negative"}, "relevance": 0.509503, "count": 2}, {"text": "derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509311, "count": 4}, {"text": "Rule", "sentiment": {"score": -0.881961, "label": "negative"}, "relevance": 0.509232, "count": 2}]}, "extracted_metadata": {"sha1": "a41d45b3d4ee70fda22b631302065687563d6aa0", "filename": "1543584732774.zip-11bdd826557656507fafc86661974b90.xml", "file_type": "json"}, "external_links": ["http://otp.investis.com/clients/uk/barclays1/rns/regulatory-story.aspx?cid=68&newsid=1213350", "https://www.businesswire.com/news/home/20181130005206/en/", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.thetakeoverpanel.org.uk&esheet=51906713&newsitemid=20181130005206&lan=en-US&anchor=www.thetakeoverpanel.org.uk&index=1&md5=7bc3e38e1aaa87792f9173f98d5cc818", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.thetakeoverpanel.org.uk&esheet=51906713&newsitemid=20181130005206&lan=en-US&anchor=www.thetakeoverpanel.org.uk&index=2&md5=46fb72edd4b1b09ef71865c25c41f2ad", "http://www.publicnow.com/view/F2A4F798FE29FF779F7BF3C59C86889A17A246C3"], "title": "Barclays : Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD", "forum_title": "Markets : News, Companies, Press Releases - Marketscreener.com"}, {"id": "cpKSAzPS-c5VpC7zuZ_roXtufqrepYDF4vaS1lnQemVV8CbKEiiaVO1qVI0TKXJ_", "result_metadata": {"score": 32.87224}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Barclays", "relevance": 0.972986, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "United Kingdom", "relevance": 0.700474, "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.5607, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.904926, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "PLC UK Regulatory Announcement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.968946, "count": 1}, {"text": "FORM", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.618372, "count": 1}, {"text": "TAKEDA PHARMACEUTICAL CO LTD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.40095, "count": 1}]}, "crawl_date": "2018-11-29T15:07:41Z", "url": "https://www.businesswire.com/news/home/20181129005361/en/BARCLAYS-PLC-UK-Regulatory-Announcement-FORM-8.3", "host": "businesswire.com", "text": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC. are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "main_image_url": "http://www.businesswire.com/images/bwlogo_square.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-29T12:41:00-06:00", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.745411, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.712121, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.577726, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Class of Product Nature", "relevance": 0.574071, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS", "relevance": 0.552449, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.542936, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Contacts BARCLAYS PLC", "relevance": 0.528079, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.512936, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.470329, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.453349, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,374,000 1.31%", "relevance": 0.453349, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,521,600 1.32%", "relevance": 0.453349, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,941,600 1.38%", "relevance": 0.453349, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,174,574 1.41%", "relevance": 0.453349, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "13,141,086 1.65%", "relevance": 0.453349, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "13,861,235 1.74%", "relevance": 0.453349, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "34,837,260 4.38%", "relevance": 0.453349, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "35,176,835 4.43%", "relevance": 0.453349, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.453349, "type": "Quantity"}], "sentiment": {"document": {"score": 0.648912, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 34,837,260 4.38% 35,176,835 4.43% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "agreements"}, {"text": "options"}, {"text": "TOTAL"}], "entities": [{"type": "Quantity", "text": "10,521,600 1.32"}, {"type": "Quantity", "text": "10,941,600 1.38"}, {"type": "Quantity", "text": "34,837,260 4.38"}, {"type": "Quantity", "text": "35,176,835 4.43"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,174,574 1.41% 13,861,235 1.74% (2) Cash-settled derivatives: 13,141,086 1.65% 10,374,000 1.31% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 34,837,260 4.38% 35,176,835 4.43% All interests and all short positions should be disclosed.", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "34,837,260 4.38% 35,176,835 4.43% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "34,837,260 4.38"}, {"type": "Quantity", "text": "35,176,835 4.43"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,174,574 1.41% 13,861,235 1.74% (2) Cash-settled derivatives: 13,141,086 1.65% 10,374,000 1.31% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 34,837,260 4.38% 35,176,835 4.43% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 29 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Receipt", "keywords": [{"text": "Receipt"}]}, "sentence": " Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 660187 Time of Receipt (offset from UTC): 20181129T115940+0000 Contacts BARCLAYS PLC", "object": {"text": "from UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "offset", "normalized": "offset"}}], "concepts": [{"text": "Option", "relevance": 0.982282, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.74156, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.703979, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.629468, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.5101, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option style", "relevance": 0.412905, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Options", "relevance": 0.412697, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Moneyness", "relevance": 0.380338, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Security", "relevance": 0.351604, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "United States dollar", "relevance": 0.332242, "dbpedia_resource": "http://dbpedia.org/resource/United_States_dollar"}, {"text": "Contract", "relevance": 0.332175, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Bond", "relevance": 0.328281, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "December", "relevance": 0.318017, "dbpedia_resource": "http://dbpedia.org/resource/December"}, {"text": "Unit type", "relevance": 0.305428, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Barclays", "relevance": 0.297954, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}], "categories": [{"score": 0.860183, "label": "/real estate/buying and selling homes"}, {"score": 0.799821, "label": "/finance/financial news"}, {"score": 0.792193, "label": "/finance/investing"}], "relations": [{"type": "populationOf", "sentence": "LONDON- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \"Code\") 1.", "score": 0.465196, "arguments": [{"text": "8.3", "location": [13, 16], "entities": [{"type": "Cardinal", "text": "8.3"}]}, {"text": "LONDON", "location": [0, 6], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}]}, {"type": "basedIn", "sentence": "Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 660187 Time of Receipt (offset from UTC): 20181129T115940+0000 Contacts BARCLAYS PLC", "score": 0.626381, "arguments": [{"text": "UTC", "location": [10019, 10022], "entities": [{"type": "Organization", "text": "UTC"}]}, {"text": "Receipt", "location": [9998, 10005], "entities": [{"type": "GeopoliticalEntity", "text": "Receipt"}]}]}, {"type": "employedBy", "sentence": "JPY Ordinary NPV Sale 15,300 4,212.0980 JPY Ordinary NPV Sale 15,600 4,163.7371 JPY Ordinary NPV Sale 29,000 4,181.6000 JPY Ordinary NPV Sale 33,400 4,241.2274 JPY Ordinary NPV Sale 44,300 4,204.0993 JPY Ordinary NPV Sale 66,200 4,192.7522 JPY Ordinary NPV Sale 122,700 4,194.8842 JPY Ordinary NPV Sale 659,800 4,198.8252 JPY Ordinary NPV Sale 696,000 4,197.5274 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV SWAP Long 33,400 4,241.2274 JPY Ordinary NPV SWAP Short 400 4,207.0000 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American,", "score": 0.500498, "arguments": [{"text": "Cash", "location": [4923, 4927], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Product Nature", "location": [4969, 4983], "entities": [{"type": "Organization", "text": "Product Nature", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "JPY Ordinary NPV Sale 15,300 4,212.0980 JPY Ordinary NPV Sale 15,600 4,163.7371 JPY Ordinary NPV Sale 29,000 4,181.6000 JPY Ordinary NPV Sale 33,400 4,241.2274 JPY Ordinary NPV Sale 44,300 4,204.0993 JPY Ordinary NPV Sale 66,200 4,192.7522 JPY Ordinary NPV Sale 122,700 4,194.8842 JPY Ordinary NPV Sale 659,800 4,198.8252 JPY Ordinary NPV Sale 696,000 4,197.5274 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV SWAP Long 33,400 4,241.2274 JPY Ordinary NPV SWAP Short 400 4,207.0000 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American,", "score": 0.657678, "arguments": [{"text": "i", "location": [5222, 5223], "entities": [{"type": "Person", "text": "JPY Ordinary NPV Purchase"}]}, {"text": "Writing", "location": [5225, 5232], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4.", "score": 0.582263, "arguments": [{"text": "Price", "location": [5822, 5827], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [5832, 5836], "entities": [{"type": "Organization", "text": "Type e.g. American"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [6196, 6202], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [6213, 6220], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 29 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [7122, 7128], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [7136, 7140], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the \"Code\") 1.", "score": 0.522588, "arguments": [{"text": "Rule 8", "location": [7568, 7574], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [7582, 7595], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [7203, 7227], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [7195, 7200], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [9714, 9738], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [9706, 9711], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [7362, 7367], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [7381, 7408], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [9873, 9878], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [9892, 9919], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC.", "score": 0.419441, "arguments": [{"text": "person", "location": [7644, 7650], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [7676, 7688], "entities": [{"type": "Organization", "text": "BARCLAYS PLC Category Code", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "RELEVANT SECURITIES", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.762653, "count": 6}, {"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.652816, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.639173, "count": 2}, {"text": "JPY Ordinary NPV Purchase", "sentiment": {"score": 0.968095, "label": "positive"}, "relevance": 0.599716, "count": 13}, {"text": "USD Ordinary NPV Purchase", "sentiment": {"score": 0.968095, "label": "positive"}, "relevance": 0.598506, "count": 1}, {"text": "unit security securities ADR Purchase", "sentiment": {"score": 0.968095, "label": "positive"}, "relevance": 0.592516, "count": 1}, {"text": "Name of offeror", "sentiment": {"score": 0.598359, "label": "positive"}, "relevance": 0.584648, "count": 2}, {"text": "Details of any open stock", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.584424, "count": 1}, {"text": "Takeover Code", "sentiment": {"score": 0.584183, "label": "positive"}, "relevance": 0.580862, "count": 2}, {"text": "Full name of discloser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.580427, "count": 1}, {"text": "additional class of relevant security", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.578407, "count": 2}, {"text": "short positions", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.574055, "count": 3}, {"text": "relevant Purchase", "sentiment": {"score": 0.968095, "label": "positive"}, "relevance": 0.56611, "count": 1}, {"text": "USD ADR Purchase", "sentiment": {"score": 0.968095, "label": "positive"}, "relevance": 0.564459, "count": 4}, {"text": "Date position", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.549291, "count": 1}, {"text": "Panel\u2019s Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.545804, "count": 2}, {"text": "sale Number of Price", "sentiment": {"score": 0.968095, "label": "positive"}, "relevance": 0.542492, "count": 1}, {"text": "Purchases", "sentiment": {"score": 0.968095, "label": "positive"}, "relevance": 0.538774, "count": 1}, {"text": "Class of relevant security", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.538117, "count": 2}, {"text": "currency of all prices", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.53739, "count": 2}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.53662, "count": 1}, {"text": "relevant securities of the offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535929, "count": 1}, {"text": "Ordinary NPV Call Options", "sentiment": {"score": 0.839232, "label": "positive"}, "relevance": 0.533647, "count": 8}, {"text": "Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529903, "count": 1}, {"text": "options", "sentiment": {"score": 0.77123, "label": "positive"}, "relevance": 0.529571, "count": 5}, {"text": "copy table", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.529484, "count": 2}, {"text": "nature of the rights", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.529397, "count": 1}, {"text": "Sequence Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525961, "count": 1}, {"text": "Class of Product Nature", "sentiment": {"score": 0.968095, "label": "positive"}, "relevance": 0.525659, "count": 1}, {"text": "POSITIONS OF THE PERSON", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.524853, "count": 1}, {"text": "voting rights", "sentiment": {"score": 0.770001, "label": "positive"}, "relevance": 0.523601, "count": 1}, {"text": "Expiry date Option money", "sentiment": {"score": 0.568074, "label": "positive"}, "relevance": 0.521048, "count": 1}, {"text": "TAKEDA PHARMACEUTICAL CO LTD", "sentiment": {"score": 0.598359, "label": "positive"}, "relevance": 0.520797, "count": 2}, {"text": "INTERESTS", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.517896, "count": 3}, {"text": "employee options", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.517809, "count": 1}, {"text": "controller of interest", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.517718, "count": 1}, {"text": "PERSON", "sentiment": {"score": 0.54238, "label": "positive"}, "relevance": 0.516532, "count": 7}, {"text": "identity of offeror", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.515748, "count": 1}, {"text": "Ordinary NPV Interests Short Positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515679, "count": 1}, {"text": "agreements", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.515258, "count": 5}, {"text": "Supplemental Form", "sentiment": {"score": 0.708155, "label": "positive"}, "relevance": 0.514158, "count": 4}, {"text": "option arrangement", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.513612, "count": 1}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.513502, "count": 2}, {"text": "voting rights of any relevant securities", "sentiment": {"score": 0.770001, "label": "positive"}, "relevance": 0.512862, "count": 1}, {"text": "Contact name", "sentiment": {"score": -0.881961, "label": "negative"}, "relevance": 0.512806, "count": 1}, {"text": "relation", "sentiment": {"score": 0.664279, "label": "positive"}, "relevance": 0.512416, "count": 5}, {"text": "Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.511701, "count": 1}, {"text": "Code", "sentiment": {"score": -0.29311, "mixed": "1", "label": "negative"}, "relevance": 0.511191, "count": 5}, {"text": "Details", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.51085, "count": 2}, {"text": "FORM", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.509953, "count": 2}]}, "extracted_metadata": {"sha1": "24435e30821bc6fc1ba531a6293229293ea03015", "filename": "1543504061902.zip-d682a8abd2f1cf51a562fbccdc0a6f9a.xml", "file_type": "json"}, "title": "BARCLAYS PLC UK Regulatory Announcement: FORM 8.3 - TAKEDA PHARMACEUTICAL CO LTD", "forum_title": "All News | Business Wire"}, {"id": "HIsddD2fMJagFGvjcucC4pRn2MWuzPI8uteDL_MwTqZ-SNbTtQpWEPG6oN56YBk9", "result_metadata": {"score": 32.29287}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management UK", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.92115, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.607673, "label": "/finance/investing/brokerages"}, {"score": 0.605701, "label": "/finance/investing/funds/mutual funds"}, {"score": 0.597169, "label": "/finance/bank"}], "relations": [{"type": "agentOf", "sentence": "Daiwa Asset Management UK Regulatory Announcement: Form 8.3 - Takeda Pharmaceutical Company Limited", "score": 0.991221, "arguments": [{"text": "Daiwa Asset Management UK Regulatory", "location": [0, 36], "entities": [{"type": "Organization", "text": "Daiwa Asset Management UK Regulatory", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Announcement", "location": [37, 49], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}], "keywords": [{"text": "Takeda Pharmaceutical Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.752509, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.603694, "count": 1}, {"text": "Daiwa Asset Management UK Regulatory Announcement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518959, "count": 1}]}, "crawl_date": "2018-11-30T12:44:49Z", "url": "https://www.businesswire.com/news/home/20181129005898/en/Daiwa-Asset-Management-UK-Regulatory-Announcement-Form", "host": "businesswire.com", "text": "Ltd.", "main_image_url": "http://www.businesswire.com/images/bwlogo_square.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-30T07:00:00-06:00", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management Co. Ltd", "relevance": 0.727875, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management", "relevance": 0.640588, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management Europe", "relevance": 0.621952, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.567394, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.546175, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.250646, "label": "positive"}, "text": "Erich Berner", "relevance": 0.529542, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.501728, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.497938, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.490609, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.490609, "type": "Quantity"}], "sentiment": {"document": {"score": 0.459796, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree", "object": {"text": "for each offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "29 November 2018 (f) In addition to the company in 1(c) above,", "keywords": [{"text": "addition"}, {"text": "company"}]}, "sentence": " 29 November 2018 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "object": {"text": "the discloser making disclosures", "keywords": [{"text": "disclosures"}, {"text": "discloser"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \u201cN/A\u201d", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}]}, "sentence": " All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Details, including nature of the rights concerned and relevant percentages: N/A", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "increasing/reducing a long/short position", "keywords": [{"text": "long/short position"}]}, "sentence": " Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position", "object": {"text": "e.g. opening/closing a long/short position", "keywords": [{"text": "long/short position"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit - - - - - - - - (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit - - - - - (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " None (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020-7597-7056 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "020-7597-7056 Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " Telephone number*: 020-7597-7056 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "*If the discloser", "keywords": [{"text": "discloser"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "a natural person", "keywords": [{"text": "natural person"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a natural person, a telephone number", "keywords": [{"text": "natural person"}, {"text": "telephone number"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "contact information", "keywords": [{"text": "contact information"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "provided", "normalized": "provide"}}, {"subject": {"text": "contact information", "keywords": [{"text": "contact information"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "provided to the Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "provided contact information", "keywords": [{"text": "contact information"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "to the Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "has been provided", "normalized": "have be provide"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Receipt", "keywords": [{"text": "Receipt"}]}, "sentence": " Short Name: Daiwa Asset Management Category Code: RET Sequence Number: 660234 Time of Receipt (offset from UTC): 20181130T045231+0000 Contacts Daiwa Asset Management", "object": {"text": "from UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "offset", "normalized": "offset"}}], "concepts": [{"text": "Option", "relevance": 0.98344, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Offer and acceptance", "relevance": 0.519167, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Call option", "relevance": 0.518583, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.500842, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Contract", "relevance": 0.463321, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Put option", "relevance": 0.420894, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Grammatical number", "relevance": 0.412338, "dbpedia_resource": "http://dbpedia.org/resource/Grammatical_number"}, {"text": "Bond", "relevance": 0.405102, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Unit type", "relevance": 0.389998, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Option contract", "relevance": 0.3856, "dbpedia_resource": "http://dbpedia.org/resource/Option_contract"}, {"text": "Balance sheet", "relevance": 0.382676, "dbpedia_resource": "http://dbpedia.org/resource/Balance_sheet"}, {"text": "Security", "relevance": 0.379969, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Stock", "relevance": 0.373602, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.359176, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Uniform Commercial Code", "relevance": 0.357158, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Legal person", "relevance": 0.355294, "dbpedia_resource": "http://dbpedia.org/resource/Legal_person"}], "categories": [{"score": 0.924431, "label": "/real estate/buying and selling homes"}, {"score": 0.83407, "label": "/finance/financial news"}, {"score": 0.701463, "label": "/finance/investing/day trading"}], "relations": [{"type": "managerOf", "sentence": "N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Company Limited (the Offeror) (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure 29 November 2018 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "score": 0.463222, "arguments": [{"text": "manager", "location": [718, 725], "entities": [{"type": "Person", "text": "manager"}]}, {"text": "Takeda Pharmaceutical Company Limited", "location": [644, 681], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "(a) Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit ORD Sale 4,800 4236 JPY ORD Sale 16,100 4236 JPY ORD Purchase 200 4169.98 JPY ORD Purchase 22,000 4236 JPY ORD Sale 5,800 4236 JPY (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit - - - - - (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American,", "score": 0.787954, "arguments": [{"text": "i", "location": [3340, 3341], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Writing", "location": [3343, 3350], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "European etc. Expiry date Option money paid/ received per unit - - - - - - - - (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit - - - - - (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) - - - - 4.", "score": 0.591687, "arguments": [{"text": "Price", "location": [3966, 3971], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [3976, 3980], "entities": [{"type": "Organization", "text": "ORD Sale"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [4348, 4354], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [4365, 4372], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 30 November 2018 Contact name: Erich Berner (Daiwa Asset Management Europe) Telephone number*: 020-7597-7056 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.545365, "arguments": [{"text": "Erich Berner", "location": [5184, 5196], "entities": [{"type": "Person", "text": "Erich Berner"}]}, {"text": "Daiwa Asset Management Europe", "location": [5198, 5227], "entities": [{"type": "Organization", "text": "Daiwa Asset Management Europe", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 30 November 2018 Contact name: Erich Berner (Daiwa Asset Management Europe) Telephone number*: 020-7597-7056 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.842228, "arguments": [{"text": "Rule 8", "location": [5287, 5293], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [5301, 5305], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [5368, 5392], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5360, 5365], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.", "score": 0.83842, "arguments": [{"text": "Market Surveillance Unit", "location": [5647, 5671], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5639, 5644], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [5703, 5708], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [5722, 5749], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "basedIn", "sentence": "Short Name: Daiwa Asset Management Category Code: RET Sequence Number: 660234 Time of Receipt (offset from UTC): 20181130T045231+0000 Contacts Daiwa Asset Management", "score": 0.434823, "arguments": [{"text": "UTC", "location": [5859, 5862], "entities": [{"type": "Organization", "text": "UTC"}]}, {"text": "Receipt", "location": [5838, 5845], "entities": [{"type": "GeopoliticalEntity", "text": "Receipt"}]}]}], "keywords": [{"text": "RELEVANT SECURITIES", "sentiment": {"score": 0.38069, "label": "positive"}, "relevance": 0.757472, "count": 5}, {"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": 0.38069, "label": "positive"}, "relevance": 0.688628, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.626969, "count": 2}, {"text": "Full name of discloser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.61283, "count": 1}, {"text": "Short positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.610742, "count": 1}, {"text": "short positions", "sentiment": {"score": -0.798933, "label": "negative"}, "relevance": 0.584916, "count": 3}, {"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.581231, "count": 1}, {"text": "additional class of relevant security", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.572593, "count": 2}, {"text": "Details of any open stock", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.571586, "count": 1}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.568239, "count": 1}, {"text": "unit ORD Sale", "sentiment": {"score": 0.698751, "label": "positive"}, "relevance": 0.56293, "count": 1}, {"text": "Telephone number", "sentiment": {"score": -0.908997, "label": "negative"}, "relevance": 0.5629, "count": 2}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": 0.38069, "label": "positive"}, "relevance": 0.562464, "count": 1}, {"text": "sale Number of securities Price", "sentiment": {"score": 0.698751, "label": "positive"}, "relevance": 0.546813, "count": 1}, {"text": "Takeover Code", "sentiment": {"score": 0.38069, "label": "positive"}, "relevance": 0.545473, "count": 1}, {"text": "POSITIONS OF THE PERSON", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.544361, "count": 1}, {"text": "natural person", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.543854, "count": 1}, {"text": "JPY ORD Sale", "sentiment": {"score": 0.698751, "label": "positive"}, "relevance": 0.538439, "count": 2}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.534081, "count": 1}, {"text": "Sequence Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533905, "count": 1}, {"text": "currency of all prices", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532878, "count": 1}, {"text": "Class of relevant security", "sentiment": {"score": 0.704735, "label": "positive"}, "relevance": 0.532523, "count": 2}, {"text": "copy table", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.531188, "count": 2}, {"text": "relevant securities of the offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530889, "count": 1}, {"text": "Daiwa Asset Management Co. Ltd", "sentiment": {"score": -0.798933, "label": "negative"}, "relevance": 0.530213, "count": 1}, {"text": "cash offer", "sentiment": {"score": -0.5347, "label": "negative"}, "relevance": 0.529662, "count": 1}, {"text": "Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529129, "count": 1}, {"text": "PERSON", "sentiment": {"score": 0.520503, "label": "positive"}, "relevance": 0.529007, "count": 6}, {"text": "voting rights", "sentiment": {"score": 0.770001, "label": "positive"}, "relevance": 0.528795, "count": 1}, {"text": "option arrangement", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.527305, "count": 1}, {"text": "naming of nominee", "sentiment": {"score": -0.798933, "label": "negative"}, "relevance": 0.525182, "count": 1}, {"text": "controller of interests", "sentiment": {"score": -0.798933, "label": "negative"}, "relevance": 0.524914, "count": 1}, {"text": "contact information", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.523221, "count": 1}, {"text": "nature of the rights", "sentiment": {"score": 0.704735, "label": "positive"}, "relevance": 0.521, "count": 1}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.5205, "count": 1}, {"text": "Panel\u2019s Market Surveillance Unit", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.520411, "count": 2}, {"text": "voting rights of any relevant securities", "sentiment": {"score": 0.770001, "label": "positive"}, "relevance": 0.519376, "count": 1}, {"text": "vehicle companies", "sentiment": {"score": -0.798933, "label": "negative"}, "relevance": 0.518565, "count": 1}, {"text": "Contact name", "sentiment": {"score": -0.908997, "label": "negative"}, "relevance": 0.518091, "count": 1}, {"text": "INTERESTS", "sentiment": {"score": 0.38069, "label": "positive"}, "relevance": 0.51662, "count": 3}, {"text": "November", "sentiment": {"score": -0.908997, "label": "negative"}, "relevance": 0.516362, "count": 2}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.516141, "count": 2}, {"text": "agreements", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.516087, "count": 3}, {"text": "options", "sentiment": {"score": 0.343063, "mixed": "1", "label": "positive"}, "relevance": 0.515719, "count": 4}, {"text": "Owner", "sentiment": {"score": -0.798933, "label": "negative"}, "relevance": 0.515305, "count": 1}, {"text": "Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514299, "count": 1}, {"text": "Purchases", "sentiment": {"score": 0.698751, "label": "positive"}, "relevance": 0.513214, "count": 1}, {"text": "offer", "sentiment": {"score": 0.618287, "mixed": "1", "label": "positive"}, "relevance": 0.512886, "count": 3}, {"text": "Expiry date Option money", "sentiment": {"score": 0.699268, "label": "positive"}, "relevance": 0.511141, "count": 1}, {"text": "Number of securities Exercise price", "sentiment": {"score": 0.699268, "label": "positive"}, "relevance": 0.511051, "count": 1}]}, "extracted_metadata": {"sha1": "0ef79c42c91a0cc402f3881cbc69a910354c258a", "filename": "1543581889720.zip-e2d9a2342589358e7750f25ac892f36e.xml", "file_type": "json"}, "external_links": ["http://www.thetakeoverpanel.org.uk"], "title": "Daiwa Asset Management UK Regulatory Announcement: Form 8.3 - Takeda Pharmaceutical Company Limited", "forum_title": "All News | Business Wire"}, {"id": "COocXnH534k18ZR_i6OJP5gpfoo69r9WbKS_iw3lofu1xQH32Fqx7o9tnQuLbjKh", "result_metadata": {"score": 31.938513}, "author": "tanuj", "enriched_title": {"entities": [], "sentiment": {"document": {"score": -0.938935, "label": "negative"}}, "semantic_roles": [], "concepts": [{"text": "Major depressive disorder", "relevance": 0.949819, "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}, {"text": "Dysthymia", "relevance": 0.880267, "dbpedia_resource": "http://dbpedia.org/resource/Dysthymia"}], "categories": [{"score": 0.994659, "label": "/health and fitness/disorders/mental disorder/bipolar disorder"}, {"score": 0.994501, "label": "/health and fitness/disorders/mental disorder/depression"}, {"score": 0.903494, "label": "/health and fitness/disorders/mental disorder/panic and anxiety"}], "relations": [], "keywords": [{"text": "Major Depressive Disorder", "sentiment": {"score": -0.938935, "label": "negative"}, "relevance": 0.999998, "count": 1}, {"text": "Impressive Expansion", "sentiment": {"score": -0.938935, "label": "negative"}, "relevance": 0.00774, "count": 1}]}, "crawl_date": "2018-11-29T23:42:17Z", "url": "https://www.findmarketresearch.org/2018/11/major-depressive-disorder-market-to-reflect-impressive-expansion-during-2015-2021-3/", "host": "findmarketresearch.org", "text": "Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., AstraZeneca Plc, Alkermes, Takeda Pharmaceutical Company Limited, Naurex, Euthymics Bioscience, Inc., e-Therapeutics plc, Eli Lilly and Company, and Pfizer Inc.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-29T05:59:00+05:00", "enriched_text": {"entities": [{"count": 10, "sentiment": {"score": -0.719536, "label": "negative"}, "text": "depressive disorder", "relevance": 0.90674, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}, {"count": 2, "sentiment": {"score": -0.568224, "label": "negative"}, "text": "North America", "relevance": 0.139064, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": -0.38955, "label": "negative"}, "text": "depression", "relevance": 0.138719, "type": "HealthCondition"}, {"count": 2, "sentiment": {"score": -0.850614, "label": "negative"}, "text": "dysthymia", "relevance": 0.13845, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Dysthymia", "dbpedia_resource": "http://dbpedia.org/resource/Dysthymia"}}, {"count": 2, "sentiment": {"score": -0.542704, "label": "negative"}, "text": "Asia", "relevance": 0.135811, "type": "Location", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "H. Lundbeck A/S", "relevance": 0.122266, "type": "Company", "disambiguation": {"subtype": [], "name": "Lundbeck", "dbpedia_resource": "http://dbpedia.org/resource/Lundbeck"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly", "relevance": 0.116173, "type": "Person", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca Plc", "relevance": 0.110508, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Aripiprazole", "relevance": 0.108142, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "R&D", "relevance": 0.106852, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.105938, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.105441, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 2, "sentiment": {"score": -0.542704, "label": "negative"}, "text": "India", "relevance": 0.105244, "type": "Location", "disambiguation": {"subtype": ["HumanLanguage", "Region", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"count": 1, "sentiment": {"score": -0.317828, "label": "negative"}, "text": "Escitalopram", "relevance": 0.105103, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.503696, "label": "negative"}, "text": "U.S.", "relevance": 0.105003, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Otsuka Pharmaceutical Co.", "relevance": 0.104877, "type": "Company", "disambiguation": {"subtype": [], "name": "Otsuka Pharmaceutical", "dbpedia_resource": "http://dbpedia.org/resource/Otsuka_Pharmaceutical"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Quetiapine", "relevance": 0.103726, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Canada", "relevance": 0.101106, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Duloxetine", "relevance": 0.100012, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Venlafaxine", "relevance": 0.0988951, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc", "relevance": 0.0985845, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vilazodone", "relevance": 0.097189, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Milnacipran", "relevance": 0.0968666, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.654068, "label": "negative"}, "text": "Spain", "relevance": 0.0919957, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Kingdom of Spain (Napoleonic)", "dbpedia_resource": "http://dbpedia.org/resource/Kingdom_of_Spain_(Napoleonic)"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Company", "relevance": 0.0883773, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "France", "relevance": 0.0871054, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmDirector", "Country"], "name": "France", "dbpedia_resource": "http://dbpedia.org/resource/France"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Germany", "relevance": 0.0869234, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Euthymics Bioscience, Inc.", "relevance": 0.0857186, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.K.", "relevance": 0.0853318, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 1, "sentiment": {"score": 0.244607, "label": "positive"}, "text": "China", "relevance": 0.0847061, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Alkermes", "relevance": 0.0819498, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.542704, "label": "negative"}, "text": "Japan", "relevance": 0.0805308, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Italy", "relevance": 0.0776148, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "25%", "relevance": 0.0776148, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "10%", "relevance": 0.0776148, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "five years", "relevance": 0.0776148, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "44 years", "relevance": 0.0776148, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12%", "relevance": 0.0776148, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "20%", "relevance": 0.0776148, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "5%", "relevance": 0.0776148, "type": "Quantity"}], "sentiment": {"document": {"score": -0.830082, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Major depressive disorder", "keywords": [{"text": "Major depressive disorder"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "sentence": "Major depressive disorder, also known as major depression and clinical depression, is a mental disorder characterized by loss of interest and pleasure in enjoyable environment.", "object": {"text": "as major depression and clinical depression", "keywords": [{"text": "major depression"}, {"text": "clinical depression"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "also known", "normalized": "also know"}}, {"subject": {"text": "Major depressive disorder, also known as major depression and clinical depression,", "keywords": [{"text": "Major depressive disorder"}, {"text": "clinical depression"}, {"text": "major depression"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "sentence": "Major depressive disorder, also known as major depression and clinical depression, is a mental disorder characterized by loss of interest and pleasure in enjoyable environment.", "object": {"text": "a mental disorder characterized by loss of interest and pleasure in enjoyable environment", "keywords": [{"text": "enjoyable environment"}, {"text": "mental disorder"}, {"text": "pleasure"}, {"text": "loss"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by loss of interest and pleasure in enjoyable environment", "keywords": [{"text": "enjoyable environment"}, {"text": "pleasure"}, {"text": "loss"}]}, "sentence": "Major depressive disorder, also known as major depression and clinical depression, is a mental disorder characterized by loss of interest and pleasure in enjoyable environment.", "object": {"text": "a mental disorder", "keywords": [{"text": "mental disorder"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "action": {"verb": {"text": "characterize", "tense": "past"}, "text": "characterized", "normalized": "characterize"}}, {"subject": {"text": "by major depression", "keywords": [{"text": "major depression"}]}, "sentence": " People are affected in different ways by major depression.", "object": {"text": "People", "keywords": [{"text": "People"}]}, "action": {"verb": {"text": "affect", "tense": "past"}, "text": "are affected", "normalized": "be affect"}}, {"subject": {"text": "Some people", "keywords": [{"text": "people"}]}, "sentence": " Some people have trouble sleeping, feel agitated and irritable, and have sudden weight loss.", "object": {"text": "trouble sleeping", "keywords": [{"text": "trouble sleeping"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Some people", "keywords": [{"text": "people"}]}, "sentence": " Some people have trouble sleeping, feel agitated and irritable, and have sudden weight loss.", "object": {"text": "sudden weight loss", "keywords": [{"text": "sudden weight loss"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "they"}, "sentence": " Moreover, they can have other mental and physical symptoms such as fatigue, memory loss, feeling of hopelessness, body aches, headaches, and thoughts of suicide.", "object": {"text": "other mental and physical symptoms such as fatigue", "keywords": [{"text": "physical symptoms"}, {"text": "fatigue"}]}, "action": {"verb": {"text": "have", "tense": "future"}, "text": "can have", "normalized": "can have"}}, {"subject": {"text": "Major depressive disorder", "keywords": [{"text": "Major depressive disorder"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "sentence": " Major depressive disorder can affect people in any stage of life.", "object": {"text": "people", "keywords": [{"text": "people"}]}, "action": {"verb": {"text": "affect", "tense": "future"}, "text": "can affect", "normalized": "can affect"}}, {"subject": {"text": "those"}, "sentence": " In adults, major depressive disorder is most common in those who are 25-44 years of age.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "major depression", "keywords": [{"text": "major depression"}]}, "sentence": " Within an entire lifetime, major depression affects 10% \u2013 25% of women and 5% \u2013 12% of men.", "object": {"text": "10% \u2013 25% of women and 5% \u2013 12% of men", "keywords": [{"text": "women"}, {"text": "men"}], "entities": [{"type": "Quantity", "text": "10"}, {"type": "Quantity", "text": "12"}, {"type": "Quantity", "text": "25"}, {"type": "Quantity", "text": "5"}]}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affects", "normalized": "affect"}}, {"subject": {"text": "people", "keywords": [{"text": "people"}]}, "sentence": " It is estimated that 10% \u2013 25% of people who develop major depressive disorder are previously diagnosed with dysthymia (dysthymic disorder), a form of depression.", "object": {"text": "major depressive disorder", "keywords": [{"text": "major depressive disorder"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "develop", "normalized": "develop"}}, {"subject": {"text": "10% \u2013 25% of people who develop major depressive disorder", "keywords": [{"text": "major depressive disorder"}, {"text": "people"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}, {"type": "Quantity", "text": "10"}, {"type": "Quantity", "text": "25"}]}, "sentence": " It is estimated that 10% \u2013 25% of people who develop major depressive disorder are previously diagnosed with dysthymia (dysthymic disorder), a form of depression.", "object": {"text": "previously diagnosed with dysthymia", "keywords": [{"text": "dysthymia"}], "entities": [{"type": "HealthCondition", "text": "dysthymia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Dysthymia", "dbpedia_resource": "http://dbpedia.org/resource/Dysthymia"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Some people", "keywords": [{"text": "people"}]}, "sentence": " Some people may suffer from dysthymia and major depressive disorder at the same time.", "object": {"text": "from dysthymia and major depressive disorder", "keywords": [{"text": "major depressive disorder"}, {"text": "dysthymia"}], "entities": [{"type": "HealthCondition", "text": "dysthymia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Dysthymia", "dbpedia_resource": "http://dbpedia.org/resource/Dysthymia"}}, {"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "action": {"verb": {"text": "suffer", "tense": "future"}, "text": "may suffer", "normalized": "may suffer"}}, {"subject": {"text": "The presence of both conditions at the same time", "keywords": [{"text": "presence"}, {"text": "conditions"}, {"text": "time"}]}, "sentence": " The presence of both conditions at the same time is known as double depression.", "object": {"text": "known as double depression", "keywords": [{"text": "double depression"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The presence of both conditions at the same time", "keywords": [{"text": "presence"}, {"text": "conditions"}, {"text": "time"}]}, "sentence": " The presence of both conditions at the same time is known as double depression.", "object": {"text": "as double depression", "keywords": [{"text": "double depression"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "is known", "normalized": "be know"}}, {"subject": {"text": "The development of major depressive disorder", "keywords": [{"text": "major depressive disorder"}, {"text": "development"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "sentence": " The development of major depressive disorder may be related to certain medical conditions.", "object": {"text": "related to certain medical conditions", "keywords": [{"text": "certain medical conditions"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "may be", "normalized": "may be"}}, {"subject": {"text": "The development of major depressive disorder", "keywords": [{"text": "major depressive disorder"}, {"text": "development"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "sentence": " The development of major depressive disorder may be related to certain medical conditions.", "object": {"text": "to certain medical conditions", "keywords": [{"text": "certain medical conditions"}]}, "action": {"verb": {"text": "relate", "tense": "future"}, "text": "related", "normalized": "relate"}}, {"subject": {"text": "people", "keywords": [{"text": "people"}]}, "sentence": " Approximately 20% \u2013 25% of people who have cancer, diabetes, stroke, and myocardial infarctions are likely to develop major depressive disorder.", "object": {"text": "cancer, diabetes", "keywords": [{"text": "diabetes"}, {"text": "cancer"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Approximately 20% \u2013 25% of people who have cancer, diabetes, stroke, and myocardial infarctions", "keywords": [{"text": "myocardial infarctions"}, {"text": "diabetes"}, {"text": "stroke"}, {"text": "people"}], "entities": [{"type": "Quantity", "text": "20"}, {"type": "Quantity", "text": "25"}]}, "sentence": " Approximately 20% \u2013 25% of people who have cancer, diabetes, stroke, and myocardial infarctions are likely to develop major depressive disorder.", "object": {"text": "major depressive disorder", "keywords": [{"text": "major depressive disorder"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "to develop", "normalized": "to develop"}}, {"subject": {"text": "The global major depressive disorder market", "keywords": [{"text": "major depressive disorder"}, {"text": "market"}]}, "sentence": " The global major depressive disorder market is categorized based on various types of therapeutic drugs used to manage this medical condition.", "object": {"text": "on various types of therapeutic drugs used to manage this medical condition", "keywords": [{"text": "therapeutic drugs"}, {"text": "various types"}, {"text": "medical condition"}]}, "action": {"verb": {"text": "categorize", "tense": "past"}, "text": "is categorized", "normalized": "be categorize"}}, {"subject": {"text": "the report", "keywords": [{"text": "report"}]}, "sentence": " Based on type of therapeutic drug, the report covers selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, antidepressants, and antipsychotics.", "object": {"text": "selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, antidepressants, and antipsychotics", "keywords": [{"text": "serotonin reuptake inhibitors"}, {"text": "serotonin-norepinephrine reuptake inhibitors"}]}, "action": {"verb": {"text": "cover", "tense": "present"}, "text": "covers", "normalized": "cover"}}, {"subject": {"text": "Lexapro (Escitalopram), Viibryd (Vilazodone), Effexor (Venlafaxine), Cymbalta (Duloxetine), Pristiq (Desvenlafaxine), Fetzima (Levomilnacipran), and Savella (Milnacipran)", "keywords": [{"text": "Cymbalta"}, {"text": "Savella"}], "entities": [{"type": "Drug", "text": "Escitalopram"}, {"type": "Drug", "text": "Vilazodone"}, {"type": "Drug", "text": "Venlafaxine"}, {"type": "Drug", "text": "Duloxetine"}, {"type": "Drug", "text": "Milnacipran"}]}, "sentence": " Major brands of selective serotonin-reuptake inhibitors include Lexapro (Escitalopram), Viibryd (Vilazodone), Effexor (Venlafaxine), Cymbalta (Duloxetine), Pristiq (Desvenlafaxine), Fetzima (Levomilnacipran), and Savella (Milnacipran).", "object": {"text": "Major brands of selective serotonin-reuptake inhibitors", "keywords": [{"text": "selective serotonin-reuptake inhibitors"}, {"text": "Major brands"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Antidepressants, such as Noradrenaline, Specific Serotonergic Antidepressants, Norepinephrine-Dopamine Reuptake Inhibitors, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, and Brintellix (Vortioxetine),", "keywords": [{"text": "Monoamine Oxidase Inhibitors"}, {"text": "Specific Serotonergic Antidepressants"}, {"text": "Tricyclic Antidepressants"}, {"text": "Norepinephrine-Dopamine Reuptake Inhibitors"}]}, "sentence": " Antidepressants, such as Noradrenaline, Specific Serotonergic Antidepressants, Norepinephrine-Dopamine Reuptake Inhibitors, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, and Brintellix (Vortioxetine), are commonly used in the management of major depressive disorder.", "object": {"text": "commonly used in the management of major depressive disorder", "keywords": [{"text": "major depressive disorder"}, {"text": "management"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Antidepressants, such as Noradrenaline, Specific Serotonergic Antidepressants, Norepinephrine-Dopamine Reuptake Inhibitors, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, and Brintellix (Vortioxetine),", "keywords": [{"text": "Monoamine Oxidase Inhibitors"}, {"text": "Specific Serotonergic Antidepressants"}, {"text": "Tricyclic Antidepressants"}, {"text": "Norepinephrine-Dopamine Reuptake Inhibitors"}]}, "sentence": " Antidepressants, such as Noradrenaline, Specific Serotonergic Antidepressants, Norepinephrine-Dopamine Reuptake Inhibitors, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, and Brintellix (Vortioxetine), are commonly used in the management of major depressive disorder.", "object": {"text": "in the management of major depressive disorder", "keywords": [{"text": "major depressive disorder"}, {"text": "management"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "action": {"verb": {"text": "use", "tense": "past"}, "text": "are commonly used", "normalized": "be commonly use"}}, {"subject": {"text": "Abilify"}, "sentence": " Major brands of antipsychotics include Abilify (Aripiprazole) and Seroquel XR (Quetiapine).", "object": {"text": "antipsychotics", "keywords": [{"text": "antipsychotics"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " In terms of geography, North America dominates the global major depressive disorder market due to increased awareness about various depression conditions in the region.", "object": {"text": "the global major depressive disorder market due to increased awareness about various depression conditions in the region", "keywords": [{"text": "major depressive disorder"}, {"text": "various depression conditions"}]}, "action": {"verb": {"text": "dominate", "tense": "present"}, "text": "dominates", "normalized": "dominate"}}, {"subject": {"text": "The U.S.", "keywords": [{"text": "U.S"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " The U.S. represents the largest market for major depressive disorder in North America, followed by Canada.", "object": {"text": "the largest market for major depressive disorder in North America, followed by Canada", "keywords": [{"text": "major depressive disorder"}, {"text": "largest market"}, {"text": "North America"}, {"text": "Canada"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Canada", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}]}, "action": {"verb": {"text": "represent", "tense": "present"}, "text": "represents", "normalized": "represent"}}, {"subject": {"text": "This market in Asia", "keywords": [{"text": "market"}, {"text": "Asia"}], "entities": [{"type": "Location", "text": "Asia", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}]}, "sentence": " This market in Asia is expected to expand at a significant rate over the next five years.", "action": {"verb": {"text": "expand", "tense": "future"}, "text": "is expected to expand", "normalized": "be expect to expand"}}, {"subject": {"text": "various companies", "keywords": [{"text": "various companies"}]}, "sentence": " This is due to various companies setting up manufacturing facilities in the region.", "object": {"text": "manufacturing facilities in the region", "keywords": [{"text": "facilities"}, {"text": "region"}]}, "action": {"verb": {"text": "set", "tense": "present"}, "text": "setting", "normalized": "set"}}, {"subject": {"text": "awareness", "keywords": [{"text": "awareness"}]}, "sentence": " Moreover, increasing awareness about various depression episodes and rise in geriatric population are also driving the growth of the market in the region.", "object": {"text": "about various depression episodes and rise in geriatric population", "keywords": [{"text": "various depression episodes"}, {"text": "geriatric population"}], "entities": [{"type": "HealthCondition", "text": "depression"}]}, "action": {"verb": {"text": "increase", "tense": "present"}, "text": "increasing", "normalized": "increase"}}, {"subject": {"text": "increasing awareness about various depression episodes and rise in geriatric population", "keywords": [{"text": "various depression episodes"}, {"text": "geriatric population"}], "entities": [{"type": "HealthCondition", "text": "depression"}]}, "sentence": " Moreover, increasing awareness about various depression episodes and rise in geriatric population are also driving the growth of the market in the region.", "object": {"text": "the growth of the market in the region", "keywords": [{"text": "growth"}, {"text": "market"}, {"text": "region"}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "are also driving", "normalized": "be also drive"}}, {"subject": {"text": "India, China, and Japan", "keywords": [{"text": "India"}, {"text": "China"}, {"text": "Japan"}], "entities": [{"type": "Location", "text": "India", "disambiguation": {"subtype": ["HumanLanguage", "Region", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " India, China, and Japan are expected to be the fastest growing major depressive disorder markets in Asia.", "object": {"text": "the fastest growing major depressive disorder markets in Asia", "keywords": [{"text": "major depressive disorder"}, {"text": "markets"}, {"text": "Asia"}], "entities": [{"type": "Location", "text": "India", "disambiguation": {"subtype": ["HumanLanguage", "Region", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"type": "Location", "text": "Asia", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "are expected to be", "normalized": "be expect to be"}}, {"subject": {"text": "investments", "keywords": [{"text": "investments"}]}, "sentence": " Increased investments in R&D in the pharmaceutical sector and introduction of innovative drugs have also fueled the growth of this market.", "action": {"verb": {"text": "Increased", "tense": "past"}, "text": "Increased", "normalized": "Increased"}}, {"subject": {"text": "the growth of this market", "keywords": [{"text": "growth"}, {"text": "market"}]}, "sentence": " Increased investments in R&D in the pharmaceutical sector and introduction of innovative drugs have also fueled the growth of this market.", "object": {"text": "Increased investments in R&D in the pharmaceutical sector and introduction of innovative drugs", "keywords": [{"text": "pharmaceutical sector"}, {"text": "innovative drugs"}, {"text": "investments"}, {"text": "R&D"}], "entities": [{"type": "Location", "text": "R&D", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "fuel", "tense": "past"}, "text": "have also fueled", "normalized": "have also fuel"}}, {"subject": {"text": "The ongoing development of drugs with properties, such as improved safety and high patient compliance,", "keywords": [{"text": "high patient compliance"}, {"text": "ongoing development"}, {"text": "improved safety"}, {"text": "drugs"}]}, "sentence": " The ongoing development of drugs with properties, such as improved safety and high patient compliance, are also supporting the growth of the global major depressive disorder market.", "object": {"text": "the growth of the global major depressive disorder market", "keywords": [{"text": "major depressive disorder"}, {"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "support", "tense": "present"}, "text": "are also supporting", "normalized": "be also support"}}, {"subject": {"text": "Therapies, such as biological therapy, meditation, and physiotherapy,", "keywords": [{"text": "biological therapy"}, {"text": "physiotherapy"}, {"text": "Therapies"}, {"text": "meditation"}]}, "sentence": " Therapies, such as biological therapy, meditation, and physiotherapy, have immense potential to spur the growth of this market.", "object": {"text": "immense potential to spur the growth of this market", "keywords": [{"text": "immense potential"}, {"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Therapies, such as biological therapy, meditation, and physiotherapy,", "keywords": [{"text": "biological therapy"}, {"text": "physiotherapy"}, {"text": "Therapies"}, {"text": "meditation"}]}, "sentence": " Therapies, such as biological therapy, meditation, and physiotherapy, have immense potential to spur the growth of this market.", "object": {"text": "the growth of this market", "keywords": [{"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "spur", "tense": "future"}, "text": "to spur", "normalized": "to spur"}}, {"subject": {"text": "by various governments", "keywords": [{"text": "various governments"}]}, "sentence": " However, stringent regulations imposed by various governments hamper the growth of global major depressive disorder market.", "object": {"text": "stringent regulations", "keywords": [{"text": "stringent regulations"}]}, "action": {"verb": {"text": "impose", "tense": "past"}, "text": "imposed", "normalized": "impose"}}, {"subject": {"text": "stringent regulations imposed by various governments", "keywords": [{"text": "stringent regulations"}, {"text": "various governments"}]}, "sentence": " However, stringent regulations imposed by various governments hamper the growth of global major depressive disorder market.", "object": {"text": "the growth of global major depressive disorder market", "keywords": [{"text": "major depressive disorder"}, {"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "hamper", "tense": "present"}, "text": "hamper", "normalized": "hamper"}}, {"subject": {"text": "drugs", "keywords": [{"text": "drugs"}]}, "sentence": " Moreover, the patent expiries of some blockbuster drugs (drugs that have an annual sale of USD 1.0 million and above) and risk of complications and side-effects associated with antidepressants have hindered the growth of the market.", "object": {"text": "an annual sale of USD 1.0 million and above", "keywords": [{"text": "annual sale"}, {"text": "USD"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "side-effects", "keywords": [{"text": "side-effects"}]}, "sentence": " Moreover, the patent expiries of some blockbuster drugs (drugs that have an annual sale of USD 1.0 million and above) and risk of complications and side-effects associated with antidepressants have hindered the growth of the market.", "object": {"text": "with antidepressants", "keywords": [{"text": "antidepressants"}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "side-effects associated with antidepressants", "keywords": [{"text": "side-effects"}, {"text": "antidepressants"}]}, "sentence": " Moreover, the patent expiries of some blockbuster drugs (drugs that have an annual sale of USD 1.0 million and above) and risk of complications and side-effects associated with antidepressants have hindered the growth of the market.", "object": {"text": "the growth of the market", "keywords": [{"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "hinder", "tense": "past"}, "text": "have hindered", "normalized": "have hinder"}}, {"subject": {"text": "The major companies", "keywords": [{"text": "major companies"}], "entities": [{"type": "Company", "text": "H. Lundbeck A/S", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Lundbeck", "dbpedia_resource": "http://dbpedia.org/resource/Lundbeck"}}]}, "sentence": " The major companies operating in this market are H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., AstraZeneca Plc, Alkermes, Takeda Pharmaceutical Company Limited, Naurex, Euthymics Bioscience, Inc., e-Therapeutics plc, Eli Lilly and Company, and Pfizer Inc.", "action": {"verb": {"text": "operate", "tense": "present"}, "text": "operating", "normalized": "operate"}}], "concepts": [{"text": "Selective serotonin reuptake inhibitor", "relevance": 0.970618, "dbpedia_resource": "http://dbpedia.org/resource/Selective_serotonin_reuptake_inhibitor"}, {"text": "Sertraline", "relevance": 0.754347, "dbpedia_resource": "http://dbpedia.org/resource/Sertraline"}, {"text": "Major depressive disorder", "relevance": 0.699734, "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}, {"text": "Dysthymia", "relevance": 0.666055, "dbpedia_resource": "http://dbpedia.org/resource/Dysthymia"}, {"text": "Venlafaxine", "relevance": 0.643223, "dbpedia_resource": "http://dbpedia.org/resource/Venlafaxine"}, {"text": "Bipolar disorder", "relevance": 0.595892, "dbpedia_resource": "http://dbpedia.org/resource/Bipolar_disorder"}, {"text": "Serotonin", "relevance": 0.583045, "dbpedia_resource": "http://dbpedia.org/resource/Serotonin"}, {"text": "Paroxetine", "relevance": 0.561728, "dbpedia_resource": "http://dbpedia.org/resource/Paroxetine"}, {"text": "Citalopram", "relevance": 0.513725, "dbpedia_resource": "http://dbpedia.org/resource/Citalopram"}, {"text": "Mood disorder", "relevance": 0.512006, "dbpedia_resource": "http://dbpedia.org/resource/Mood_disorder"}, {"text": "Escitalopram", "relevance": 0.499236, "dbpedia_resource": "http://dbpedia.org/resource/Escitalopram"}, {"text": "Tricyclic antidepressant", "relevance": 0.495877, "dbpedia_resource": "http://dbpedia.org/resource/Tricyclic_antidepressant"}, {"text": "Fluoxetine", "relevance": 0.482646, "dbpedia_resource": "http://dbpedia.org/resource/Fluoxetine"}, {"text": "Antidepressant", "relevance": 0.430483, "dbpedia_resource": "http://dbpedia.org/resource/Antidepressant"}, {"text": "Atypical depression", "relevance": 0.418475, "dbpedia_resource": "http://dbpedia.org/resource/Atypical_depression"}, {"text": "Suicide", "relevance": 0.398479, "dbpedia_resource": "http://dbpedia.org/resource/Suicide"}, {"text": "Norepinephrine reuptake inhibitor", "relevance": 0.390351, "dbpedia_resource": "http://dbpedia.org/resource/Norepinephrine_reuptake_inhibitor"}, {"text": "Bupropion", "relevance": 0.38793, "dbpedia_resource": "http://dbpedia.org/resource/Bupropion"}, {"text": "Imipramine", "relevance": 0.372183, "dbpedia_resource": "http://dbpedia.org/resource/Imipramine"}, {"text": "Schizophrenia", "relevance": 0.35445, "dbpedia_resource": "http://dbpedia.org/resource/Schizophrenia"}, {"text": "Monoamine oxidase inhibitor", "relevance": 0.351243, "dbpedia_resource": "http://dbpedia.org/resource/Monoamine_oxidase_inhibitor"}], "categories": [{"score": 0.996903, "label": "/health and fitness/disorders/mental disorder/depression"}, {"score": 0.984085, "label": "/health and fitness/disorders/mental disorder/bipolar disorder"}, {"score": 0.976252, "label": "/health and fitness/disorders/mental disorder/panic and anxiety"}], "relations": [{"type": "hasAttribute", "sentence": "People are affected in different ways by major depression.", "score": 0.895334, "arguments": [{"text": "People", "location": [177, 183], "entities": [{"type": "Person", "text": "People"}]}, {"text": "depression", "location": [224, 234], "entities": [{"type": "HealthCondition", "text": "depression"}]}]}, {"type": "hasAttribute", "sentence": "Approximately 20% - 25% of people who have cancer, diabetes, stroke, and myocardial infarctions are likely to develop major depressive disorder.", "score": 0.813019, "arguments": [{"text": "who", "location": [1192, 1195], "entities": [{"type": "Person", "text": "people"}]}, {"text": "cancer", "location": [1201, 1207], "entities": [{"type": "HealthCondition", "text": "stroke"}]}]}, {"type": "locatedAt", "sentence": "Major brands of selective serotonin-reuptake inhibitors include Lexapro (Escitalopram), Viibryd (Vilazodone), Effexor (Venlafaxine), Cymbalta (Duloxetine), Pristiq (Desvenlafaxine), Fetzima (Levomilnacipran), and Savella (Milnacipran).", "score": 0.672047, "arguments": [{"text": "inhibitors", "location": [1667, 1677], "entities": [{"type": "Person", "text": "inhibitors"}]}, {"text": "Lexapro", "location": [1686, 1693], "entities": [{"type": "GeopoliticalEntity", "text": "Lexapro"}]}]}, {"type": "locatedAt", "sentence": "Major brands of selective serotonin-reuptake inhibitors include Lexapro (Escitalopram), Viibryd (Vilazodone), Effexor (Venlafaxine), Cymbalta (Duloxetine), Pristiq (Desvenlafaxine), Fetzima (Levomilnacipran), and Savella (Milnacipran).", "score": 0.681218, "arguments": [{"text": "Lexapro", "location": [1686, 1693], "entities": [{"type": "GeopoliticalEntity", "text": "Lexapro"}]}, {"text": "Escitalopram", "location": [1695, 1707], "entities": [{"type": "GeopoliticalEntity", "text": "Escitalopram"}]}]}, {"type": "playsRoleOf", "sentence": "Major brands of selective serotonin-reuptake inhibitors include Lexapro (Escitalopram), Viibryd (Vilazodone), Effexor (Venlafaxine), Cymbalta (Duloxetine), Pristiq (Desvenlafaxine), Fetzima (Levomilnacipran), and Savella (Milnacipran).", "score": 0.419738, "arguments": [{"text": "Milnacipran", "location": [1844, 1855], "entities": [{"type": "Person", "text": "Levomilnacipran"}]}, {"text": "Savella", "location": [1835, 1842], "entities": [{"type": "Person", "text": "Savella"}]}]}, {"type": "hasAttribute", "sentence": "Antidepressants, such as Noradrenaline, Specific Serotonergic Antidepressants, Norepinephrine-Dopamine Reuptake Inhibitors, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, and Brintellix (Vortioxetine), are commonly used in the management of major depressive disorder.", "score": 0.490678, "arguments": [{"text": "Vortioxetine", "location": [2055, 2067], "entities": [{"type": "Person", "text": "Vortioxetine"}]}, {"text": "depressive disorder", "location": [2115, 2134], "entities": [{"type": "HealthCondition", "text": "depressive disorder"}]}]}, {"type": "productOf", "sentence": "Major brands of antipsychotics include Abilify (Aripiprazole) and Seroquel XR (Quetiapine).", "score": 0.527122, "arguments": [{"text": "Seroquel XR", "location": [2202, 2213], "entities": [{"type": "Product", "text": "Seroquel XR"}]}, {"text": "Abilify", "location": [2175, 2182], "entities": [{"type": "Organization", "text": "Abilify", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "In terms of geography, North America dominates the global major depressive disorder market due to increased awareness about various depression conditions in the region.", "score": 0.469682, "arguments": [{"text": "depression", "location": [2360, 2370], "entities": [{"type": "HealthCondition", "text": "depression"}]}, {"text": "depressive disorder", "location": [2292, 2311], "entities": [{"type": "HealthCondition", "text": "depressive disorder"}]}]}, {"type": "locatedAt", "sentence": "In Europe, Germany, France, the U.K., Italy, and Spain account for a major share of the major depressive disorder market.", "score": 0.943846, "arguments": [{"text": "Europe", "location": [2507, 2513], "entities": [{"type": "GeopoliticalEntity", "text": "Europe"}]}, {"text": "Germany", "location": [2515, 2522], "entities": [{"type": "GeopoliticalEntity", "text": "Germany", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "In Europe, Germany, France, the U.K., Italy, and Spain account for a major share of the major depressive disorder market.", "score": 0.568243, "arguments": [{"text": "Europe", "location": [2507, 2513], "entities": [{"type": "GeopoliticalEntity", "text": "Europe"}]}, {"text": "France", "location": [2524, 2530], "entities": [{"type": "GeopoliticalEntity", "text": "France", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "In Europe, Germany, France, the U.K., Italy, and Spain account for a major share of the major depressive disorder market.", "score": 0.773073, "arguments": [{"text": "U.K.", "location": [2536, 2540], "entities": [{"type": "GeopoliticalEntity", "text": "U.K."}]}, {"text": "Italy", "location": [2542, 2547], "entities": [{"type": "GeopoliticalEntity", "text": "Italy", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "hasAttribute", "sentence": "Moreover, they can have other mental and physical symptoms such as fatigue, memory loss, feeling of hopelessness, body aches, headaches, and thoughts of suicide.", "score": 0.791566, "arguments": [{"text": "they", "location": [339, 343], "entities": [{"type": "Person", "text": "People"}]}, {"text": "mental", "location": [359, 365], "entities": [{"type": "HealthCondition", "text": "mental disorder"}]}]}, {"type": "ownerOf", "sentence": "This is due to various companies setting up manufacturing facilities in the region.", "score": 0.230617, "arguments": [{"text": "companies", "location": [2739, 2748], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "facilities", "location": [2774, 2784], "entities": [{"type": "Facility", "text": "facilities"}]}]}, {"type": "locatedAt", "sentence": "This is due to various companies setting up manufacturing facilities in the region.", "score": 0.897746, "arguments": [{"text": "facilities", "location": [2774, 2784], "entities": [{"type": "Facility", "text": "facilities"}]}, {"text": "region", "location": [2792, 2798], "entities": [{"type": "GeopoliticalEntity", "text": "Lexapro"}]}]}, {"type": "hasAttribute", "sentence": "In recent times, increased demand for therapeutic products for the treatment of this medical condition is a key driver for the global major depressive disorder market.", "score": 0.690833, "arguments": [{"text": "driver", "location": [3173, 3179], "entities": [{"type": "Person", "text": "driver"}]}, {"text": "depressive disorder", "location": [3201, 3220], "entities": [{"type": "HealthCondition", "text": "depressive disorder"}]}]}, {"type": "locatedAt", "sentence": "Moreover, the patent expiries of some blockbuster drugs (drugs that have an annual sale of USD 1.0 million and above) and risk of complications and side-effects associated with antidepressants have hindered the growth of the market.", "score": 0.323359, "arguments": [{"text": "drugs", "location": [3852, 3857], "entities": [{"type": "Substance", "text": "drugs"}]}, {"text": "blockbuster", "location": [3840, 3851], "entities": [{"type": "Facility", "text": "blockbuster"}]}]}, {"type": "employedBy", "sentence": "The major companies operating in this market are H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., AstraZeneca Plc, Alkermes, Takeda Pharmaceutical Company Limited, Naurex, Euthymics Bioscience, Inc., e-Therapeutics plc, Eli Lilly and Company, and Pfizer Inc.  //www.persistencemarketresearch.com/samples/4190", "score": 0.435451, "arguments": [{"text": "H. Lundbeck A/S", "location": [4256, 4271], "entities": [{"type": "Person", "text": "H. Lundbeck A/S"}]}, {"text": "companies", "location": [4217, 4226], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Moreover, they can have other mental and physical symptoms such as fatigue, memory loss, feeling of hopelessness, body aches, headaches, and thoughts of suicide.", "score": 0.428244, "arguments": [{"text": "fatigue", "location": [396, 403], "entities": [{"type": "HealthCondition", "text": "fatigue"}]}, {"text": "mental", "location": [359, 365], "entities": [{"type": "HealthCondition", "text": "mental disorder"}]}]}, {"type": "hasAttribute", "sentence": "Major depressive disorder can affect people in any stage of life.", "score": 0.668099, "arguments": [{"text": "people", "location": [528, 534], "entities": [{"type": "Person", "text": "People"}]}, {"text": "depressive disorder", "location": [497, 516], "entities": [{"type": "HealthCondition", "text": "depressive disorder"}]}]}, {"type": "hasAttribute", "sentence": "In adults, major depressive disorder is most common in those who are 25-44 years of age.", "score": 0.629755, "arguments": [{"text": "adults", "location": [560, 566], "entities": [{"type": "Person", "text": "adults"}]}, {"text": "depressive disorder", "location": [574, 593], "entities": [{"type": "HealthCondition", "text": "depressive disorder"}]}]}, {"type": "hasAttribute", "sentence": "Within an entire lifetime, major depression affects 10% - 25% of women and 5% - 12% of men.", "score": 0.490187, "arguments": [{"text": "women", "location": [711, 716], "entities": [{"type": "Person", "text": "women"}]}, {"text": "depression", "location": [679, 689], "entities": [{"type": "HealthCondition", "text": "depression"}]}]}, {"type": "hasAttribute", "sentence": "It is estimated that 10% - 25% of people who develop major depressive disorder are previously diagnosed with dysthymia (dysthymic disorder), a form of depression.", "score": 0.80017, "arguments": [{"text": "who", "location": [779, 782], "entities": [{"type": "Person", "text": "people"}]}, {"text": "depressive disorder", "location": [797, 816], "entities": [{"type": "HealthCondition", "text": "depressive disorder"}]}]}, {"type": "hasAttribute", "sentence": "Some people may suffer from dysthymia and major depressive disorder at the same time.", "score": 0.90085, "arguments": [{"text": "people", "location": [906, 912], "entities": [{"type": "Person", "text": "people"}]}, {"text": "dysthymia", "location": [929, 938], "entities": [{"type": "HealthCondition", "text": "dysthymic disorder"}]}]}, {"type": "hasAttribute", "sentence": "Some people may suffer from dysthymia and major depressive disorder at the same time.", "score": 0.769645, "arguments": [{"text": "people", "location": [906, 912], "entities": [{"type": "Person", "text": "people"}]}, {"text": "depressive disorder", "location": [949, 968], "entities": [{"type": "HealthCondition", "text": "depressive disorder"}]}]}], "keywords": [{"text": "Major depressive disorder", "sentiment": {"score": -0.966209, "label": "negative"}, "relevance": 0.850622, "count": 7}, {"text": "major depression", "sentiment": {"score": -0.963607, "label": "negative"}, "relevance": 0.683165, "count": 2}, {"text": "various types of therapeutic drugs", "sentiment": {"score": -0.905715, "label": "negative"}, "relevance": 0.637497, "count": 1}, {"text": "selective serotonin reuptake inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.627138, "count": 1}, {"text": "global major depressive disorder market", "sentiment": {"score": -0.716207, "mixed": "1", "label": "negative"}, "relevance": 0.623851, "count": 4}, {"text": "mental disorder", "sentiment": {"score": -0.975916, "label": "negative"}, "relevance": 0.599906, "count": 1}, {"text": "various companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.59018, "count": 1}, {"text": "major depression affects", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.560394, "count": 1}, {"text": "patent expiries of some blockbuster drugs", "sentiment": {"score": -0.873505, "label": "negative"}, "relevance": 0.556652, "count": 1}, {"text": "ongoing development of drugs", "sentiment": {"score": -0.574117, "label": "negative"}, "relevance": 0.555487, "count": 1}, {"text": "entire lifetime", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.55224, "count": 1}, {"text": "type of therapeutic drug", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.548502, "count": 1}, {"text": "recent times", "sentiment": {"score": -0.945976, "label": "negative"}, "relevance": 0.546922, "count": 1}, {"text": "largest market", "sentiment": {"score": -0.867058, "label": "negative"}, "relevance": 0.546483, "count": 1}, {"text": "serotonin-norepinephrine reuptake inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.544101, "count": 1}, {"text": "clinical depression", "sentiment": {"score": -0.975916, "label": "negative"}, "relevance": 0.544054, "count": 1}, {"text": "development of major depressive disorder", "sentiment": {"score": -0.796549, "label": "negative"}, "relevance": 0.544002, "count": 1}, {"text": "physical symptoms", "sentiment": {"score": -0.982804, "label": "negative"}, "relevance": 0.541612, "count": 1}, {"text": "biological therapy", "sentiment": {"score": 0.888806, "label": "positive"}, "relevance": 0.541445, "count": 1}, {"text": "Otsuka Pharmaceutical Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.538288, "count": 1}, {"text": "North America", "sentiment": {"score": -0.871745, "label": "negative"}, "relevance": 0.536387, "count": 2}, {"text": "Monoamine Oxidase Inhibitors", "sentiment": {"score": -0.850658, "label": "negative"}, "relevance": 0.536164, "count": 1}, {"text": "dysthymic disorder", "sentiment": {"score": -0.899566, "label": "negative"}, "relevance": 0.532675, "count": 1}, {"text": "major companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532526, "count": 1}, {"text": "acquisitions of drug manufacturing companies", "sentiment": {"score": -0.951678, "label": "negative"}, "relevance": 0.532432, "count": 1}, {"text": "Tricyclic Antidepressants", "sentiment": {"score": -0.850658, "label": "negative"}, "relevance": 0.532059, "count": 1}, {"text": "medical conditions", "sentiment": {"score": -0.797961, "label": "negative"}, "relevance": 0.530081, "count": 1}, {"text": "side-effects", "sentiment": {"score": -0.873505, "label": "negative"}, "relevance": 0.527507, "count": 1}, {"text": "H. Lundbeck A", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52725, "count": 1}, {"text": "People", "sentiment": {"score": -0.951038, "label": "negative"}, "relevance": 0.527149, "count": 6}, {"text": "stringent regulations", "sentiment": {"score": -0.905388, "label": "negative"}, "relevance": 0.526664, "count": 1}, {"text": "introduction of innovative drugs", "sentiment": {"score": 0.748368, "label": "positive"}, "relevance": 0.52466, "count": 1}, {"text": "AstraZeneca Plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524476, "count": 1}, {"text": "various governments", "sentiment": {"score": -0.905388, "label": "negative"}, "relevance": 0.523994, "count": 1}, {"text": "Takeda Pharmaceutical Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521975, "count": 1}, {"text": "different ways", "sentiment": {"score": -0.951038, "label": "negative"}, "relevance": 0.521505, "count": 1}, {"text": "memory loss", "sentiment": {"score": -0.982804, "label": "negative"}, "relevance": 0.520767, "count": 1}, {"text": "Therapies", "sentiment": {"score": 0.888806, "label": "positive"}, "relevance": 0.518809, "count": 1}, {"text": "medical condition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517088, "count": 1}, {"text": "growth of the market", "sentiment": {"score": -0.838056, "label": "negative"}, "relevance": 0.516856, "count": 2}, {"text": "antidepressants", "sentiment": {"score": -0.915057, "label": "negative"}, "relevance": 0.516773, "count": 3}, {"text": "annual sale of USD", "sentiment": {"score": -0.873505, "label": "negative"}, "relevance": 0.516225, "count": 1}, {"text": "Specific Serotonergic Antidepressants", "sentiment": {"score": -0.850658, "label": "negative"}, "relevance": 0.515835, "count": 1}, {"text": "presence of both conditions", "sentiment": {"score": -0.807323, "label": "negative"}, "relevance": 0.512944, "count": 1}, {"text": "Europe", "sentiment": {"score": -0.903133, "label": "negative"}, "relevance": 0.512532, "count": 1}, {"text": "e-Therapeutics plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512455, "count": 1}, {"text": "Norepinephrine-Dopamine Reuptake Inhibitors", "sentiment": {"score": -0.850658, "label": "negative"}, "relevance": 0.512318, "count": 1}, {"text": "management of major depressive disorder", "sentiment": {"score": -0.850658, "label": "negative"}, "relevance": 0.511941, "count": 1}, {"text": "terms of geography", "sentiment": {"score": -0.843666, "label": "negative"}, "relevance": 0.511878, "count": 1}, {"text": "India", "sentiment": {"score": -0.874844, "label": "negative"}, "relevance": 0.510481, "count": 1}]}, "extracted_metadata": {"sha1": "57381cc0d2ca922a5c04f8c6e4abf1bbeb862b5b", "filename": "1543534937478.zip-21abf3326875a23632a0e865bcf08d77.xml", "file_type": "json"}, "external_links": ["https://www.persistencemarketresearch.com/market-research/major-depressive-disorder-market.asp", "https://www.persistencemarketresearch.com/samples/4190"], "title": "Major Depressive Disorder to Reflect Impressive Expansion", "forum_title": "Research Insights | Find Market Research - Part 90"}, {"id": "OK06zHbGhikYtiYkfg8Nz64sghU19UbIH0jPHfHk3HlDouUiYxFkYMIF1VDZhH88", "result_metadata": {"score": 31.755177}, "author": "MarketScreener", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "multiple myeloma", "relevance": 0.33, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Multiple myeloma", "dbpedia_resource": "http://dbpedia.org/resource/Multiple_myeloma"}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "MMRF", "keywords": [{"text": "MMRF"}]}, "sentence": "MMRF launches MyDRUG multiple myeloma platform trial", "object": {"text": "MyDRUG multiple myeloma platform trial", "keywords": [{"text": "MyDRUG multiple myeloma"}], "entities": [{"type": "HealthCondition", "text": "multiple myeloma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Multiple myeloma", "dbpedia_resource": "http://dbpedia.org/resource/Multiple_myeloma"}}]}, "action": {"verb": {"text": "launch", "tense": "present"}, "text": "launches", "normalized": "launch"}}], "concepts": [{"text": "Multiple myeloma", "relevance": 0.926496, "dbpedia_resource": "http://dbpedia.org/resource/Multiple_myeloma"}, {"text": "Multiple Myeloma Research Foundation", "relevance": 0.830628, "dbpedia_resource": "http://dbpedia.org/resource/Multiple_Myeloma_Research_Foundation"}, {"text": "Multiple Myeloma Research Consortium", "relevance": 0.800228, "dbpedia_resource": "http://dbpedia.org/resource/Multiple_Myeloma_Research_Consortium"}], "categories": [{"score": 0.692916, "label": "/health and fitness/disease/cancer"}, {"score": 0.631113, "label": "/health and fitness/disease/cancer/brain tumor"}, {"score": 0.615383, "label": "/society/crime/personal offense/homicide"}], "relations": [], "keywords": [{"text": "myeloma platform trial", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.847146, "count": 1}, {"text": "MMRF", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.429757, "count": 1}, {"text": "MyDRUG", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.193168, "count": 1}]}, "crawl_date": "2018-11-29T19:23:32Z", "url": "https://www.marketscreener.com/news/forex-economy/news/MMRF-launches-MyDRUG-multiple-myeloma-platform-trial--27682556/", "host": "marketscreener.com", "text": "Takeda Pharmaceuticals Co.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-29T19:06:00+01:00", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Kathy Giusti", "relevance": 0.930278, "type": "Person", "disambiguation": {"subtype": ["BoardMember"], "name": "Kathy Giusti", "dbpedia_resource": "http://dbpedia.org/resource/Kathy_Giusti"}}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "MMRF", "relevance": 0.92324, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.333902, "label": "negative"}, "text": "multiple myeloma", "relevance": 0.90765, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Multiple myeloma", "dbpedia_resource": "http://dbpedia.org/resource/Multiple_myeloma"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Multiple Myeloma Research Foundation", "relevance": 0.785535, "type": "Organization", "disambiguation": {"subtype": [], "name": "Multiple Myeloma Research Foundation", "dbpedia_resource": "http://dbpedia.org/resource/Multiple_Myeloma_Research_Foundation"}}, {"count": 4, "sentiment": {"score": -0.764142, "label": "negative"}, "text": "MyDRUG", "relevance": 0.773618, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Venclexta", "relevance": 0.766631, "type": "Person"}, {"count": 2, "sentiment": {"score": -0.41301, "label": "negative"}, "text": "dexamethasone", "relevance": 0.596821, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Darzalex", "relevance": 0.499857, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Agios Pharmaceuticals Inc.", "relevance": 0.489009, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceuticals Co. Ltd.", "relevance": 0.486997, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson", "relevance": 0.484639, "type": "Company", "disambiguation": {"subtype": ["AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "NYSE", "relevance": 0.482772, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Harvard Business School Kraft Precision Medicine Accelerator", "relevance": 0.477532, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.S.", "relevance": 0.469169, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly & Co.", "relevance": 0.466819, "type": "Company", "disambiguation": {"subtype": [], "name": "Eli Lilly and Company", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly_and_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MEK", "relevance": 0.459699, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ninlaro ixazomib", "relevance": 0.453498, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Celgene Corp.", "relevance": 0.437008, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Celgene", "dbpedia_resource": "http://dbpedia.org/resource/Celgene"}}, {"count": 1, "sentiment": {"score": 0.372055, "label": "positive"}, "text": "Genentech Inc.", "relevance": 0.424986, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "co-chair", "relevance": 0.420838, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "FDA", "relevance": 0.419402, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Darzalex", "relevance": 0.417997, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Exelixis Inc.", "relevance": 0.417312, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pomalyst pomalidomide", "relevance": 0.414713, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "founder", "relevance": 0.41281, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.328226, "label": "positive"}, "text": "Tokyo", "relevance": 0.396875, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AbbVie Inc.", "relevance": 0.39511, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.372055, "label": "positive"}, "text": "t", "relevance": 0.389488, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "eight years", "relevance": 0.389488, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "36 months", "relevance": 0.389488, "type": "Quantity"}], "sentiment": {"document": {"score": 0.371206, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "The Multiple Myeloma Research Foundation", "keywords": [{"text": "Multiple Myeloma Research"}], "entities": [{"type": "Organization", "text": "Multiple Myeloma Research Foundation", "disambiguation": {"subtype": ["Organization"], "name": "Multiple Myeloma Research Foundation", "dbpedia_resource": "http://dbpedia.org/resource/Multiple_Myeloma_Research_Foundation"}}]}, "sentence": "The Multiple Myeloma Research Foundation launched the collaborative MyDRUG platform trial to identify new treatment options for molecularly defined subgroups of patients.", "object": {"text": "the collaborative MyDRUG platform trial to identify new treatment options for molecularly defined subgroups of patients", "keywords": [{"text": "collaborative MyDRUG platform"}, {"text": "new treatment options"}, {"text": "subgroups"}]}, "action": {"verb": {"text": "launch", "tense": "past"}, "text": "launched", "normalized": "launch"}}, {"subject": {"text": "The Phase I/II signal-finding study", "keywords": [{"text": "Phase I/II"}, {"text": "signal-finding study"}]}, "sentence": " The Phase I/II signal-finding study builds off the patient group's 2011 CoMMpass trial, which was designed to identify molecular drivers of MM.", "object": {"text": "off the patient group's 2011 CoMMpass trial, which was designed to identify molecular drivers of MM", "keywords": [{"text": "patient group"}, {"text": "CoMMpass trial"}, {"text": "molecular drivers"}]}, "action": {"verb": {"text": "build", "tense": "present"}, "text": "builds", "normalized": "build"}}, {"subject": {"text": "the patient group's 2011 CoMMpass trial", "keywords": [{"text": "patient group"}, {"text": "CoMMpass trial"}]}, "sentence": " The Phase I/II signal-finding study builds off the patient group's 2011 CoMMpass trial, which was designed to identify molecular drivers of MM.", "object": {"text": "molecular drivers of MM", "keywords": [{"text": "MM"}, {"text": "molecular drivers"}]}, "action": {"verb": {"text": "identify", "tense": "past"}, "text": "was designed to identify", "normalized": "be design to identify"}}, {"subject": {"text": "MMRF", "keywords": [{"text": "MMRF"}], "entities": [{"type": "Company", "text": "MMRF"}]}, "sentence": " MMRF said MyDRUG is the first platform trial exclusively in multiple myeloma.", "object": {"text": "MyDRUG is the first platform trial exclusively in multiple myeloma", "keywords": [{"text": "multiple myeloma"}, {"text": "platform trial"}, {"text": "MyDRUG"}], "entities": [{"type": "Company", "text": "MyDRUG"}, {"type": "Company", "text": "MyDRUG"}, {"type": "HealthCondition", "text": "multiple myeloma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Multiple myeloma", "dbpedia_resource": "http://dbpedia.org/resource/Multiple_myeloma"}}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "MyDRUG", "keywords": [{"text": "MyDRUG"}], "entities": [{"type": "Company", "text": "MyDRUG"}]}, "sentence": " MyDRUG will contain at least five arms defined by molecular signature and patients who harbor those signatures will then receive a specific targeted agent that has shown activity in that pathway.", "object": {"text": "at least five arms defined by molecular signature and patients who harbor those signatures will", "keywords": [{"text": "molecular signature"}, {"text": "signatures"}, {"text": "arms"}, {"text": "patients"}]}, "action": {"verb": {"text": "contain", "tense": "future"}, "text": "will contain", "normalized": "will contain"}}, {"subject": {"text": "by molecular signature and patients who harbor those signatures will", "keywords": [{"text": "molecular signature"}, {"text": "signatures"}, {"text": "patients"}]}, "sentence": " MyDRUG will contain at least five arms defined by molecular signature and patients who harbor those signatures will then receive a specific targeted agent that has shown activity in that pathway.", "object": {"text": "at least five arms", "keywords": [{"text": "arms"}]}, "action": {"verb": {"text": "define", "tense": "past"}, "text": "defined", "normalized": "define"}}, {"subject": {"text": "molecular signature and patients", "keywords": [{"text": "molecular signature"}, {"text": "patients"}]}, "sentence": " MyDRUG will contain at least five arms defined by molecular signature and patients who harbor those signatures will then receive a specific targeted agent that has shown activity in that pathway.", "object": {"text": "those signatures", "keywords": [{"text": "signatures"}]}, "action": {"verb": {"text": "harbor", "tense": "present"}, "text": "harbor", "normalized": "harbor"}}, {"subject": {"text": "those signatures", "keywords": [{"text": "signatures"}]}, "sentence": " MyDRUG will contain at least five arms defined by molecular signature and patients who harbor those signatures will then receive a specific targeted agent that has shown activity in that pathway.", "object": {"text": "a specific targeted agent that has shown activity in that pathway", "keywords": [{"text": "specific targeted agent"}, {"text": "pathway"}, {"text": "activity"}]}, "action": {"verb": {"text": "receive", "tense": "future"}, "text": "receive", "normalized": "receive"}}, {"subject": {"text": "a specific targeted agent", "keywords": [{"text": "specific targeted agent"}]}, "sentence": " MyDRUG will contain at least five arms defined by molecular signature and patients who harbor those signatures will then receive a specific targeted agent that has shown activity in that pathway.", "object": {"text": "shown activity in that pathway", "keywords": [{"text": "pathway"}, {"text": "activity"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "a specific targeted agent", "keywords": [{"text": "specific targeted agent"}]}, "sentence": " MyDRUG will contain at least five arms defined by molecular signature and patients who harbor those signatures will then receive a specific targeted agent that has shown activity in that pathway.", "object": {"text": "activity", "keywords": [{"text": "activity"}]}, "action": {"verb": {"text": "show", "tense": "past"}, "text": "has shown", "normalized": "have show"}}, {"subject": {"text": "Patients", "keywords": [{"text": "Patients"}]}, "sentence": " Patients who do not have one of these activating mutations will receive Darzalex daratumumab from J&J.", "object": {"text": "one of these activating mutations", "keywords": [{"text": "activating mutations"}]}, "action": {"verb": {"text": "have", "tense": "present", "negated": true}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Patients who do not have one of these activating mutations", "keywords": [{"text": "activating mutations"}, {"text": "Patients"}]}, "sentence": " Patients who do not have one of these activating mutations will receive Darzalex daratumumab from J&J.", "object": {"text": "Darzalex daratumumab", "keywords": [{"text": "Darzalex daratumumab"}], "entities": [{"type": "Company", "text": "Darzalex"}]}, "action": {"verb": {"text": "receive", "tense": "future"}, "text": "will receive", "normalized": "will receive"}}, {"subject": {"text": "patients", "keywords": [{"text": "patients"}]}, "sentence": " Except in the Venclexta and Darzalex arms, patients will first receive the targeted treatment in combination with dexamethasone for two cycles to measure target engagement.", "object": {"text": "the targeted treatment in combination", "keywords": [{"text": "targeted treatment"}, {"text": "combination"}]}, "action": {"verb": {"text": "receive", "tense": "future"}, "text": "receive", "normalized": "receive"}}, {"subject": {"text": "target engagement", "keywords": [{"text": "target engagement"}]}, "sentence": " Except in the Venclexta and Darzalex arms, patients will first receive the targeted treatment in combination with dexamethasone for two cycles to measure target engagement.", "object": {"text": "dexamethasone for two cycles", "keywords": [{"text": "dexamethasone"}, {"text": "cycles"}], "entities": [{"type": "Drug", "text": "dexamethasone"}]}, "action": {"verb": {"text": "measure", "tense": "future"}, "text": "to measure", "normalized": "to measure"}}, {"subject": {"text": "engagement", "keywords": [{"text": "engagement"}]}, "sentence": " If engagement is successful, patients will continue on to receive the targeted agent plus Ninlaro ixazomib, Pomalyst pomalidomide and dexamethasone.", "object": {"text": "successful"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "patients", "keywords": [{"text": "patients"}]}, "sentence": " If engagement is successful, patients will continue on to receive the targeted agent plus Ninlaro ixazomib, Pomalyst pomalidomide and dexamethasone.", "object": {"text": "on to receive the targeted agent plus Ninlaro ixazomib, Pomalyst pomalidomide and dexamethasone", "keywords": [{"text": "targeted agent"}, {"text": "Ninlaro ixazomib"}, {"text": "Pomalyst pomalidomide"}, {"text": "dexamethasone"}], "entities": [{"type": "Person", "text": "Ninlaro ixazomib"}, {"type": "Person", "text": "Pomalyst pomalidomide"}, {"type": "Drug", "text": "dexamethasone"}]}, "action": {"verb": {"text": "continue", "tense": "future"}, "text": "will continue", "normalized": "will continue"}}, {"subject": {"text": "patients", "keywords": [{"text": "patients"}]}, "sentence": " If engagement is successful, patients will continue on to receive the targeted agent plus Ninlaro ixazomib, Pomalyst pomalidomide and dexamethasone.", "object": {"text": "the targeted agent plus Ninlaro ixazomib, Pomalyst pomalidomide and dexamethasone", "keywords": [{"text": "targeted agent"}, {"text": "dexamethasone"}, {"text": "Ninlaro ixazomib"}, {"text": "Pomalyst pomalidomide"}], "entities": [{"type": "Person", "text": "Ninlaro ixazomib"}, {"type": "Person", "text": "Pomalyst pomalidomide"}, {"type": "Drug", "text": "dexamethasone"}]}, "action": {"verb": {"text": "receive", "tense": "future"}, "text": "to receive", "normalized": "to receive"}}, {"subject": {"text": "Most of these drugs", "keywords": [{"text": "drugs"}]}, "sentence": " \"Most of these drugs have already been tested in other cancers but we want to first see if it's hitting the target in multiple myeloma, then we'll move them into the combinations,\" said Kathy Giusti", "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Most of these drugs", "keywords": [{"text": "drugs"}]}, "sentence": " \"Most of these drugs have already been tested in other cancers but we want to first see if it's hitting the target in multiple myeloma, then we'll move them into the combinations,\" said Kathy Giusti", "object": {"text": "tested in other cancers", "keywords": [{"text": "cancers"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Most of these drugs", "keywords": [{"text": "drugs"}]}, "sentence": " \"Most of these drugs have already been tested in other cancers but we want to first see if it's hitting the target in multiple myeloma, then we'll move them into the combinations,\" said Kathy Giusti", "action": {"verb": {"text": "test", "tense": "past"}, "text": "tested", "normalized": "test"}}, {"subject": {"text": "we"}, "sentence": " \"Most of these drugs have already been tested in other cancers but we want to first see if it's hitting the target in multiple myeloma, then we'll move them into the combinations,\" said Kathy Giusti", "object": {"text": "to first see if it's hitting the target in multiple myeloma", "keywords": [{"text": "multiple myeloma"}, {"text": "target"}], "entities": [{"type": "HealthCondition", "text": "multiple myeloma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Multiple myeloma", "dbpedia_resource": "http://dbpedia.org/resource/Multiple_myeloma"}}]}, "action": {"verb": {"text": "want", "tense": "present"}, "text": "want", "normalized": "want"}}, {"subject": {"text": "we"}, "sentence": " \"Most of these drugs have already been tested in other cancers but we want to first see if it's hitting the target in multiple myeloma, then we'll move them into the combinations,\" said Kathy Giusti", "object": {"text": "if it's hitting the target in multiple myeloma", "keywords": [{"text": "multiple myeloma"}, {"text": "target"}], "entities": [{"type": "HealthCondition", "text": "multiple myeloma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Multiple myeloma", "dbpedia_resource": "http://dbpedia.org/resource/Multiple_myeloma"}}]}, "action": {"verb": {"text": "see", "tense": "present"}, "text": "see", "normalized": "see"}}, {"subject": {"text": "it"}, "sentence": " \"Most of these drugs have already been tested in other cancers but we want to first see if it's hitting the target in multiple myeloma, then we'll move them into the combinations,\" said Kathy Giusti", "object": {"text": "hitting the target in multiple myeloma", "keywords": [{"text": "multiple myeloma"}, {"text": "target"}], "entities": [{"type": "HealthCondition", "text": "multiple myeloma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Multiple myeloma", "dbpedia_resource": "http://dbpedia.org/resource/Multiple_myeloma"}}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "has", "normalized": "has"}}, {"subject": {"text": "it"}, "sentence": " \"Most of these drugs have already been tested in other cancers but we want to first see if it's hitting the target in multiple myeloma, then we'll move them into the combinations,\" said Kathy Giusti", "object": {"text": "the target", "keywords": [{"text": "target"}]}, "action": {"verb": {"text": "hit", "tense": "present"}, "text": "hitting", "normalized": "hit"}}, {"subject": {"text": "we"}, "sentence": " \"Most of these drugs have already been tested in other cancers but we want to first see if it's hitting the target in multiple myeloma, then we'll move them into the combinations,\" said Kathy Giusti", "object": {"text": "them"}, "action": {"verb": {"text": "move", "tense": "future"}, "text": "move", "normalized": "move"}}, {"subject": {"text": "Kathy Giusti", "keywords": [{"text": "Kathy Giusti"}], "entities": [{"type": "Person", "text": "Kathy Giusti", "disambiguation": {"subtype": ["BoardMember"], "name": "Kathy Giusti", "dbpedia_resource": "http://dbpedia.org/resource/Kathy_Giusti"}}]}, "sentence": " \"Most of these drugs have already been tested in other cancers but we want to first see if it's hitting the target in multiple myeloma, then we'll move them into the combinations,\" said Kathy Giusti", "object": {"text": "Most of these drugs have already been tested in other cancers but we want to first see if it's hitting the target in multiple myeloma, then we'll move them into the combinations", "keywords": [{"text": "multiple myeloma"}, {"text": "cancers"}, {"text": "combinations"}, {"text": "drugs"}], "entities": [{"type": "HealthCondition", "text": "multiple myeloma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Multiple myeloma", "dbpedia_resource": "http://dbpedia.org/resource/Multiple_myeloma"}}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Venclexta and Darzalex", "keywords": [{"text": "Venclexta"}, {"text": "Darzalex"}], "entities": [{"type": "Person", "text": "Venclexta"}, {"type": "Person", "text": "Darzalex"}]}, "sentence": " Because Venclexta and Darzalex have already been studied in the broader MM population, patients receiving those agents will be given the triplet combination.", "object": {"text": "already been studied in the broader MM population", "keywords": [{"text": "broader MM population"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Venclexta and Darzalex", "keywords": [{"text": "Venclexta"}, {"text": "Darzalex"}], "entities": [{"type": "Person", "text": "Venclexta"}, {"type": "Person", "text": "Darzalex"}]}, "sentence": " Because Venclexta and Darzalex have already been studied in the broader MM population, patients receiving those agents will be given the triplet combination.", "object": {"text": "studied in the broader MM population", "keywords": [{"text": "broader MM population"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Venclexta and Darzalex", "keywords": [{"text": "Venclexta"}, {"text": "Darzalex"}], "entities": [{"type": "Person", "text": "Venclexta"}, {"type": "Person", "text": "Darzalex"}]}, "sentence": " Because Venclexta and Darzalex have already been studied in the broader MM population, patients receiving those agents will be given the triplet combination.", "action": {"verb": {"text": "study", "tense": "past"}, "text": "studied", "normalized": "study"}}, {"subject": {"text": "patients", "keywords": [{"text": "patients"}]}, "sentence": " Because Venclexta and Darzalex have already been studied in the broader MM population, patients receiving those agents will be given the triplet combination.", "object": {"text": "those agents", "keywords": [{"text": "agents"}]}, "action": {"verb": {"text": "receive", "tense": "present"}, "text": "receiving", "normalized": "receive"}}, {"subject": {"text": "those agents", "keywords": [{"text": "agents"}]}, "sentence": " Because Venclexta and Darzalex have already been studied in the broader MM population, patients receiving those agents will be given the triplet combination.", "object": {"text": "given the triplet combination", "keywords": [{"text": "triplet combination"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Darzalex", "keywords": [{"text": "Darzalex"}]}, "sentence": " Darzalex is approved to treat MM in various settings, including first-, second- and third-line MM.", "object": {"text": "approved to treat MM in various settings", "keywords": [{"text": "various settings"}, {"text": "MM"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Darzalex", "keywords": [{"text": "Darzalex"}]}, "sentence": " Darzalex is approved to treat MM in various settings, including first-, second- and third-line MM.", "object": {"text": "to treat MM in various settings, including first-, second- and third-line MM", "keywords": [{"text": "third-line MM"}, {"text": "various settings"}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "approved", "normalized": "approve"}}, {"subject": {"text": "Darzalex", "keywords": [{"text": "Darzalex"}]}, "sentence": " Darzalex is approved to treat MM in various settings, including first-, second- and third-line MM.", "object": {"text": "MM", "keywords": [{"text": "MM"}]}, "action": {"verb": {"text": "treat", "tense": "future"}, "text": "is approved to treat", "normalized": "be approve to treat"}}, {"subject": {"text": "first-, second- and third-line MM", "keywords": [{"text": "third-line MM"}]}, "sentence": " Darzalex is approved to treat MM in various settings, including first-, second- and third-line MM.", "object": {"text": "various settings", "keywords": [{"text": "various settings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Venclexta", "keywords": [{"text": "Venclexta"}], "entities": [{"type": "Person", "text": "Venclexta"}]}, "sentence": " Venclexta is in Phase III testing for relapsed or refractory MM and is also available to certain MM patients under an expanded access program.", "object": {"text": "in Phase III", "keywords": [{"text": "Phase"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "MMRF", "keywords": [{"text": "MMRF"}], "entities": [{"type": "Company", "text": "MMRF"}]}, "sentence": " MMRF used data from the longitudinal CoMMPass trial to identify the molecular profiles and assign treatment arms.", "object": {"text": "data", "keywords": [{"text": "data"}]}, "action": {"verb": {"text": "use", "tense": "past"}, "text": "used", "normalized": "use"}}, {"subject": {"text": "CoMMpass", "keywords": [{"text": "CoMMpass"}]}, "sentence": " CoMMpass is a sequencing study that is following 1,000 patients for eight years to determine how molecular profiles change with response and retreatment (see \"Following CoMMpass\").", "object": {"text": "a sequencing study", "keywords": [{"text": "sequencing study"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a sequencing study", "keywords": [{"text": "sequencing study"}]}, "sentence": " CoMMpass is a sequencing study that is following 1,000 patients for eight years to determine how molecular profiles change with response and retreatment (see \"Following CoMMpass\").", "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a sequencing study", "keywords": [{"text": "sequencing study"}]}, "sentence": " CoMMpass is a sequencing study that is following 1,000 patients for eight years to determine how molecular profiles change with response and retreatment (see \"Following CoMMpass\").", "object": {"text": "1,000 patients for eight years to determine how molecular profiles change with response and retreatment", "keywords": [{"text": "molecular profiles"}, {"text": "patients"}, {"text": "response"}, {"text": "retreatment"}], "entities": [{"type": "Quantity", "text": "eight years"}]}, "action": {"verb": {"text": "follow", "tense": "present"}, "text": "is following", "normalized": "be follow"}}, {"subject": {"text": "retreatment", "keywords": [{"text": "retreatment"}]}, "sentence": " CoMMpass is a sequencing study that is following 1,000 patients for eight years to determine how molecular profiles change with response and retreatment (see \"Following CoMMpass\").", "action": {"verb": {"text": "see", "tense": "present"}, "text": "see", "normalized": "see"}}, {"subject": {"text": "We"}, "sentence": " \"We had the data, we sequenced the genome and can now identify these subtypes,\" said Giusti.", "object": {"text": "the data", "keywords": [{"text": "data"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "we"}, "sentence": " \"We had the data, we sequenced the genome and can now identify these subtypes,\" said Giusti.", "object": {"text": "the genome", "keywords": [{"text": "genome"}]}, "action": {"verb": {"text": "sequence", "tense": "past"}, "text": "sequenced", "normalized": "sequence"}}, {"subject": {"text": "these subtypes", "keywords": [{"text": "subtypes"}]}, "sentence": " \"We had the data, we sequenced the genome and can now identify these subtypes,\" said Giusti.", "action": {"verb": {"text": "identify", "tense": "future"}, "text": "identify", "normalized": "identify"}}, {"subject": {"text": "Giusti", "keywords": [{"text": "Giusti"}], "entities": [{"type": "Person", "text": "Kathy Giusti"}]}, "sentence": " \"We had the data, we sequenced the genome and can now identify these subtypes,\" said Giusti.", "object": {"text": "We had the data, we sequenced the genome and can now identify these subtypes", "keywords": [{"text": "subtypes"}, {"text": "genome"}, {"text": "data"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "high-risk patients", "keywords": [{"text": "high-risk patients"}]}, "sentence": " MyDRUG will enroll high-risk patients who have relapsed in the last 18-36 months of starting their second-line treatment.", "object": {"text": "relapsed"}, "action": {"verb": {"text": "have", "tense": "future"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "high-risk patients", "keywords": [{"text": "high-risk patients"}]}, "sentence": " MyDRUG will enroll high-risk patients who have relapsed in the last 18-36 months of starting their second-line treatment.", "action": {"verb": {"text": "relapse", "tense": "past"}, "text": "have relapsed", "normalized": "have relapse"}}, {"subject": {"text": "The primary endpoint of the study", "keywords": [{"text": "primary endpoint"}, {"text": "study"}]}, "sentence": " The primary endpoint of the study is the proportion of patients with a partial response or better after two consecutive assessments, with progression-free survival (PFS) and overall survival (OS) among the secondary endpoints.", "object": {"text": "the proportion of patients", "keywords": [{"text": "proportion"}, {"text": "patients"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "We"}, "sentence": " \"We want this to be a signal-finding study to know if this agent could work in myeloma and be on a registration path or not,\" Giusti said.", "object": {"text": "this to be a signal-finding study to know if this agent could work in myeloma and be on a registration path or not", "keywords": [{"text": "registration path"}, {"text": "signal-finding study"}, {"text": "myeloma"}]}, "action": {"verb": {"text": "want", "tense": "present"}, "text": "want", "normalized": "want"}}, {"subject": {"text": "this agent", "keywords": [{"text": "agent"}]}, "sentence": " \"We want this to be a signal-finding study to know if this agent could work in myeloma and be on a registration path or not,\" Giusti said.", "action": {"verb": {"text": "work", "tense": "future"}, "text": "could work", "normalized": "could work"}}], "concepts": [{"text": "Multiple Myeloma Research Foundation", "relevance": 0.985848, "dbpedia_resource": "http://dbpedia.org/resource/Multiple_Myeloma_Research_Foundation"}, {"text": "Multiple Myeloma Research Consortium", "relevance": 0.86882, "dbpedia_resource": "http://dbpedia.org/resource/Multiple_Myeloma_Research_Consortium"}, {"text": "Kathy Giusti", "relevance": 0.723644, "dbpedia_resource": "http://dbpedia.org/resource/Kathy_Giusti"}, {"text": "Multiple myeloma", "relevance": 0.71473, "dbpedia_resource": "http://dbpedia.org/resource/Multiple_myeloma"}, {"text": "Thalidomide", "relevance": 0.519601, "dbpedia_resource": "http://dbpedia.org/resource/Thalidomide"}, {"text": "Cancer research", "relevance": 0.477546, "dbpedia_resource": "http://dbpedia.org/resource/Cancer_research"}], "categories": [{"score": 0.944839, "label": "/health and fitness/disease/cancer"}, {"score": 0.91889, "label": "/health and fitness/disease/cancer/brain tumor"}, {"score": 0.907742, "label": "/health and fitness/therapy"}], "relations": [{"type": "agentOf", "sentence": "The Phase I/II signal-finding study builds off the patient group's 2011 CoMMpass trial, which was designed to identify molecular drivers of MM.", "score": 0.789083, "arguments": [{"text": "patient group", "location": [222, 235], "entities": [{"type": "Organization", "text": "Exelixis Inc."}]}, {"text": "trial", "location": [252, 257], "entities": [{"type": "EventLegal", "text": "trial"}]}]}, {"type": "affectedBy", "sentence": "If engagement is successful, patients will continue on to receive the targeted agent plus Ninlaro ixazomib, Pomalyst pomalidomide and dexamethasone.", "score": 0.589399, "arguments": [{"text": "patients", "location": [1537, 1545], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "receive", "location": [1566, 1573], "entities": [{"type": "EntertainmentAward", "text": "receive"}]}]}, {"type": "agentOf", "sentence": "\"Most of these drugs have already been tested in other cancers but we want to first see if it's hitting the target in multiple myeloma, then we'll move them into the combinations,\" said Kathy Giusti founder of MMRF and co-chair at the Harvard Business School Kraft Precision Medicine Accelerator.", "score": 0.808878, "arguments": [{"text": "Kathy Giusti", "location": [1843, 1855], "entities": [{"type": "Person", "text": "Kathy Giusti"}]}, {"text": "said", "location": [1838, 1842], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "\"Most of these drugs have already been tested in other cancers but we want to first see if it's hitting the target in multiple myeloma, then we'll move them into the combinations,\" said Kathy Giusti founder of MMRF and co-chair at the Harvard Business School Kraft Precision Medicine Accelerator.", "score": 0.341771, "arguments": [{"text": "founder", "location": [1856, 1863], "entities": [{"type": "Person", "text": "founder"}]}, {"text": "said", "location": [1838, 1842], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "partOfMany", "sentence": "Because Venclexta and Darzalex have already been studied in the broader MM population, patients receiving those agents will be given the triplet combination.", "score": 0.548561, "arguments": [{"text": "Venclexta", "location": [1962, 1971], "entities": [{"type": "Person", "text": "Venclexta venetoclax"}]}, {"text": "population", "location": [2029, 2039], "entities": [{"type": "Person", "text": "population"}]}]}, {"type": "partOfMany", "sentence": "Because Venclexta and Darzalex have already been studied in the broader MM population, patients receiving those agents will be given the triplet combination.", "score": 0.507764, "arguments": [{"text": "Darzalex", "location": [1976, 1984], "entities": [{"type": "Person", "text": "Darzalex"}]}, {"text": "population", "location": [2029, 2039], "entities": [{"type": "Person", "text": "population"}]}]}, {"type": "residesIn", "sentence": "Darzalex is approved to treat MM in various settings, including first-, second- and third-line MM.", "score": 0.454608, "arguments": [{"text": "Darzalex", "location": [2112, 2120], "entities": [{"type": "Person", "text": "Darzalex"}]}, {"text": "MM", "location": [2142, 2144], "entities": [{"type": "GeopoliticalEntity", "text": "MM"}]}]}, {"type": "affectedBy", "sentence": "MMRF used data from the longitudinal CoMMPass trial to identify the molecular profiles and assign treatment arms.", "score": 0.744354, "arguments": [{"text": "MMRF", "location": [2354, 2358], "entities": [{"type": "Person", "text": "MMRF"}]}, {"text": "trial", "location": [2400, 2405], "entities": [{"type": "EventLegal", "text": "trial"}]}]}, {"type": "agentOf", "sentence": "\"We had the data, we sequenced the genome and can now identify these subtypes,\" said Giusti.", "score": 0.985744, "arguments": [{"text": "Giusti", "location": [2734, 2740], "entities": [{"type": "Person", "text": "Kathy Giusti"}]}, {"text": "said", "location": [2729, 2733], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "\"We want this to be a signal-finding study to know if this agent could work in myeloma and be on a registration path or not,\" Giusti said.", "score": 0.99684, "arguments": [{"text": "Giusti", "location": [3217, 3223], "entities": [{"type": "Person", "text": "Kathy Giusti"}]}, {"text": "said", "location": [3224, 3228], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "employedBy", "sentence": "MMRF has been working with the drug companies as well as FDA over the last several months to develop the protocol.", "score": 0.419726, "arguments": [{"text": "MMRF", "location": [3230, 3234], "entities": [{"type": "Person", "text": "MMRF"}]}, {"text": "drug companies", "location": [3261, 3275], "entities": [{"type": "Organization", "text": "drug companies"}]}]}, {"type": "locatedAt", "sentence": "The trial will include 17 centers in the U.S. and will start enrolling patients in the next month.", "score": 0.384806, "arguments": [{"text": "trial", "location": [3349, 3354], "entities": [{"type": "EventLegal", "text": "trial"}]}, {"text": "U.S.", "location": [3386, 3390], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "timeOf", "sentence": "The Phase I/II signal-finding study builds off the patient group's 2011 CoMMpass trial, which was designed to identify molecular drivers of MM.", "score": 0.862947, "arguments": [{"text": "2011 CoMMpass", "location": [238, 251], "entities": [{"type": "Date", "text": "2011 CoMMpass"}]}, {"text": "trial", "location": [252, 257], "entities": [{"type": "EventLegal", "text": "trial"}]}]}, {"type": "locatedAt", "sentence": "The trial will include 17 centers in the U.S. and will start enrolling patients in the next month.", "score": 0.441065, "arguments": [{"text": "patients", "location": [3416, 3424], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "U.S.", "location": [3386, 3390], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Takeda Pharmaceuticals Co. Ltd. (Tokyo:4502) markets Ninlaro; Celgene Corp. (NASDAQ:CELG) markets Pomalyst. .", "score": 0.602801, "arguments": [{"text": "Takeda Pharmaceuticals Co. Ltd.", "location": [3444, 3475], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals Co. Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Tokyo", "location": [3477, 3482], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}]}, {"type": "residesIn", "sentence": "The Phase I/II signal-finding study builds off the patient group's 2011 CoMMpass trial, which was designed to identify molecular drivers of MM.", "score": 0.443751, "arguments": [{"text": "drivers", "location": [300, 307], "entities": [{"type": "Person", "text": "drivers"}]}, {"text": "MM", "location": [311, 313], "entities": [{"type": "GeopoliticalEntity", "text": "MM"}]}]}, {"type": "agentOf", "sentence": "MMRF said MyDRUG is the first platform trial exclusively in multiple myeloma.", "score": 0.993944, "arguments": [{"text": "MMRF", "location": [315, 319], "entities": [{"type": "Person", "text": "MMRF"}]}, {"text": "said", "location": [320, 324], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "employedBy", "sentence": "Patients with RAF/RAS alterations will receive MEK inhibitor Cotellic cobimetinib from Exelixis Inc. (NASDAQ:EXEL); patients with IDH-activating mutations will receive IDH2 inhibitor Idhifa enasidenib from Agios Pharmaceuticals Inc. (NASDAQ:AGIO); CDK4/6 inhibitor Verzenio abemaciclib from Eli Lilly & Co. (NYSE:LLY) will be given to patients with CDK pathway alterations; patients that have fibroblast growth factor receptor 3 (FGFR3) activating alterations will receive erdafitinib from Johnson & Johnson (NYSE:JNJ); and Venclexta venetoclax from AbbVie Inc. (NYSE:ABBV) and Genentech Inc. will treat patients with t(11;14) translocations.", "score": 0.498342, "arguments": [{"text": "Verzenio abemaciclib", "location": [854, 874], "entities": [{"type": "Person", "text": "Verzenio abemaciclib"}]}, {"text": "Eli Lilly & Co.", "location": [880, 895], "entities": [{"type": "Organization", "text": "Eli Lilly & Co."}]}]}, {"type": "employedBy", "sentence": "Patients with RAF/RAS alterations will receive MEK inhibitor Cotellic cobimetinib from Exelixis Inc. (NASDAQ:EXEL); patients with IDH-activating mutations will receive IDH2 inhibitor Idhifa enasidenib from Agios Pharmaceuticals Inc. (NASDAQ:AGIO); CDK4/6 inhibitor Verzenio abemaciclib from Eli Lilly & Co. (NYSE:LLY) will be given to patients with CDK pathway alterations; patients that have fibroblast growth factor receptor 3 (FGFR3) activating alterations will receive erdafitinib from Johnson & Johnson (NYSE:JNJ); and Venclexta venetoclax from AbbVie Inc. (NYSE:ABBV) and Genentech Inc. will treat patients with t(11;14) translocations.", "score": 0.504132, "arguments": [{"text": "Venclexta venetoclax", "location": [1113, 1133], "entities": [{"type": "Person", "text": "Venclexta venetoclax"}]}, {"text": "AbbVie Inc.", "location": [1139, 1150], "entities": [{"type": "Organization", "text": "AbbVie Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Patients who do not have one of these activating mutations will receive Darzalex daratumumab from J&J. Except in the Venclexta and Darzalex arms, patients will first receive the targeted treatment in combination with dexamethasone for two cycles to measure target engagement.", "score": 0.516228, "arguments": [{"text": "Venclexta", "location": [1349, 1358], "entities": [{"type": "Person", "text": "Venclexta venetoclax"}]}, {"text": "patients", "location": [1378, 1386], "entities": [{"type": "Person", "text": "patients"}]}]}, {"type": "ownerOf", "sentence": "Patients who do not have one of these activating mutations will receive Darzalex daratumumab from J&J. Except in the Venclexta and Darzalex arms, patients will first receive the targeted treatment in combination with dexamethasone for two cycles to measure target engagement.", "score": 0.695142, "arguments": [{"text": "Darzalex", "location": [1363, 1371], "entities": [{"type": "Person", "text": "Darzalex"}]}, {"text": "arms", "location": [1372, 1376], "entities": [{"type": "Weapon", "text": "arms"}]}]}, {"type": "partOfMany", "sentence": "Patients who do not have one of these activating mutations will receive Darzalex daratumumab from J&J. Except in the Venclexta and Darzalex arms, patients will first receive the targeted treatment in combination with dexamethasone for two cycles to measure target engagement.", "score": 0.501247, "arguments": [{"text": "Darzalex", "location": [1363, 1371], "entities": [{"type": "Person", "text": "Darzalex"}]}, {"text": "patients", "location": [1378, 1386], "entities": [{"type": "Person", "text": "patients"}]}]}], "keywords": [{"text": "subgroups of patients", "sentiment": {"score": -0.457854, "label": "negative"}, "relevance": 0.774944, "count": 1}, {"text": "Venclexta venetoclax", "sentiment": {"score": 0.323109, "label": "positive"}, "relevance": 0.645571, "count": 1}, {"text": "patient group", "sentiment": {"score": 0.247341, "label": "positive"}, "relevance": 0.635623, "count": 1}, {"text": "collaborative MyDRUG platform trial", "sentiment": {"score": -0.457854, "label": "negative"}, "relevance": 0.620428, "count": 1}, {"text": "Multiple Myeloma Research Foundation", "sentiment": {"score": -0.457854, "label": "negative"}, "relevance": 0.592804, "count": 1}, {"text": "RAS alterations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.590239, "count": 1}, {"text": "study builds", "sentiment": {"score": 0.247341, "label": "positive"}, "relevance": 0.580938, "count": 1}, {"text": "fibroblast growth factor receptor", "sentiment": {"score": 0.323109, "label": "positive"}, "relevance": 0.580651, "count": 1}, {"text": "Exelixis Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.561479, "count": 1}, {"text": "molecular drivers of MM", "sentiment": {"score": 0.247341, "label": "positive"}, "relevance": 0.558214, "count": 1}, {"text": "CDK4/6 inhibitor Verzenio abemaciclib", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.555107, "count": 1}, {"text": "MEK inhibitor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.554754, "count": 1}, {"text": "target engagement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.552705, "count": 1}, {"text": "progression-free survival", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.550243, "count": 1}, {"text": "Agios Pharmaceuticals Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.547566, "count": 1}, {"text": "Darzalex daratumumab", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.547487, "count": 1}, {"text": "drug companies", "sentiment": {"score": 0.412351, "label": "positive"}, "relevance": 0.54247, "count": 1}, {"text": "CoMMpass trial", "sentiment": {"score": 0.247341, "label": "positive"}, "relevance": 0.54111, "count": 1}, {"text": "CDK pathway alterations", "sentiment": {"score": 0.323109, "label": "positive"}, "relevance": 0.540116, "count": 1}, {"text": "IDH2 inhibitor Idhifa enasidenib", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531773, "count": 1}, {"text": "Johnson", "sentiment": {"score": 0.323109, "label": "positive"}, "relevance": 0.529981, "count": 2}, {"text": "overall survival", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529156, "count": 1}, {"text": "primary endpoint of the study", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528146, "count": 1}, {"text": "various settings", "sentiment": {"score": 0.550848, "label": "positive"}, "relevance": 0.52814, "count": 1}, {"text": "NYSE", "sentiment": {"score": 0.323109, "label": "positive"}, "relevance": 0.523045, "count": 3}, {"text": "patients", "sentiment": {"score": 0.488247, "label": "positive"}, "relevance": 0.522811, "count": 12}, {"text": "signal-finding study", "sentiment": {"score": 0.763734, "label": "positive"}, "relevance": 0.521325, "count": 1}, {"text": "Phase III testing", "sentiment": {"score": -0.602731, "label": "negative"}, "relevance": 0.520282, "count": 1}, {"text": "molecular signature", "sentiment": {"score": 0.435531, "label": "positive"}, "relevance": 0.517377, "count": 1}, {"text": "Phase", "sentiment": {"score": 0.247341, "label": "positive"}, "relevance": 0.517289, "count": 1}, {"text": "new treatment options", "sentiment": {"score": -0.457854, "label": "negative"}, "relevance": 0.516032, "count": 1}, {"text": "drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515697, "count": 1}, {"text": "broader MM population", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514763, "count": 1}, {"text": "signal", "sentiment": {"score": 0.247341, "label": "positive"}, "relevance": 0.513751, "count": 1}, {"text": "NASDAQ", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513731, "count": 3}, {"text": "Darzalex arms", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.511235, "count": 1}, {"text": "study", "sentiment": {"score": 0.780442, "label": "positive"}, "relevance": 0.511226, "count": 1}, {"text": "agent", "sentiment": {"score": 0.613316, "label": "positive"}, "relevance": 0.511201, "count": 3}, {"text": "Eli Lilly", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510714, "count": 1}, {"text": "mutations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509875, "count": 2}, {"text": "first platform trial", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509816, "count": 1}, {"text": "AbbVie Inc.", "sentiment": {"score": 0.323109, "label": "positive"}, "relevance": 0.509652, "count": 1}, {"text": "longitudinal CoMMPass trial", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509637, "count": 1}, {"text": "pathway", "sentiment": {"score": 0.435531, "label": "positive"}, "relevance": 0.509582, "count": 1}, {"text": "response", "sentiment": {"score": 0.780442, "label": "positive"}, "relevance": 0.50924, "count": 1}, {"text": "data", "sentiment": {"score": 0.688222, "label": "positive"}, "relevance": 0.509053, "count": 2}, {"text": "FGFR3", "sentiment": {"score": 0.323109, "label": "positive"}, "relevance": 0.508553, "count": 1}, {"text": "RAF", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.508397, "count": 1}, {"text": "Cotellic cobimetinib", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.508246, "count": 1}, {"text": "alterations", "sentiment": {"score": 0.323109, "label": "positive"}, "relevance": 0.50801, "count": 1}]}, "extracted_metadata": {"sha1": "d807f2d5ebe8d2d222b7d331b4d55ed52524b3b7", "filename": "1543519412393.zip-eacc2ff1f2f58bc9ef3cdc6d9f07f240.xml", "file_type": "json"}, "external_links": ["http://www.facebook.com/sharer.php?u=https://www.marketscreener.com/news/MMRF-launches-MyDRUG-multiple-myeloma-platform-trial--27682556/", "https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.marketscreener.com%2Fnews%2FMMRF-launches-MyDRUG-multiple-myeloma-platform-trial--27682556%2F&text=MMRF+launches+MyDRUG+multiple+myeloma+platform+trial"], "title": "MMRF launches MyDRUG multiple myeloma platform trial", "forum_title": "Markets : News, Economy &amp; Forex, All News - Marketscreener.com"}, {"id": "MQzsZQq1xl76K64kDHqfT06IYVPkfqXAZepCphO01oVt2rMPwom9QeLSXXMNDPoa", "result_metadata": {"score": 31.460163}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Nomura Holdings", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Nomura Holdings", "dbpedia_resource": "http://dbpedia.org/resource/Nomura_Holdings"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.92115, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Companies based in Osaka Prefecture", "relevance": 0.904628, "dbpedia_resource": "http://dbpedia.org/resource/Companies_based_in_Osaka_Prefecture"}], "categories": [{"score": 0.631786, "label": "/business and industrial/company"}, {"score": 0.60819, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.570502, "label": "/finance/investing"}], "relations": [], "keywords": [{"text": "Nomura Holdings", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.993637, "count": 1}, {"text": "DD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.636757, "count": 1}, {"text": "Inc Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.534541, "count": 1}, {"text": "Takeda Pharmaceutical Company Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.257133, "count": 1}]}, "crawl_date": "2018-11-30T11:42:45Z", "url": "https://www.moneyam.com/action/news/showArticle?id=6227670", "host": "moneyam.com", "text": "NA (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Company Limited (d) Status of person making the disclosure: e.g. offeror, offeree, person acting in concert with the offeror/offeree (specify name of offeror/offeree) Joint Financial Advisor to", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-30T11:30:00Z", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.859887, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Nomura Holdings Inc.", "relevance": 0.526658, "type": "Company", "disambiguation": {"subtype": [], "name": "Nomura Holdings", "dbpedia_resource": "http://dbpedia.org/resource/Nomura_Holdings"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Joint Financial Advisor", "relevance": 0.408336, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.357667, "type": "JobTitle"}], "sentiment": {"document": {"score": -0.356739, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \"N/A\" YES / NO / N/A If YES, specify which: NO 2.", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the offeror or offeree", "keywords": [{"text": "offeror"}, {"text": "offeree"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing Class of relevant security: JP3463 4", "object": {"text": "following the dealing Class of relevant security", "keywords": [{"text": "relevant security"}, {"text": "Class"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}], "concepts": [{"text": "Uniform Commercial Code", "relevance": 0.912849, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.8811, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Offer and acceptance", "relevance": 0.863152, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Companies based in Osaka Prefecture", "relevance": 0.819101, "dbpedia_resource": "http://dbpedia.org/resource/Companies_based_in_Osaka_Prefecture"}], "categories": [{"score": 0.795787, "label": "/real estate/buying and selling homes"}, {"score": 0.739365, "label": "/finance/financial news"}, {"score": 0.728276, "label": "/finance/investing/funds/mutual funds"}], "relations": [], "keywords": [{"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.769026, "count": 2}, {"text": "Full name of discloser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.750705, "count": 1}, {"text": "offeree Takeda Pharmaceutical Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.731395, "count": 1}, {"text": "relevant securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.655374, "count": 1}, {"text": "short positions", "sentiment": {"score": -0.798933, "label": "negative"}, "relevance": 0.645061, "count": 2}, {"text": "vehicle companies", "sentiment": {"score": -0.798933, "label": "negative"}, "relevance": 0.635755, "count": 1}, {"text": "cash offer", "sentiment": {"score": -0.567742, "label": "negative"}, "relevance": 0.604838, "count": 1}, {"text": "Status of person", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.601964, "count": 1}, {"text": "Nomura Holdings Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.601037, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.577613, "count": 1}, {"text": "controller of interests", "sentiment": {"score": -0.798933, "label": "negative"}, "relevance": 0.573475, "count": 1}, {"text": "naming of nominee", "sentiment": {"score": -0.798933, "label": "negative"}, "relevance": 0.568347, "count": 1}, {"text": "Takeda Pharmaceutical Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.558651, "count": 1}, {"text": "possible cash offer", "sentiment": {"score": -0.567742, "label": "negative"}, "relevance": 0.55439, "count": 1}, {"text": "Joint Financial Advisor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.54867, "count": 1}, {"text": "disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542161, "count": 3}, {"text": "offer", "sentiment": {"score": -0.567742, "label": "negative"}, "relevance": 0.532569, "count": 1}, {"text": "POSITIONS OF THE PERSON", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.529681, "count": 1}, {"text": "form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52588, "count": 1}, {"text": "trust", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522182, "count": 1}, {"text": "disclosures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521118, "count": 1}, {"text": "Owner", "sentiment": {"score": -0.798933, "label": "negative"}, "relevance": 0.521115, "count": 1}, {"text": "Date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518774, "count": 1}, {"text": "person", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517874, "count": 1}, {"text": "addition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517036, "count": 1}, {"text": "November", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516884, "count": 1}, {"text": "NA", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514525, "count": 1}, {"text": "additional class of relevant security", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.514027, "count": 1}, {"text": "positions", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.513864, "count": 1}, {"text": "Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513349, "count": 1}, {"text": "concert", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512847, "count": 1}, {"text": "relation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512003, "count": 1}, {"text": "trustee", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.511996, "count": 1}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.511764, "count": 1}, {"text": "company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.511332, "count": 1}, {"text": "respect", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510148, "count": 1}, {"text": "state", "sentiment": {"score": -0.567742, "label": "negative"}, "relevance": 0.508745, "count": 1}, {"text": "party", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.506903, "count": 1}, {"text": "beneficiaries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.506561, "count": 1}, {"text": "separate form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.506411, "count": 1}, {"text": "relevant securities of the offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.492534, "count": 1}, {"text": "copy table", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.487089, "count": 1}, {"text": "offeree", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.48688, "count": 6}, {"text": "dealing Class of relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.48419, "count": 1}, {"text": "offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.447764, "count": 3}, {"text": "JP3463", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.429425, "count": 1}, {"text": "discloser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.426979, "count": 1}, {"text": "appropriate", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.420506, "count": 1}, {"text": "settlor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.418983, "count": 1}]}, "extracted_metadata": {"sha1": "917a8f9a5d0de4783b728c4e0d58bf810da8d057", "filename": "1543578165991.zip-da0935598616ff7d286311e703ecea13.xml", "file_type": "json"}, "title": "Nomura Holdings, Inc Form 8 (DD) - Takeda Pharmaceutical Company Ltd", "forum_title": "MoneyAM News"}, {"id": "NYTEF8-J-pPHP0xoTqms3lZ5vZc5eFKVtsuehpouKfSbivxwJ9lafC50vT74kdXw", "result_metadata": {"score": 29.92039}, "author": "sproutnews", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Lansoprazole", "relevance": 0.33, "type": "Drug"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Revenue", "relevance": 0.935406, "dbpedia_resource": "http://dbpedia.org/resource/Revenue"}, {"text": "Marketing", "relevance": 0.854838, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "Capitalism", "relevance": 0.801094, "dbpedia_resource": "http://dbpedia.org/resource/Capitalism"}, {"text": "Gross margin", "relevance": 0.65697, "dbpedia_resource": "http://dbpedia.org/resource/Gross_margin"}], "categories": [{"score": 0.96233, "label": "/automotive and vehicles/cars/hybrid"}, {"score": 0.909333, "label": "/automotive and vehicles/electric vehicles"}, {"score": 0.825719, "label": "/real estate/buying and selling homes"}], "relations": [], "keywords": [{"text": "Global Lansoprazole Industry Sales", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.998998, "count": 1}, {"text": "Market Share", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.893569, "count": 1}, {"text": "Revenue", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.63129, "count": 1}, {"text": "Regions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.555596, "count": 1}, {"text": "Gross Margin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.474414, "count": 1}]}, "crawl_date": "2018-11-30T14:59:29Z", "url": "http://sproutnews.com/global-lansoprazole-industry-sales-revenue-gross-margin-market-share-by-regions-2013-2025/", "host": "sproutnews.com", "text": "Key companies profiled in this report are Takeda Pharmaceutical, Teva Pharms, Sandoz, Gsk, Dr.", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-30T06:57:00Z", "enriched_text": {"entities": [{"count": 12, "sentiment": {"score": 0.184185, "label": "positive"}, "text": "Lansoprazole", "relevance": 0.882043, "type": "Drug"}, {"count": 2, "sentiment": {"score": 0.619373, "label": "positive"}, "text": "Lansoprazole Market", "relevance": 0.547711, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Global Lansoprazole Manufacturers", "relevance": 0.450903, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Lansoprazole Industry", "relevance": 0.434336, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical", "relevance": 0.181537, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pune", "relevance": 0.156722, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Pune", "dbpedia_resource": "http://dbpedia.org/resource/Pune"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Nang Kuang Pharmaceutical", "relevance": 0.139852, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Suzhou Yushi Pharmaceutical Co.", "relevance": 0.135465, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "India", "relevance": 0.132174, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cisen Pharmaceutical", "relevance": 0.128108, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Youcare Pharmaceutical Group", "relevance": 0.127747, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sun Pharmaceutical Industries", "relevance": 0.126758, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer", "relevance": 0.123302, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0.307543, "label": "positive"}, "text": "Taj Pharma", "relevance": 0.122597, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva Pharms", "relevance": 0.118519, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Hope Pharma", "relevance": 0.117886, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Changzhou Siyao Pharmaceuticals", "relevance": 0.117353, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dr. Reddy", "relevance": 0.11413, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mylan", "relevance": 0.108626, "type": "Company", "disambiguation": {"subtype": [], "name": "Mylan", "dbpedia_resource": "http://dbpedia.org/resource/Mylan"}}, {"count": 1, "sentiment": {"score": -0.41628, "label": "negative"}, "text": "Lepu Pharmaceuticals", "relevance": 0.108507, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Krka", "relevance": 0.101996, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.294896, "label": "positive"}, "text": "Beijing Honglin Pharma.", "relevance": 0.101698, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Luoxin Biotechnology", "relevance": 0.100659, "type": "Company"}], "sentiment": {"document": {"score": 0.629687, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "That"}, "sentence": " That makes this report so invaluable, resources, for the leaders as well as the new entrants in the Industry", "object": {"text": "this report", "keywords": [{"text": "report"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "makes", "normalized": "make"}}, {"subject": {"text": "Global Lansoprazole Market report", "keywords": [{"text": "Global Lansoprazole Market"}], "entities": [{"type": "Drug", "text": "Lansoprazole"}]}, "sentence": " Global Lansoprazole Market report is replete with detailed analysis from a thorough research, especially on questions that border on market size, development environment, futuristic developments, operation situation, pathways and trend of Lansoprazole.", "object": {"text": "replete with detailed analysis from a thorough research, especially on questions that border on market size, development environment, futuristic developments, operation situation, pathways and trend of Lansoprazole", "keywords": [{"text": "thorough research"}, {"text": "futuristic developments"}, {"text": "operation situation"}, {"text": "detailed analysis"}], "entities": [{"type": "Drug", "text": "Lansoprazole"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "All these"}, "sentence": " All these are offshoots of understanding the current situation that the industry is in, especially in 2018.", "object": {"text": "offshoots of understanding the current situation", "keywords": [{"text": "current situation"}, {"text": "offshoots"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The"}, "sentence": " The will chart the course for a more comprehensive organization and discernment of the competition situation in the Lansoprazole market.", "object": {"text": "the course for a more comprehensive organization and discernment of the competition situation in the Lansoprazole market", "keywords": [{"text": "Lansoprazole market"}, {"text": "competition situation"}, {"text": "comprehensive organization"}, {"text": "discernment"}], "entities": [{"type": "Company", "text": "Lansoprazole Market"}]}, "action": {"verb": {"text": "chart", "tense": "future"}, "text": "will chart", "normalized": "will chart"}}, {"subject": {"text": "this"}, "sentence": " As this will help manufacturers and investors alike, to have a better understanding of the direction in which the Lansoprazole Market is headed.", "object": {"text": "manufacturers and investors alike", "keywords": [{"text": "investors"}, {"text": "manufacturers"}]}, "action": {"verb": {"text": "help", "tense": "future"}, "text": "will help", "normalized": "will help"}}, {"subject": {"text": "one"}, "sentence": " With this Lansoprazole Market report, one is sure to keep up with information on the dogged competition for market share and control, between elite manufacturers.", "object": {"text": "with information on the dogged competition for market share and control", "keywords": [{"text": "dogged competition"}, {"text": "market share"}, {"text": "information"}, {"text": "control"}]}, "action": {"verb": {"text": "keep", "tense": "future"}, "text": "to keep", "normalized": "to keep"}}, {"subject": {"text": "It"}, "sentence": " It also features, price, production, and revenue.", "object": {"text": "production, and revenue", "keywords": [{"text": "revenue"}, {"text": "production"}]}, "action": {"verb": {"text": "feature", "tense": "present"}, "text": "features", "normalized": "feature"}}, {"subject": {"text": "you"}, "sentence": " It is where you will understand the politics and tussle of gaining control of a huge chunk of the market share.", "object": {"text": "the politics and tussle of gaining control of a huge chunk of the market share", "keywords": [{"text": "huge chunk"}, {"text": "tussle"}, {"text": "market share"}, {"text": "politics"}]}, "action": {"verb": {"text": "understand", "tense": "future"}, "text": "will understand", "normalized": "will understand"}}, {"subject": {"text": "you"}, "sentence": " It is where you will understand the politics and tussle of gaining control of a huge chunk of the market share.", "object": {"text": "control", "keywords": [{"text": "control"}]}, "action": {"verb": {"text": "gain", "tense": "future"}, "text": "gaining", "normalized": "gain"}}, {"subject": {"text": "this report", "keywords": [{"text": "report"}]}, "sentence": " As long as you are in search of key Industry data and information that can readily be accessed, you can rest assured that this report got them covered.", "object": {"text": "them covered"}, "action": {"verb": {"text": "get", "tense": "past"}, "text": "got", "normalized": "get"}}, {"subject": {"text": "Key companies", "keywords": [{"text": "Key companies"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " Key companies profiled in this report are Takeda Pharmaceutical, Teva Pharms, Sandoz, Gsk, Dr. Reddy\u2019s, Pfizer, Taj Pharma, Mylan, Cisen Pharmaceutical, Lepu Pharmaceuticals, Nang Kuang Pharmaceutical, Luoxin Biotechnology, Beijing Honglin Pharma., Suzhou Yushi Pharmaceutical Co., Changzhou Siyao Pharmaceuticals, Youcare Pharmaceutical Group, Hope Pharma, Sun Pharmaceutical Industries, Krka and others.", "action": {"verb": {"text": "profile", "tense": "past"}, "text": "profiled", "normalized": "profile"}}, {"subject": {"text": "it"}, "sentence": " When taking a good look at this report, based on the product, it is evident that the report shows the rate of production, price, revenue, and market share as well as of the growth of each product type.", "object": {"text": "a good look at this report", "keywords": [{"text": "good look"}, {"text": "report"}]}, "action": {"verb": {"text": "take", "tense": "present"}, "text": "taking", "normalized": "take"}}, {"subject": {"text": "this report", "keywords": [{"text": "report"}]}, "sentence": " When taking a good look at this report, based on the product, it is evident that the report shows the rate of production, price, revenue, and market share as well as of the growth of each product type.", "object": {"text": "on the product", "keywords": [{"text": "product"}]}, "action": {"verb": {"text": "base", "tense": "past"}, "text": "based", "normalized": "base"}}, {"subject": {"text": "the rate of production, price, revenue, and market share as well as of the growth of each product type", "keywords": [{"text": "market share"}, {"text": "product type"}, {"text": "revenue"}, {"text": "rate"}]}, "sentence": " When taking a good look at this report, based on the product, it is evident that the report shows the rate of production, price, revenue, and market share as well as of the growth of each product type.", "object": {"text": "evident that the report shows", "keywords": [{"text": "report"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the report", "keywords": [{"text": "report"}]}, "sentence": " When taking a good look at this report, based on the product, it is evident that the report shows the rate of production, price, revenue, and market share as well as of the growth of each product type.", "object": {"text": "the rate of production, price, revenue, and market share as well as of the growth of each product type", "keywords": [{"text": "market share"}, {"text": "product type"}, {"text": "revenue"}, {"text": "rate"}]}, "action": {"verb": {"text": "show", "tense": "present"}, "text": "shows", "normalized": "show"}}, {"subject": {"text": "emphasis", "keywords": [{"text": "emphasis"}]}, "sentence": " And emphasis is laid on the end users, as well as on the applications of the product.", "object": {"text": "laid on the end users", "keywords": [{"text": "end users"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "emphasis", "keywords": [{"text": "emphasis"}]}, "sentence": " And emphasis is laid on the end users, as well as on the applications of the product.", "object": {"text": "on the end users", "keywords": [{"text": "end users"}]}, "action": {"verb": {"text": "lay", "tense": "past"}, "text": "is laid", "normalized": "be lay"}}, {"subject": {"text": "one report", "keywords": [{"text": "report"}]}, "sentence": " It is one report that hasn\u2019t shied away from taking a critical look at the current status and future outlook for the consumption/sales of these products, by the end users and applications.", "object": {"text": "n\u2019t shied"}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}], "concepts": [{"text": "Marketing", "relevance": 0.953384, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "Pharmacology", "relevance": 0.70193, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Pharmaceutical drug", "relevance": 0.596389, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Pharmacy", "relevance": 0.56767, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacy"}, {"text": "Novartis", "relevance": 0.562969, "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}, {"text": "Manufacturing", "relevance": 0.536533, "dbpedia_resource": "http://dbpedia.org/resource/Manufacturing"}, {"text": "Medicine", "relevance": 0.435284, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Revenue", "relevance": 0.428645, "dbpedia_resource": "http://dbpedia.org/resource/Revenue"}, {"text": "Industry", "relevance": 0.418152, "dbpedia_resource": "http://dbpedia.org/resource/Industry"}, {"text": "Capitalism", "relevance": 0.415362, "dbpedia_resource": "http://dbpedia.org/resource/Capitalism"}, {"text": "Gross margin", "relevance": 0.414078, "dbpedia_resource": "http://dbpedia.org/resource/Gross_margin"}, {"text": "Marketing research", "relevance": 0.41091, "dbpedia_resource": "http://dbpedia.org/resource/Marketing_research"}, {"text": "Abbas Kiarostami", "relevance": 0.40986, "dbpedia_resource": "http://dbpedia.org/resource/Abbas_Kiarostami"}, {"text": "Pharmaceutical Research and Manufacturers of America", "relevance": 0.409103, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_Research_and_Manufacturers_of_America"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.408857, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.835073, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.810109, "label": "/business and industrial/manufacturing"}, {"score": 0.784906, "label": "/business and industrial/paper industry"}], "relations": [{"type": "agentOf", "sentence": "As long as you are in search of key Industry data and information that can readily be accessed, you can rest assured that this report got them covered.", "score": 0.769801, "arguments": [{"text": "you", "location": [1658, 1661], "entities": [{"type": "Person", "text": "you"}]}, {"text": "assured", "location": [1671, 1678], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "employedBy", "sentence": "All the queries about this report can be asked at: https://www.themarketreports.com/report/ask-your-query/1143237 List of Chapters: 2 Global Lansoprazole Market Competitions by Manufacturers 3 Global Lansoprazole Capacity, Production, Revenue (Value) by Region (2013-2018) 4 Global Lansoprazole Supply (Production), Consumption, Export, Import by Region (2013-2018) 5 Global Lansoprazole Production, Revenue (Value), Price Trend by Type 6 Global Lansoprazole Market Analysis by Application 7 Global Lansoprazole Manufacturers Profiles/Analysis 8 Lansoprazole Manufacturing Cost Analysis 9 Industrial Chain, Sourcing Strategy and Downstream Buyers 10 Marketing Strategy Analysis, Distributors/Traders 11 Market Effect Factors Analysis 12 Global Lansoprazole Market Forecast (2018-2025) 13 Research Findings and Conclusion 14 Appendix", "score": 0.552661, "arguments": [{"text": "Price Trend", "location": [3204, 3215], "entities": [{"type": "Person", "text": "Price Trend"}]}, {"text": "Type 6 Global Lansoprazole Market Analysis", "location": [3219, 3261], "entities": [{"type": "Organization", "text": "Type 6 Global Lansoprazole Market Analysis"}]}]}, {"type": "employedBy", "sentence": "All the queries about this report can be asked at: https://www.themarketreports.com/report/ask-your-query/1143237 List of Chapters: 2 Global Lansoprazole Market Competitions by Manufacturers 3 Global Lansoprazole Capacity, Production, Revenue (Value) by Region (2013-2018) 4 Global Lansoprazole Supply (Production), Consumption, Export, Import by Region (2013-2018) 5 Global Lansoprazole Production, Revenue (Value), Price Trend by Type 6 Global Lansoprazole Market Analysis by Application 7 Global Lansoprazole Manufacturers Profiles/Analysis 8 Lansoprazole Manufacturing Cost Analysis 9 Industrial Chain, Sourcing Strategy and Downstream Buyers 10 Marketing Strategy Analysis, Distributors/Traders 11 Market Effect Factors Analysis 12 Global Lansoprazole Market Forecast (2018-2025) 13 Research Findings and Conclusion 14 Appendix", "score": 0.480865, "arguments": [{"text": "Traders", "location": [3479, 3486], "entities": [{"type": "Person", "text": "Traders"}]}, {"text": "Distributors", "location": [3466, 3478], "entities": [{"type": "Organization", "text": "Distributors"}]}]}, {"type": "employedBy", "sentence": "Key companies profiled in this report are Takeda Pharmaceutical, Teva Pharms, Sandoz, Gsk, Dr. Reddy's, Pfizer, Taj Pharma, Mylan, Cisen Pharmaceutical, Lepu Pharmaceuticals, Nang Kuang Pharmaceutical, Luoxin Biotechnology, Beijing Honglin Pharma., Suzhou Yushi Pharmaceutical Co., Changzhou Siyao Pharmaceuticals, Youcare Pharmaceutical Group, Hope Pharma, Sun Pharmaceutical Industries, Krka and others.", "score": 0.572252, "arguments": [{"text": "Honglin Pharma.", "location": [1946, 1961], "entities": [{"type": "Person", "text": "Honglin Pharma."}]}, {"text": "Beijing", "location": [1938, 1945], "entities": [{"type": "GeopoliticalEntity", "text": "Beijing", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOfMany", "sentence": "Key companies profiled in this report are Takeda Pharmaceutical, Teva Pharms, Sandoz, Gsk, Dr. Reddy's, Pfizer, Taj Pharma, Mylan, Cisen Pharmaceutical, Lepu Pharmaceuticals, Nang Kuang Pharmaceutical, Luoxin Biotechnology, Beijing Honglin Pharma., Suzhou Yushi Pharmaceutical Co., Changzhou Siyao Pharmaceuticals, Youcare Pharmaceutical Group, Hope Pharma, Sun Pharmaceutical Industries, Krka and others.", "score": 0.490999, "arguments": [{"text": "Honglin Pharma.", "location": [1946, 1961], "entities": [{"type": "Person", "text": "Honglin Pharma."}]}, {"text": "others", "location": [2112, 2118], "entities": [{"type": "Person", "text": "others"}]}]}, {"type": "partOfMany", "sentence": "Key companies profiled in this report are Takeda Pharmaceutical, Teva Pharms, Sandoz, Gsk, Dr. Reddy's, Pfizer, Taj Pharma, Mylan, Cisen Pharmaceutical, Lepu Pharmaceuticals, Nang Kuang Pharmaceutical, Luoxin Biotechnology, Beijing Honglin Pharma., Suzhou Yushi Pharmaceutical Co., Changzhou Siyao Pharmaceuticals, Youcare Pharmaceutical Group, Hope Pharma, Sun Pharmaceutical Industries, Krka and others.", "score": 0.968604, "arguments": [{"text": "Hope Pharma", "location": [2059, 2070], "entities": [{"type": "Person", "text": "Hope Pharma"}]}, {"text": "others", "location": [2112, 2118], "entities": [{"type": "Person", "text": "others"}]}]}, {"type": "basedIn", "sentence": "Key companies profiled in this report are Takeda Pharmaceutical, Teva Pharms, Sandoz, Gsk, Dr. Reddy's, Pfizer, Taj Pharma, Mylan, Cisen Pharmaceutical, Lepu Pharmaceuticals, Nang Kuang Pharmaceutical, Luoxin Biotechnology, Beijing Honglin Pharma., Suzhou Yushi Pharmaceutical Co., Changzhou Siyao Pharmaceuticals, Youcare Pharmaceutical Group, Hope Pharma, Sun Pharmaceutical Industries, Krka and others.", "score": 0.865801, "arguments": [{"text": "Pharmaceutical Industries", "location": [2076, 2101], "entities": [{"type": "Organization", "text": "Pharmaceutical Industries"}]}, {"text": "Sun", "location": [2072, 2075], "entities": [{"type": "GeopoliticalEntity", "text": "Sun"}]}]}, {"type": "timeOf", "sentence": "Purchase a copy of this report at: https://www.themarketreports.com/report/buy-now/1143237 When taking a good look at this report, based on the product, it is evident that the report shows the rate of production, price, revenue, and market share as well as of the growth of each product type.", "score": 0.651903, "arguments": [{"text": "https://www.themarketreports.com/report/buy-now/1143237", "location": [2155, 2210], "entities": [{"type": "Time", "text": "https://www.themarketreports.com/report/buy-now/1143237"}]}, {"text": "report", "location": [2144, 2150], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "locatedAt", "sentence": "All the queries about this report can be asked at: https://www.themarketreports.com/report/ask-your-query/1143237 List of Chapters: 2 Global Lansoprazole Market Competitions by Manufacturers 3 Global Lansoprazole Capacity, Production, Revenue (Value) by Region (2013-2018) 4 Global Lansoprazole Supply (Production), Consumption, Export, Import by Region (2013-2018) 5 Global Lansoprazole Production, Revenue (Value), Price Trend by Type 6 Global Lansoprazole Market Analysis by Application 7 Global Lansoprazole Manufacturers Profiles/Analysis 8 Lansoprazole Manufacturing Cost Analysis 9 Industrial Chain, Sourcing Strategy and Downstream Buyers 10 Marketing Strategy Analysis, Distributors/Traders 11 Market Effect Factors Analysis 12 Global Lansoprazole Market Forecast (2018-2025) 13 Research Findings and Conclusion 14 Appendix", "score": 0.882643, "arguments": [{"text": "Consumption", "location": [3103, 3114], "entities": [{"type": "GeopoliticalEntity", "text": "Consumption"}]}, {"text": "Export", "location": [3116, 3122], "entities": [{"type": "GeopoliticalEntity", "text": "Export"}]}]}, {"type": "locatedAt", "sentence": "All the queries about this report can be asked at: https://www.themarketreports.com/report/ask-your-query/1143237 List of Chapters: 2 Global Lansoprazole Market Competitions by Manufacturers 3 Global Lansoprazole Capacity, Production, Revenue (Value) by Region (2013-2018) 4 Global Lansoprazole Supply (Production), Consumption, Export, Import by Region (2013-2018) 5 Global Lansoprazole Production, Revenue (Value), Price Trend by Type 6 Global Lansoprazole Market Analysis by Application 7 Global Lansoprazole Manufacturers Profiles/Analysis 8 Lansoprazole Manufacturing Cost Analysis 9 Industrial Chain, Sourcing Strategy and Downstream Buyers 10 Marketing Strategy Analysis, Distributors/Traders 11 Market Effect Factors Analysis 12 Global Lansoprazole Market Forecast (2018-2025) 13 Research Findings and Conclusion 14 Appendix", "score": 0.669731, "arguments": [{"text": "Export", "location": [3116, 3122], "entities": [{"type": "GeopoliticalEntity", "text": "Export"}]}, {"text": "Import", "location": [3124, 3130], "entities": [{"type": "GeopoliticalEntity", "text": "Import"}]}]}, {"type": "locatedAt", "sentence": "All the queries about this report can be asked at: https://www.themarketreports.com/report/ask-your-query/1143237 List of Chapters: 2 Global Lansoprazole Market Competitions by Manufacturers 3 Global Lansoprazole Capacity, Production, Revenue (Value) by Region (2013-2018) 4 Global Lansoprazole Supply (Production), Consumption, Export, Import by Region (2013-2018) 5 Global Lansoprazole Production, Revenue (Value), Price Trend by Type 6 Global Lansoprazole Market Analysis by Application 7 Global Lansoprazole Manufacturers Profiles/Analysis 8 Lansoprazole Manufacturing Cost Analysis 9 Industrial Chain, Sourcing Strategy and Downstream Buyers 10 Marketing Strategy Analysis, Distributors/Traders 11 Market Effect Factors Analysis 12 Global Lansoprazole Market Forecast (2018-2025) 13 Research Findings and Conclusion 14 Appendix", "score": 0.515059, "arguments": [{"text": "Import", "location": [3124, 3130], "entities": [{"type": "GeopoliticalEntity", "text": "Import"}]}, {"text": "Region", "location": [3134, 3140], "entities": [{"type": "GeopoliticalEntity", "text": "Region"}]}]}], "keywords": [{"text": "Global Lansoprazole Market Research Report", "sentiment": {"score": -0.636803, "label": "negative"}, "relevance": 0.789155, "count": 1}, {"text": "Market Share", "sentiment": {"score": -0.636803, "label": "negative"}, "relevance": 0.729129, "count": 3}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.688738, "count": 1}, {"text": "detailed analysis", "sentiment": {"score": 0.956403, "label": "positive"}, "relevance": 0.662232, "count": 1}, {"text": "Global Lansoprazole Market report", "sentiment": {"score": 0.956403, "label": "positive"}, "relevance": 0.625862, "count": 1}, {"text": "search of key Industry data", "sentiment": {"score": 0.879673, "label": "positive"}, "relevance": 0.609187, "count": 1}, {"text": "Cisen Pharmaceutical", "sentiment": {"score": -0.625501, "label": "negative"}, "relevance": 0.579982, "count": 1}, {"text": "market size", "sentiment": {"score": 0.956403, "label": "positive"}, "relevance": 0.5675, "count": 1}, {"text": "good look", "sentiment": {"score": 0.879191, "label": "positive"}, "relevance": 0.561342, "count": 1}, {"text": "Content Marketing", "sentiment": {"score": 0.532381, "label": "positive"}, "relevance": 0.553111, "count": 1}, {"text": "development environment", "sentiment": {"score": 0.956403, "label": "positive"}, "relevance": 0.553048, "count": 1}, {"text": "Taj Pharma", "sentiment": {"score": -0.625501, "label": "negative"}, "relevance": 0.551811, "count": 1}, {"text": "Global Lansoprazole Market Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.544902, "count": 1}, {"text": "Lepu Pharmaceuticals", "sentiment": {"score": -0.625501, "label": "negative"}, "relevance": 0.543694, "count": 1}, {"text": "critical look", "sentiment": {"score": -0.442395, "label": "negative"}, "relevance": 0.543525, "count": 1}, {"text": "Nang Kuang Pharmaceutical", "sentiment": {"score": -0.625501, "label": "negative"}, "relevance": 0.539245, "count": 1}, {"text": "Suzhou Yushi Pharmaceutical Co.", "sentiment": {"score": -0.625501, "label": "negative"}, "relevance": 0.538668, "count": 1}, {"text": "current situation", "sentiment": {"score": 0.664024, "label": "positive"}, "relevance": 0.53863, "count": 1}, {"text": "Global Lansoprazole Manufacturers Profiles", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.538372, "count": 1}, {"text": "Lansoprazole Market report", "sentiment": {"score": 0.874964, "label": "positive"}, "relevance": 0.534851, "count": 1}, {"text": "Lansoprazole Manufacturing Cost Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533427, "count": 1}, {"text": "current status", "sentiment": {"score": -0.442395, "label": "negative"}, "relevance": 0.532977, "count": 1}, {"text": "trend of Lansoprazole", "sentiment": {"score": 0.831521, "label": "positive"}, "relevance": 0.532768, "count": 1}, {"text": "complete report", "sentiment": {"score": 0.874964, "label": "positive"}, "relevance": 0.532389, "count": 1}, {"text": "report", "sentiment": {"score": 0.806215, "mixed": "1", "label": "positive"}, "relevance": 0.530153, "count": 7}, {"text": "Lansoprazole market", "sentiment": {"score": 0.879212, "label": "positive"}, "relevance": 0.529314, "count": 2}, {"text": "Distribution News Release Broadcast", "sentiment": {"score": 0.270974, "mixed": "1", "label": "positive"}, "relevance": 0.527587, "count": 1}, {"text": "Research Findings", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526175, "count": 1}, {"text": "Key companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523021, "count": 1}, {"text": "Industrial Chain", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521663, "count": 1}, {"text": "Changzhou Siyao Pharmaceuticals", "sentiment": {"score": -0.625501, "label": "negative"}, "relevance": 0.520451, "count": 1}, {"text": "Teva Pharms", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520425, "count": 1}, {"text": "Global Lansoprazole Market Competitions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520187, "count": 1}, {"text": "manufacturers", "sentiment": {"score": 0.89972, "label": "positive"}, "relevance": 0.519902, "count": 2}, {"text": "Downstream Buyers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518083, "count": 1}, {"text": "Marketing Strategy Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517897, "count": 1}, {"text": "discernment of the competition situation", "sentiment": {"score": 0.856775, "label": "positive"}, "relevance": 0.516809, "count": 1}, {"text": "better understanding of the direction", "sentiment": {"score": 0.89972, "label": "positive"}, "relevance": 0.516763, "count": 1}, {"text": "offshoots", "sentiment": {"score": 0.664024, "label": "positive"}, "relevance": 0.516317, "count": 1}, {"text": "production", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515938, "count": 3}, {"text": "Strategy", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514897, "count": 1}, {"text": "Revenue", "sentiment": {"score": -0.636803, "label": "negative"}, "relevance": 0.514306, "count": 5}, {"text": "Honglin Pharma", "sentiment": {"score": -0.625501, "label": "negative"}, "relevance": 0.513898, "count": 1}, {"text": "Youcare Pharmaceutical Group", "sentiment": {"score": -0.625501, "label": "negative"}, "relevance": 0.513884, "count": 1}, {"text": "Luoxin Biotechnology", "sentiment": {"score": -0.625501, "label": "negative"}, "relevance": 0.513499, "count": 1}, {"text": "Dr. Reddy", "sentiment": {"score": -0.625501, "label": "negative"}, "relevance": 0.512967, "count": 1}, {"text": "information", "sentiment": {"score": 0.877332, "label": "positive"}, "relevance": 0.511564, "count": 2}, {"text": "Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510986, "count": 1}, {"text": "Global Lansoprazole Capacity", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509757, "count": 1}, {"text": "Regions", "sentiment": {"score": -0.636803, "label": "negative"}, "relevance": 0.509485, "count": 1}]}, "extracted_metadata": {"sha1": "e45331cdf77d35adafe10d6e425fe5d5c4e8f52e", "filename": "1543589969319.zip-1a778c80bf04573e3921b2a5e09c1fe2.xml", "file_type": "json"}, "external_links": ["https://www.themarketreports.com/report/ask-your-query/1143237", "https://www.themarketreports.com/report/global-lansoprazole-market-research-report-2018", "https://www.themarketreports.com/report/buy-now/1143237"], "title": "Global Lansoprazole Industry Sales, Revenue, Gross Margin, Market Share, by Regions (2013-2025)", "forum_title": "SproutNews"}]}